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Abstract 
 
cAMP  is  a  secondary  messenger  that  is  involved  in  a  variety  of  signalling 
pathways through its effectors including EPAC, PKA and ion channels. cAMP 
signalling  regulates  processes  such  as  memory,  muscle  contraction  and 
inflammatory  responses.  PDE  enzymes  offer  a  mechanism  to  negatively 
regulate  elevated  cAMP  levels  elicted  by  activators  of  adenylyl  cyclase. 
Studies  have  shown  that  cAMP  signalling  is  compartmentalised  through 
binding of PDEs to A-kinase anchoring proteins (AKAPs) that scaffold PKA 
regulatory subunits.  
 
In this study post-translational-modification of PDE4 isoforms is investigated. 
SUMOylation is a relatively newly identified post-translational modification that 
is  known  to  regulate  the  structure  and  function  of  its  substrates.  PDE4 
isoforms of the PDE4A and 4D subfamilies are SUMOylated by an E3 ligase, 
PIASy. SUMOylation alters the rolipram sensitivity and potentiates the PKA 
mediated  activation  of  the  isoforms  whilst  it  confers  protection  from  ERK-
mediated inhibition of PDE4 activity. SUMOylation alters the association of 
PDE4 isoforms with binding partners like β-Arrestin, AKAP18 δ and UBC9.  
 
Rolipram is an archetypal PDE4 specific inhibitor. In this study it is shown that 
in cells expressing a GFP tagged form of PDE4A4 undergoes redistribution 
into accretion foci upon chronic treatment with rolipram. Data suggests that 
foci  formation  requires  protein  turnover  and  is  regulated  by  signalling 
pathways such as PI3 kinase pathway, p38 MAP kinase pathway and PKC 
pathways.  Further,  the  Immunomodulatory  drug  Thalidomide
®  also  inhibits 
foci formation.  
 
PDE4 isoforms have isoforms specific N-terminal regions, which play a crucial 
role  in  sub-cellular  localisation  and  protein-protein  interactions.  It  is  shown 
here that PDE4D5 interacts with a novel RhoGAP called ARHGAP21 which 
has  been  previously  reported  to  bind  β-arrestins.  This  interaction  is 
independent of GAP activity of ARHGAP as well as PDE4 activity. Previous   iv 
reports  have  indicated  a  role  of  β-Arrestin,  PDE4  and  ARHGAP21  in 
regulation of actin cytoskeleton dynamics. Hence complex β-Arrestin-PDE4-
ARHGAP21 may play a crucial role in regulating actin dynamics.  
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Chapter 1 General introduction 
 
1.1 Cell Signalling 
 
In  multi-cellular  organisms  various  organ  systems  rely  on  complex  cell-cell 
communication to attain co-ordination. Biological mediators such as peptide 
hormones,  cytokines  and  growth  factors,  also  known  as  first  messengers, 
carry out this communication. First messengers cannot penetrate the cells so 
they  need  an  effective  messenger  to  communicate  their  signal  from  the 
plasma membrane through to the cell interior. The signals can be transduced 
to the interior of the cell by plasma membrane receptors and ion channels 
which  elicit  a  specific  and  complex  signalling  response  leading  to  the 
production  of  second  messengers,  which  generate  the  desired  intracellular 
response (Houslay and Milligan, 1997). 
 
1.2  G-protein coupled receptors 
 
G-protein  coupled  receptors  (GPCRs)  are  the  largest  family  of  plasma 
membrane receptors and comprise nearly 1000 receptor variants which relay 
the signal from plasma membrane to the interior of the cell. Binding of ligands 
such as peptide hormones initiates conformational changes in the receptor 
which  leads  to  activation  of  the  one  or  more  members  of  the  guanine-
nucleotide-binding  signal  transducing  proteins  (G-proteins)  which 
consequently generate an intracellular signal affecting a complex network of 
pathways within the cell (Luttrell, 2006 and Hollmann et al; 2005).  
 
GPCRs  possess  hepta-helical  transmembrane  structures  (7  TM).  The 
transmembrane  (TM)  domains  are  connected  to  each  other  by  alternating 
extracellular and intracellular loops. GPCRs have an extra-cellular N-terminal 
tail  and  an  intra-cellular  C-terminal  tail.  The  N-terminal  region  can  vary  in 
length  from  4-50  amino  acids  and  most  GPCRs  exhibit  at  least  one 
consensus  sequence  (Asn-X-Ser/Thr)  for  N-linked  glycosylation  within  this 
region.  The  C-terminal  region  varies  considerably  in  length  (12-359  amino   3 
acids) with the exception of the mammalian GnRH receptor, which completely 
lacks an intracellular C-terminal domain (Sealfon et al., 1997). The C-tail is 
usually  rich  in  serine  and  threonine  residues  that  are  potential  sites  for 
phosphorylation  by  GRKs  and  second  messenger  kinases  for  receptor 
desensitisation (Freedman and Lefkowitz, 1996). The C-terminal tail may also 
possess  consensus  sequences  for  palmitoylation  and  ubiquitination,  which 
regulate the signalling of GPCRs (Milligan et al; 2004, Hollmann et al, 2005, 
Yin et al; 2004). Each TM domain ranges from 20-27 amino acids in length 
and  the  orientation  of  TM  domains  in  the  plasma  membrane  is  highly 
conserved.  Various  amino  acids  in  TM  domains  are  highly  conserved  and 
they specify the ligand specificity and receptor activation of the GPCR. The 
TM  III  region  contains  a  crucial  amino  acid  residue  immediately  after  a 
conserved cysteine residue, which determines the nature of the ligand binding 
to the GPCR. If the amino acid is acidic then the ligand is more likely to be a 
biogenic amine. However, if the amino acid is basic then a peptide ligand can 
be  expected  (Hollmann  et  al;  2005  and  Yin  et  al;  2004).  The  binding  of 
biogenic  amines  to  their  receptors  is  characterised  by  a  complex  of 
interactions involving key residues in TMs III, V and VI (Strader et al., 1987). 
In these receptors, the amine of the ligand interacts with the carboxyl group of 
an  aspartate  residue  in  TM  III,  whereas  the  catechol  ring  interacts  with 
residues in TMs V and VI. Interactions of the ligand with TMIII are important 
for  binding,  while  interactions  with  TMs  V  and  VI  are  more  important  for 
receptor activation (Strader et al., 1997). 
 
Various  mechanisms  have  evolved  to  terminate  the  signalling  cascades 
through GPCRs. Agonist activation of GPCRs initiates a series of reactions 
which  result  in  the  “turn  off”  of  the  GPCR  signal,  a  process  known  as 
desensitisation,  thus  preventing  continuous  receptor-mediated  signalling 
through chronic ligand stimulation. Receptor level regulation, also known as 
homologous desensitisation, is mediated by phosphorylation of the receptor 
within its intracellular domains, via G-protein coupled receptor kinases (GRK) 
and  second messenger  kinases  such  as  cAMP-activated  Protein  Kinase  A 
(PKA) (Vaughn et al; 2006). GRK phosphorylation marks the receptor for β-
arrestin-mediated internalisation, which can lead to long-term desensitisation   4 
if the receptor is degraded and thereby down-regulated. β-arrestin is recruited 
to  the  preferentially  GRK-phosphorylated  receptors  and  acts  as  a  physical 
barrier thereby preventing the interaction between the GPCR and coupling G-
protein.    The  N-terminus  of  β-arrestin  binds  to  phosphate  groups  of  the 
phosphorylated receptors (Vaughn et al, 2006) and aids in internalisation by 
associating with endocytotic machinery including proteins like clathrin with the 
help  of  an  α-helical  motif  present  on  arrestin  (Wolfe  and  Trejo,  2007). 
Endocytosed receptors can either be returned to the plasma membrane in a 
resensitised  state  or  targeted  for  degradation.  The  mechanisms  of  GPCR 
resensitisation are thought to involve the internalisation of agonist-activated 
receptors  into  endosomal  compartments  which  contain  a  GPCR-specific 
phosphatase.  Endosomal  acidification  promotes  the  association  of  the 
receptor with the GPCR phosphatase and dephosphorylation of the receptor. 
Dephosphorylated GPCRs are subsequently recycled back to the cell surface 
where  they  can  be  again  activated  by  agonist  (Simaan  et  al;  2005). 
Alternatively,  activated  receptors  can  be  targeted  for  degradation  via  a 
process known as down regulation, which will lead to sorting of receptors for 
degradation by proteasomal/lysosomal pathway. Receptors are ‘marked’ for 
proteasomal degradation following ubiquitination, which is mediated through 
the action of an E3-ligase that interacts with β-arrestin 2 thereby ubiquitinating 
the receptor (Shenoy and Lefkowitz, 2005, Shenoy and Lefkotwitz, 2005).  
 
Heterotrimeric  G  proteins  are  guanosine  nucleotide  binding  proteins  and 
couple  to  agonist-occupied  GPCRs.  The  complex  comprises  α,  β  and  γ 
subunits which are 40-46kDa, 35kDa and 8kDa, respectively.  Gα subunits 
contain two domains, a domain involved in binding and hydrolysis of GTP that 
is  structurally  homologous  to  the  GTPases  of  monomeric  G  proteins  and 
elongation factors, and a unique helical domain, which buries the bound GTP 
in the protein core. Gα subunits undergo lipid modification, which allows for 
the attachment to the intracellular membrane and also free movement along 
the  membrane.  Four  distinct  classes  of  Gα  proteins  have  been  identified 
namely,  Gs,  Gi/o,  Gq/11  and  G12/13  (Hollmann  et  al;  2005  and  Javitch  et  al; 
1997). Each class of Gα subunit shows varying affinity for a wide variety of   5 
GPCRs  and  G-proteins  have  been  shown  to  lose  or  gain  affinity  due  to 
various  post-translational  modifications  such  as  phosphorylation  and 
palmitoylation.  When  inactive,  the  guanosine  diphosphate  (GDP)-bound  α-
subunit is tightly bound to βγ subunits and is not associated with the GPCR. 
Upon  ligand  binding  to  the  GPCR,  the  transmembrane  loops  of  receptors 
undergo conformational changes, thereby projecting out the sites that show 
high affinity for G-proteins. A GDP/GTP exchange factor (GEF) converts GDP 
on the α subunit to a GTP (guanosine triphosphate) there by activating the G-
protein complex. The activated heterotimeric complex then dissociates into α-
GTP and βγ subunits (Javitch et al; 1997). These two active complexes alter 
the  activity  of  various  effectors  thereby  initiating  a  range  of  downstream 
signaling events (Li et al; 2006). The self-regulatory GTPase activity within the 
α subunit hydrolyses the GTP into GDP and leads to re-association of the αβγ 
subunits, and thus terminating signalling (Brink et al; 2004 and Li et al; 2006). 
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Figure  1.1-Schematic  representation  of  G-protein  coupled  receptor 
signaling  
 
           GRK  GRK 
phosphorylati phosphorylati
on on   
GPCR GPCR   
Ligand Ligand   
PM PM   
G Gα α β β γ γ    
G GS S   
Adenylate  Adenylate 
cyclase cyclase   
cAMP cAMP   
G Gβ β γ γ    
Activation  Activation 
of ERK of ERK   
Intracellula Intracellula
r signaling  r signaling    
Inhibition of  Inhibition of 
Adenylyl  Adenylyl 
cyclases cyclases   
Activation of  Activation of 
GRK2 GRK2   
PKA  PKA 
phosphorylation phosphorylation   
Receptor  Receptor 
desensitization desensitization     7 
1.3  Adenylate Cyclases 
 
Adenylate  cyclases  (AC)  are  cAMP  producing  enzymes.  They  convert 
adenosine  tri-phosphate  (ATP)  into  3’5’-cyclic  adenosine  monophosphate 
(cAMP).    Ten  isoforms  of  AC  have  been  identified  and  the  isoforms  have 
distinct  distribution  and  are  differentially  regulated,  as  listed  in  table  1.1 
(Bundey and Insel, 2004). Nine of the isoforms are membrane bound while 
the other is a soluble cytosolic form (Sun et al; 2004). The membrane bound 
isoforms  show  distinct  structural  homology similar  to  DNA  polymerase  and 
possess  a  cyclase  homology  domain  that  plays  a  vital  role  in  the  catalytic 
activity  of  the  isoforms  (Cooper  and  Crosswaite,  2006).  Regulation  of 
adenylate cyclase isoforms is achieved by various mechanisms, which include 
binding of di-valent cations e.g. calcium, magnesium and manganese, binding 
of  G-proteins  and  phosphorylation.  Ca
+2/calmodulin  binding  regulates  the 
activity of isoforms 1, 3 and 8. Ca
2+ inhibits AC5 and AC6 activity, whereas 
AC2,  AC4  and  AC7  are  insensitive  to  Ca
2+  (Cooper,  2003).  Manganese-
dependent cytosolic AC10 is uniquely activated by bicarbonate ions (Sun et 
al; 2004).  
 
Phosphorylationn  is  another  major  regulator  of  adenylate  cyclase  activity. 
Various kinases are known to phosphorylate adenylate cyclases. The activity 
of  AC1,  AC2,  AC3,  AC5  and  AC7  is  enhanced  by  PKC  phosphorylation 
whereas PKC action inhibits the activity of AC4 and AC6. Phosphorylation of 
AC5, AC6 by PKA, and AC3, AC1 by calmodulin kinases (CaMK) II and IV are 
known  to  have  down-regulatory  actions  (Beazley  and  Watts,  2006).  Nitric 
Oxide (NO) has also been reported to have regulatory affects on AC activity in 
that NO donors are known to inhibit the activity of AC5 and AC6 (Cooper, 
2003).  
 
Forskolin is a labdane diterpene from the plant Plectranthus barbatus and is 
known to augment the levels of cAMP in the cells by allosterically activating 
ACs in a mechanism similar to that achieved by activated Gsα (Hurley, 1999 
and Hurley 1998).  
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Isoform  Cellular 
distribution 
                             Regulation 
AC1, 3 and 8  Lipid rafts  Stimulated  by 
calcium 
Inhibited  by  both 
Gβγ  and  Giα. 
Stimulated by Gsα 
AC2, 4 and 7  Non-rafts  Calcium 
insensitive 
Stimulated by Gβγ 
and by Gsα 
Not  effected  by 
Giα 
AC5 and 6  Lipid rafts  Inhibited  by 
Calcium 
Stimulated  by 
Gsα.  Inhibited  by 
Giα.  Not  affected 
by Gβγ 
AC9  Not known  Inhibited  by 
Calcineurin 
     ------ 
Soluble 
Isoform  
Cytosol  Not known       ------ 
 
 
 
Table 1.1- The adenylate cyclase isoforms, their cellular distribution and 
regulatory mechanisms.  
 
1.4  cAMP  
 
The  discovery  of  the  signal  functioning  of  3’,  5’  cyclic  adenosine  mono-
phosphate (cAMP) led to the now widely accepted concept of a secondary 
messenger  system  (Beavo  and  Brunton,  2002).  Cyclic  AMP  has  been 
implicated in various metabolic activities, such as ion-channel regulation, cell 
growth and differentiation (Beavo and Brunton, 2003, Houslay and Milligan, 
1997).    9 
The  levels  of  cAMP  within  cells  are  under  stringent  control,  which  if  not 
maintained can lead to erroneous signalling events and subsequently disease 
e.g. cholera. Cholera toxin catalyses the ADP ribosylation of α-Gs leading to 
constitutive adenylyl cyclase activation (Houslay and Milligan, 1997). Various 
signalling complexes as discussed below tightly regulate cAMP levels. 
 
1.5  Effectors of cAMP signalling 
 
1.5.1 Protein kinase A (PKA) 
 
Protein  phosphorylation  is  one  of  the  most  important  post-translational 
modifications. Protein kinases are a class of enzymes that phosphorylate their 
target proteins at Ser, Thr or Tyr residues (Krebs and Beavo, 1979). Protein 
kinase A provides the classic downstream effector of cAMP action (Taylor et 
al; 2005, Taylor et al; 1990, Kim et al; 2006).  
 
Protein kinase A is a tetrameric holoenzyme complex (R2C2) in its inactive 
state comprises of two catalytic(C) subunits and two regulatory (R) subunits 
(R2C2).  
 
The binding of two cAMP molecules to each of the R (regulatory) subunits 
leads  to  a  conformational  change  in  the  tetrameric  holoenzyme  complex 
subsequently  allowing  the  separation  of  the  regulatory  subunits  from  the 
catalytic  subunits  (Daniel  et  al;  1998,  Johnson  et  al;  2001,  Tasken  and 
Aandahl, 2004) (figure 1.2).  
 
There  are  four  genes  RIα,  RIβ,  RIIα,  and  RIIβ  encoding  the  regulatory 
subunits. Similarly, there are three genes for encoding the catalytic subunit, 
namely, Cα, Cβ, and Cγ (Tasken and Aandhal, 2004). A further C-subunit has 
been  identified  recently,  known  as  PrKX  and  is  encoded  by  human  X-
chromosome. This subunit binds RI regulatory subunits but not RII subunits 
(Zimmermann et al; 2000). 
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The C-subunit contains a core catalytic site flanked by amino-terminal and 
carboxyl-terminal  tails  varying  between  39-50  aminoacids  in  length.  These 
two tail regions maintain the stability of the core (Taylor et al; 2005). The N-
terminal tail of C-subunit is known to undergo post-translational modifications 
including  phosphorylation  and  myristoylation.  The  amino-terminus  of  C-
subunit  is  also  known  to  interact  with  AKIP  (A-kinase  interacting  protein), 
which  promotes  the  transportation  of  C-subunit  into  nucleus  (Taylor  et  al; 
2005) 
 
Regulatory subunits (R-subunits) play a key role in interacting with A-kinase 
anchoring proteins (AKAPs). AKAPs interact with R-subunits through their N-
terminal  region,  which  has  a  dimerization/docking  domain  whereas  the  C-
terminus portions of the R-subunits contain the sites for cAMP binding (Taylor 
et al, 2005). Dimerization of RII subunits is a prerequisite for their interaction 
with AKAPs (Tasken and Aandhal 2004). 
 
Two  different  isoforms  of  PKA  are  reported  to  exist  in  cells.  Isoform  I, 
comprises RIα and RIβ subunits whereas isoform II possesses RIIα, and RIIβ 
subunits. PKA-I is mostly cytosolic while PKA-II is known to associate with 
AKAPs  and  is  predominantly  localized  within  sub-cellular  compartments 
(McConnachie et al; 2006, Michel and Scott, 2002, Taylor et al, 1990). PKA 
phosphorylates  Ser/Thr  residues  within  various  consensus  sites.  The  most 
stringent PKA consensus motif is Arg-Arg-X-Ser/Thr but motifs including Arg-
Lys-X-Ser/Thr or Arg-Lys-X-X-Ser/Thr where X is a hydrophobic amino acid 
can also serve as PKA substrates (Kennelly and Krebs, 1991, Zetterqvist et 
al; 1976).  
 
Protein Kinase I is an endogenous inhibitor of PKA. Isoforms of PKI bind to 
and inhibits the activity of various catalytic subunits of PKA.  
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Figure 1.2: Schematic representation of activation of Protein Kinase A 
 
1.5.2 Exchange Protein Activated by cAMP (EPAC) 
 
In  1998,  De  Rooij  and  coworkers  (De  Rooij  et  al,  1998)  identified  an  881 
amino acid protein with distinct regions for cAMP binding and GEF activity 
naming  it  Exchange  Protein  Activated  by  cAMP  (EPAC)  thus  identifying 
another  effector  of  the  cAMP  signaling  cascade  (Kraemer  et  al;  2001, 
Kawasaki et al; 1998).   
 
Two  isoforms  of  EPAC  have  been  identified,  namely  EPAC1  and  EPAC2. 
Both the isoforms activate the Ras-like G-protein Rap, which in turn has two 
isoforms, namely Rap1 and Rap2.  
 
EPAC  has  an  N-terminal  DEP  (Dishevelled,  Egl-10,  Pleckstrin)  domain,  a 
cyclic nucleotide-binding domain, a Ras exchange motif (REM) and catalytic 
domains from the N-terminal towards C terminal regions in the same order. 
The DEP domain is known to be involved determining localization of EPAC 
within  the  cell.  EPAC  is  generally  associated  with  mitochondrial  and  peri-
nuclear regions of the cell (Magiera et al; 2004). EPAC2 differs from EPAC1 
in that it has an extra cAMP-binding region in its extreme N-terminus and a 
Ras  binding  domain  between  REM  and  catalytic  regions  (Rehmann  et  al; 
2003). Cyclic AMP binds EPAC and induces conformational changes in the N-
terminal region eventually leading to the activation of GEF domain. The EPAC 
GEF activity promotes the exchange of GDP for GTP on Rap. EPAC-cAMP 
complex  therefore  leads  to  activation  of  Rap1  and  Rap  2  in  a  PKA-
independent manner.  
PK PK
A A   
R  R 
subunits subunits   
C  C 
subunits subunits   
cAMP  cAMP    
Substrate  Substrate 
phosphorylation phosphorylation     12 
EPAC plays a major role in integrin-mediated cell adhesion by interacting with 
Rap1 and light chain 2 of Microtubule associated Protein 1A (MAP1A-LC2) 
(Yarwood et al; 2005, Borland et al; 2006), Rangarajan et al; 2003). It has 
also been reported that EPAC is able to interact with AKAP6, which suggests 
the  role  of  EPAC  in  spatial  and  temporal  aspects  of  cAMP  signaling 
(McConnachie et al, 2006). 
 
EPAC has also been shown to be involved in elevating intracellular calcium 
levels  via  Rap2B  activation  subsequently  leading  to  the  activation  of 
Phospholipase Cε (PLCε) (Keiper et al; 2004, Vom et al; 2004). EPAC has a 
similar  role  in activation  of  PKCε,  through PLC  and  PKD.  This  pathway  is 
suggested  to  be  involved  in  inflammatory  pain  (Hucho  et  al;  2005).  The 
elevation of intracellular calcium by EPAC has been shown to have a role in 
regulating the secretory activity of pancreatic acinar cells (Chaudhari et al; 
2007).  
 
1.5.3 Cyclic nucleotide gated ion channels (CNG ion channels) 
 
CNG  ion  channels  are  regulated  by  cyclic  nucleotides  like  cAMP  and/or 
cGMP.  They  were  first  discovered  in  vertebrate  retinal  rods  and  olfactory 
sensory neurons (Bradley et al; 2005, Pifferi et al; 2006). There are six genes 
that encode four A subunits and two B subunits of CNG. They exist in either 
homo-  or  hetero-tetrameric  states  and  the  cyclic  nucleotide  binding  occurs 
within  their  C-terminal  region  (Young  and  Krougliak,  2004,  Bradley  et  al, 
2005). Activation of a GPCR coupled adenylyl or guanylyl cyclase leads to 
increase in levels of cyclic nucleotides, which can then bind and regulate CNG 
ions channel activity. For example, CNG (A2)2-A4-B1b is present in olfactory 
sensory neurons and is sensitive to cAMP where by elevated levels of cAMP 
increase the activity of the CNG. However, CNGs are not inactivated by cyclic 
nucleotides. CNG ions channels are non-specific cation channels and their 
activity is regulated by calcium-calmodulin cascade (Bradley et al; 2005).   
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1.6  The cyclic Nucleotide phosphodiesterase (PDE) superfamily 
 
Cyclic  Nucleotide  phosphodiesterases  (PDEs)  are  a  class  of enzymes  that 
catalyse  the  hydrolysis  of  cyclic  nucleotides  into  their  respective  5` 
mononucleotides. PDEs are localised in various cellular compartments and 
they regulate the basal levels of cyclic nucleotides in the cells (Houslay and 
Adams; 2003). The PDE superfamily constitutes 11 subfamilies that differ in 
their  sequence  homology,  substrate  specificity,  regulation  and  selective 
inhibition (Lynch et al; 2006 Houslay and Adams; 2003, Houslay; 2001 and 
Houslay  and  Milligan  1997).  Despite  their  differences,  all  PDE  subfamilies 
share  a  highly  conserved  catalytic  region  with  some  structural  differences 
generated  by  the  substrate  specificity.  In  the  nomenclature  of  PDE 
superfamily, an Arabic numeral is used to indicate the family, then a capital 
letter indicating the gene within the family followed by a numeral indicating the 
splice variant are used. For example, PDE4B1 indicates subfamily 4, gene B 
and splice variant 1 (Lynch et al; 2006). Isobutylmethylxanitine (IBMX) inhibits 
all PDE enzymes except isoenzymes of PDE subfamilies 8 and 9, which are 
insensitive to it.  Table 1.2 depicts various features of PDE subfamilies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dipyridamole 
and Zaprinast 
GAF  cAMP and cGMP  A  PDE11 
Dipyridamole 
and Zaprinast 
GAF  cAMP and cGMP  A  PDE10 
Zaprinast and 
SCH51866.IBMX 
insensitive 
___  cGMP  A  PDE9 
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IBMX insensitive 
___  cAMP  A  PDE8 
BRL 50481 and 
ICI 242  
___  cAMP  A and B  PDE7 
Zaprinast and 
Sildenafil 
GAF  cGMP  A, B, and C  PDE6 
Sildenafil  GAF  cGMP  A  PDE5 
Rolipram and 
Ariflo® 
UCR   cAMP  A, B, C and D  PDE4 
Cilostimide    cAMP    A and B  PDE3 
EHNA  GAF  cAMP and cGMP  A  PDE2 
Nicarpidine and 
Vinopectine 
CaM binding  cAMP and cGMP  A, B, C  PDE1 
Selective 
inhibitors 
Regulatory 
domains 
Substrate  Genes  PDE 
Table 1.2 Classification of Cyclic nucleotide PDE superfamilies.   15 
1.6.1  Phosphodiesterase-1 
 
Phosphodiestarase1  family  of  enzymes  are  calcium-calmodulin  dependent 
dual specificity phosphodiesterases. Three genes A, B and C encode both 5’ 
and  3’  mRNA  splice  variants  of  PDE1  isoenzymes (Lugnier; 2006,  Goraya 
and Cooper; 2005, Snyder et al; 1999). PDE1A and PDE1B genes encode 
two splice variants PDE1A1, 2 and PDE1B1, 2 respectively and preferentially 
hydrolyse cGMP whereas PDE1C gene encodes five splice variants 1-5 and 
hydrolyses both cAMP and cGMP (Giembycz; 2005)  
 
PDE1  isoforms  are  dimers  and  although  they  have  been  found  in  the 
cytosolic, some studies suggest that they can exist in particulate fractions of 
olfactory neurons and plasma membrane (Goraya and Cooper; 2005, Francis 
2001). PDE1 activity can be inhibited by vinopectine and nicardipine (Houslay 
2001).  PDE1  activity  can  be  regulated  by  PKA  and  Cam  Kinase  II 
phosphorylation (Lugnier; 2006).  
 
1.6.2 Phosphodiesterase-2  
 
Beavo and coworkers (Beavo et al, 1971) first discovered phosphodiesterase 
2  in  1971  in  rat  liver  preparations  where  they  showed  that  the  enzyme 
hydrolysed cAMP more effectively in the presence of cGMP.  Three splice 
variants;  PDE2A1  PDE2A2  and  PDE2A3  respectively  are  generated  from 
PDE2 gene. PDE2A2 is more hydrophobic than the other two splice variants 
of  the  family.  PDE2  enzymes,  like  PDE1,  are  dual-specific  and  hydrolyse 
cGMP  and  cAMP  with  Km  values  10µmol/  L  and  30µmol/  L  respectively 
(Zaccolo and Movsesian; 2007).  
 
cGMP  plays  an  important  role  in  the  regulation  of  PDE2  activity.  cGMP 
activates PDE2 in all or none fashion by binding to its GAF domain located 
between the N-terminal region and catalytic region of the enzymes. At higher 
concentrations cGMP inhibits cAMP hydrolysis of PDE2 by competitive effects 
at  the  catalytic  site  (Wu  et  al;  2004).  PDE2  isoforms  have  been  shown  to 
localise to sub-cellular membrane structures such as Golgi and perinuclear   16 
membranes. Phosphorylation by PKC α-isoform has been shown to activate 
the  PDE2  enzymes  in  live  rat  Golgi  endosomal  fractions  under  PMA 
stimulation (Geoffroy et al; 1999). PDE2 enzymes can be selectively inhibited 
by EHNA and non-selectively by IBMX (Lugniere et al, 1986).  
 
1.6.3 Phosphodiesterase-3 
 
PDE3 isoforms show high affinity to both cAMP and cGMP and are inhibited 
by  cilostamide  and  milrinone.  Two  genes  A  and  B  encode  different  PDE3 
isoforms which are different from other PDEs in that they have a 44 amino 
acid  insert  in  their  catalytic  region  and  determine  their  affinity  to  cGMP 
(Manganiello  et  al;  1995).  PDE3  isoforms  show  high  affinity  to  cGMP  but 
hydrolyse  cAMP  at  a  10-fold  greater  rate  than  cGMP  and  are  therefore 
classed as being inhibited by cGMP (Beavo; 1995).   
 
PDE3A  isoforms  are  expressed  widely  in  muscle  tissue,  myocardium  and 
platelets.  However,  PDE3B  isoforms  are  expressed  in  adipocytes  and 
hepatocytes (Beavo, 1995). PDE3 enzymes are regulated by various kinases 
as well as by hormones. They are phosphorylated by both PKA and PKB/Akt. 
Phosphorylation by either kinase has been shown to activate the enzymes. 
Also,  hormones  such  as  insulin  and  glucagon  are  known  to  activate  the 
enzyme in Golgi-Endosomal fractions of rat liver tissue by the action of PKB 
and PKA, respectively (Zaccolo; 2007, Geoffroy et al, 2001, Kitamura et al; 
1999,  Beavo;  1995).    PDE3B  is  expressed  in  pancreatic  islets  where  it  is 
known to mediate the effects of leptin on insulin release. Furthermore, PDE3B 
inhibitors have been shown to increase glucose-mediated insulin release. This 
effect is attributed to the function of cGMP in islet cells. Inhibition of PDE3B in 
beta cells leads to elevation of cGMP levels which in turn leads to elevation of 
cAMP  levels  and  Ca
+2-mediated  exocytosis.  However,  PDE3B-mediated 
cross talk between cAMP-cGMP pathways in islet beta cells has not been well 
documented (Pyne and Furman, 2003). 
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1.6.4 Phosphodiesterase-5 
 
PDE5 is a cGMP-specific, rolipram-insensitive phosphodiesterase that can be 
inhibited by zaprinast (Hamet and Coquil; 1978, Lugnier et al; 1986).  PDE5 
gene encodes three splice variants from two alternate promoters (Lin et al; 
2002, Loughney et al; 1998). PDE5 isoforms are expressed in lung , kidney, 
brain and platelets where they contribute to regulation of cGMP levels (Pyne 
and  Burns,  1993,  Giordano  et  al;  2001,  Kameni  Tcheudji  et  al;  2001). 
Expression of PDE5A1 and A2 in pulmonary artery smooth muscle cells is 
elevated by hypoxic conditions (Murray et al; 2002).  
 
PDE5 activity has a vaso-relaxing effect that is mediated through nitric oxide 
(NO) and cGMP (martin et al; 1986, Schoeffter et al; 1987, Prickaerts et al; 
2004). PDE5 activity is shown regulate object and spatial memory in rodents. 
Elevation  of  cGMP  levels  by  inhibiting  PDE5  isoforms  led  to  enhanced 
memory  performance  which  was  mediated  through  hippocampal regions  in 
rodents (Prickaerts et al; 2004).   
 
Cellular  cGMP  levels  and  PKA  phosphorylation  regulate  PDE5  activity. 
Binding of cGMP to PDE5 is required for its phosphorylation by PKA, which in 
turn leads to increased affinity for cGMP (Burns et al; 1992 and Francis et al; 
2002).  Hanson  et  al;  1998,  have  shown  that  PDE5  plays  a  crucial  role  in 
perinatal vascular resistance (PVR) in ovine and murine prenatal development 
by regulating the cGMP levels. They have also shown that mRNA and protein 
levels of PDE5 decrease within the one hour of birth when PVR decreases. 
However, mRNA and protein levels of PDE5 undergo a secondary increase 
between the 4-7days after birth.  PDE5 has also been shown to be involved in 
fluid transport in malphigian tubules that form a part of arthropod excretory 
system by regulating cGMP levels (Broderick et al, 2004). 
 
PDE5A1 is known to interact with the pro-apoptotic protease caspase-3 upon 
an  apoptotic  stimulus  both  in  vitro  and  in  vivo.  This  interaction  leads  to 
cleavage and subsequent inactivation of the enzyme (Frame et al, 2003). In 
the presence of the gamma subunit of PDE6 the proteolysis of PDE5A1 by   18 
caspase-3 is increased, contrary to the action of caspase on PDE6 isoforms 
in the presence of its gamma subunit (Frame et al; 2001).  
  
1.6.5 Phosphodiesterase-6 
 
Phosphodiesterase 6 was first discovered in retinal rods. It hydrolyses cGMP 
specifically  and  is  zaprinast  inhibited  (Beavo,  1995,  Goridis  and  Viramaux, 
1974). PDE6 is a heterodimer complex containing two catalytic subunits (α in 
rods and ά in cones and a β subunit), two inhibitory subunits (γ in rods and γ’ 
in  cones),  and  a  δ  prenyl  binding  protein  (PrBP)  subunit,  all  of  which  are 
encoded by separate genes, A for α subunit, B for β subunit, C for ά, D for δ 
subunit, G for γ and H for γ’ subunits (Lugnier, 2006). As well as  binding to 
prenylated photoreceptor proteins such as  GRK7 and Rab8, PrBP binds to 
the catalytic subunits of membrane bound PDE6 and has been suggested to 
reduce  transducin-mediated  activation  of  the  phosphodiesterase  in  frogs 
(Norton et al; 2005).  
 
PDE  plays  a  major  in  visual  cycle.  Briefly,  activated  rhodopsin  activates 
transducin molecules, which are G protein heterotrimers, which exist in GDP-
bound  inactive  and  GTP-bound  active  states.  Activated,  GTP-bound 
transducin binds to catalytic subunits of PDE6 and increases affinity of the 
enzyme for cGMP and leads to hydrolysis of the cyclic nucleotide. A decrease 
in cGMP concentration activates the CNG, which leads to sensory responses 
through the optic nerve (Ionita and Pittler, 2007). PDE6 is negatively regulated 
by  individual  phosphorylation  of  PKC  and  CDK-5  (Hayashi  et  al;  2002, 
Udovichenko et al; 1994, Udovichenko et al, 1996). The degradation of PDE6 
by caspase-3 is modulated by gamma subunit of the PDE (Frame et al. 2001). 
In the presence of PDE6 rod gamma subunit casapse-3 was shown to exhibit 
reduced PDE6 proteolysis.  
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1.6.6 Phosphodiesterase-7 
 
In 1993, Michael and workers (Michaeli et al; 1993) isolated and characterised 
a cAMP phosphodiesterase different from both PDE3 and PDE4 isoforms and 
called it HCP1 (High affinity cAMP-specific PDE). It was later re-named as 
PDE7 (Beavo, 1995). PDE7 is not sensitive to cGMP and is not inhibited by 
the PDE3 and/or PDE4 selective inhibitors like milrinone and rolipram.  
 
The PDE7 family comprises two different subfamilies of isoforms, 7A and 7B 
(Han et al 1997, Gardner et al; 2000, Sasaki et al; 2000). PDE7A was initially 
thought  to  be  crucial  in  T-cell  function.  T-Cell  receptors,  Cd23  and  CD28 
when stimulated increase the expression of PDE7A and thus decrease cAMP 
levels and PKA activity in T-cells (Li et al, 1999). PDE7A is also known to be 
involved in T-cell proliferation and regulating the production of chemokines 
such as IL-2, 4 and 7 (Li et al; 1999 and Nakata et al; 2002). However, further 
studies  (Yang  et  al  2003)  showed  that  PDE7A  is  not  necessary  for  T-cell 
function. Indeed, transgenic mice lacking PDE7A gene were found to have 
functional T-cells. The absence of PDE7A did not affect the IL-2 production 
driven by Cd23 and cd28 or T-cell proliferation suggesting that T-cell function 
is not regulated by PDE7A (Yang et al; 2003)  
 
PDE7B is implicated in dopaminergic signalling. Primary striatal cells treated 
with  dopamine  showed  elevated  levels  of  PDE7B,  which  is  believed  to 
mediate  through  a  cAMP-PKA-CREB  cascade,  which  promotes  PDE7B 
transcription (Sasaki et al; 2004).   
 
1.6.7 Phosphodiesterase-8 
 
Two different subfamilies of PDE8, namely A and B, were first identified and 
cloned by three different groups from both mouse and human (Fisher et al; 
1998, Hayashi et al; 1998 and Soderling et al; 1999).  
 
PDE8A and PDE8B have 5 and 4 splice variants, respectively (Hayashi et al; 
2002, Wang et al, 2001). The PDE8 family is insensitive to the PDE4 cAMP   20 
specific selective inhibitor, rolipram and, surprisingly, the non-selective PDE 
inhibitor,  IBMX.  However,  PDE8B  subfamily  is  sensitive  to  EHNA  and 
inhibitors of PDE5 (Fisher et al, 1998). PDE8 isoforms have an N-terminus 
that is homologous to PAS domain of many signalling protein (Soderling et al 
1998). The role of the PAS domain is not known but it has been suggested it 
may  be  involved  in  either  PDE  dimer  formation  or  promote  protein-protein 
interactions.  
 
1.6.8 Phosphodiesterase-9 
 
In  1998,  Fisher  and  coworkers  (Fisher  et  al  1998)  identified 
Phosphodiesterase 9. Although the PDE9A family was originally thought to 
have only 4-splice variants (Guipponi et al; 1998, Rentero et al; 2003) at least 
20 mRNA splice variants have identified have since been identified. PDE9A1 
specifically  hydrolyses  cGMP  and  is  insensitive  to  IBMX  and  the  PDE5 
selective  inhibitor,  sildenafil.  However,  it  is  sensitive  to  the  PDE5  inhibitor 
SH51866,  which  is  also  a  PDE1  inhibitor  (Soderling  et  al;  1998).  PDE9 
isoforms  show  varied  localisation  within  the  cell  (Renetero  et  al;  2006). 
PDE9A1  isoform  is  exclusively  localised  to  the  nucleus  whereas  PDE9A5 
isoform is cytoplasmic (Wang et al, 2003).   
 
1.6.9 Phosphodiesterase –10 
 
PDE10 is dual-substrate specific enzyme family. It has two mRNA alternative 
splice  variants,  PDE10A1  and  PDE10A2  (Kotera  et  al;  1999).  PDE10A 
contains two GAF domains although its structure is significantly different from 
other  cGMP-specific  PDEs  like  PDE5  and  PDE6.  PDE10  hydrolyses  both 
cGMP and cAMP. However, it shows more affinity to cAMP (Fujishige et al; 
2000). PDE10A is inhibited by IBMX, zaprinast, SCH51866 but is not inhibited 
by sildenafil and EHNA (Soderling et al; 1999). PDE10A2 is known to localise 
to intracellular membrane fractions like Golgi apparatus (Kotera et al; 2004). 
However  upon  PKA  phosphorylation  at  Thr16,  PDE10A2  was  shown  to 
localise to cytosol suggesting the role of PKA in determining the sub-cellular 
localisation of the isoform (Kotera et al; 2004).   21 
1.6.10 Phosphodiesterase-11 
 
PDE11 is also a dual-substrate specific family of PDEs and is sensitive to 
IBMX,  dipyridamole  and  zaprinast  (Fawcett  et  al;  2000).  Despite  the  dual 
substrate specificity and presence of GAF domains these enzymes are not 
activated by either of the cyclic nucleotides. (Yuasa et al, 2000). So far, four 
splice variants have been identified of which PDE11A3 and PDE11A4 are well 
characterised. Interestingly, PDE11A4 contains two complete GAF domains 
whereas PDE11A3 contains one complete and one incomplete GAF domains. 
Also,  PDE11A4  contains  putative  phosphorylation  sites  for  both  PKA  and 
PKG.  However,  PDE11A3  lacks  phosphorylation  sites  for  both  the  kinases 
suggesting that these isoforms differ in their N-terminal regions, which is a 
common phenomenon observed on PDE superfamily (Hetman et al; 2000 and 
Yuasa et al, 2000).   
   22 
 
 
 
 
 
Figure  1.3  Modular  structures  of  PDE  enzyme-superfamily  (Adapted 
from Lynch et al, 2006) 
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1.7 cAMP Phosphodiesterase 4  
 
1.7.1  Phosphodiesterase gene and structure 
   
Phosphodiesterase-4 (PDE4) enzymes are a family of more than 20 isoforms 
encoded by four genes A, B, C and D (Conti et al 2003, Houslay et al; 2005, 
Houslay  et  al,  2004).  The  dunce
+ PDE4  gene  was  cloned  from  Drosophila 
melanogaster (Davis et al; 1989) and was used to identify the mammalian 
homologues  by  Swinnen  and  coworkers  (Swinnen  et  al;  1989).  They  also 
showed that the different PDE4 isoforms arise by alternative mRNA splicing 
which was confirmed and extended in studies of the human forms (Bolger et 
al; 1996).  
 
Genes  encoding  PDE4  isoforms  are  located  on  various  chromosomes. 
PDE4D subfamily is located on chromosome 5 in humans and chromosome 2 
in rats, whereas PDE4B subfamily is located on human chromosome 1 and 
rat chromosome 5 (Szpirer et al, 1995). PDE4A and PDE4C are located on 
chromosome  19  at  19p13.2  and  p13.1  respectively  (Engels  et  al;  1995, 
Horton et al; 1995, Sullivan et al; 1994). The mRNA splice variation generates 
PDE4  isoforms  each  possessing  a  unique  N-terminal  region  with  two 
upstream  conserved  regions  (UCR1  and  UCR2)  and  a  highly  conserved 
catalytic  unit  (Bolger  et  al;  1996).  The  residues  of  the  extreme  C-terminal 
region of the catalytic unit are unique to each of the four sub families (Bolger 
et al; 1996).  The UCR1 is 60 amino acids in length and the UCR2 has 80 
amino acids long. The UCR1 domain is linked to the UCR2 by linker region 
1(LR1) which is 24 amino acids long and UCR2 is linked to the catalytic unit 
(320-350  amino  acids  in  length) by  LR2,  which  is  10-28 amino  acids  long 
(Conti and Jin; 1999, Houslay and Adams, 2003, Lynch et al 2006).  
 
 PDE4 isoforms can be classified into three groups; Long, short and super-
short  forms.  Long  forms  have  a unique  N-terminal  region,  complete  UCR1 
and UCR2 regions, catalytic region and a C-terminal region. Short forms lack 
the UCR1 region while super-short forms lack UCR1 and have an N-terminally 
truncated UCR2. A representation of PDE4 structure is shown in Figure 1.4.    24 
 
 
 
 
 
 
 
  
Figure 1.4 Schematic of modular structures of PDE4 isoforms 
 
1.7.2  Catalytic Domain 
 
          Interpreting  the  mechanisms  involving  the  catalytic  activity  of  PDE4 
isoforms requires knowledge of PDE4 structure. Xu and coworkers (Xu et al; 
2000)  were  the  first  to  determine  the  structure  of  a  PDE  catalytic  domain, 
namely the catalytic unit of PDE4B. It was determined that catalytic domain of 
the PDE4 has 17α helices, which form 3 distinct sub domains. The first sub-
domain contains four α helices connected by two inter-connecting loops. The 
second sub-domain contains two α helices that are oriented perpendicular to 
two  anti-parallel  α  helices.  The  third  sub-domain  is  composed  of  five  of α 
helices and an extended β-hairpin loop (Xu et al 2000). 
 
          A  deep  pocket  of  21  residues  in  the  COOH-terminal  sub-domain 
extends into the junction of the three sub-domains. All 21 residues are highly 
conserved in all the 11 PDE families. Twenty of these residues lie near the 
pocket and 12 lie within the pocket.  The pocket accommodates a molecule of 
either cAMP substrate or 5’AMP product and is lined with negatively charged 
and hydrophobic amino acids (Xu et al 2000).  The deep pocket serves as a 
substrate-binding site and has two divalent cation binding sites. Metal binding 
site 1 (Me1) is the deeper set and holds the ion by four direct interactions with 
His
238, His
274, Asp
275, and Asp
392. Metal binding site 2 is slightly superficial in 
location and is close to the Me1. The Me1 is usually occupied by a Zn
+2 ion 
and is very tightly held. The Me2 can bind Mn
+2, Mg
+2 or Zn
+2. However, the 
Short 
Super- short 
Long 
Catalytic unit 
Isoform-specific 
N-terminal region 
UCR1
1 
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physiologically relevant ion is thought to be Mg
+2 (Houslay MD and Adams 
DR; 2003).  
 
Depending upon the kinetics of rolipram binding to the catalytic unit, the PDE4 
isoforms can exist in two conformational states namely a high affinity rolipram 
binding  site  (HARBS)  and  or  a  low  affinity  rolipram  binding  site  (LARBS) 
(Souness and Rao; 1997). The LARBS conformation is seen in the inactive 
enzyme and the HARBS is seen in catalytically active enzyme. Divalent cation
 
binding plays an important role in releasing the product of cAMP hydrolysis 
from the catalytic site (Laliberte et al; 2002, Liu et al; 2001). PDE4 isoforms 
upon phosphorylation and activation by PKA change their affinity to rolipram 
and  convert  to  a  HARBS  conformation  (Hoffmann  et  al,  1998).  PDE4 
interaction with various binding partners such as SRC tyrosyl kinases, XAP2, 
RACK1  has  has  also  been  shown  to  change  the  rolipram  affinity  of  the 
isoforms (Bolger et al; 2003 and McPhee et al; 1996, Yarwood et al 1999). 
(Please refer to appendix II for an Image of catalytic subunit) 
 
1.7.3                PDE4 isoforms 
 
1.7.3.1  Phosphodiesterase- 4A 
 
PDE4A  isoforms  differ  from  other  PDE4  subfamilies  in  that  they  their  C 
terminus  is  not  conserved  and  that  they  are  not  inhibited  by  ERK 
phosphorylation  (Mackenzie  et  al,  2000).  PDE4A1  is  a  super-short  form 
(Sullivan et al; 1998). PDE4A4 is human homologue of rat PDE4A5 both of 
which are long forms. PDE4A7 is the only PDE4 isoform that is spliced both 
on the 3’ and 5’ ends of the mRNA transcript (Sullivan, 1998) and it lacks the 
residues that confer catalytic activity (Johnston et al, 2004). PDE4A10 and 
4A11  are  also  long  forms  (Wallace  et  al;  2005  and  Rena  et  al  2001). 
PDE4A10  is  known  to  be  upregulated  in  differentiated  monocytes  and 
macrophages  (Shepherd  et  al;  2004).  PDE4A11  is  localised  to  both 
particulate and soluble cellular fractions (Wallace et al; 2005).   
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1.7.3.2  Phosphodiesterase -4B 
 
PDE4B1, 4B3 and 4B4 are long forms so far reported from PDE4B subfamily. 
PDE4B1  is  a  human  isoform  whereas  B3  and  B4  are  expressed  in  rat 
(Shepherd,  2003  and  Huston  et  al; 1997). PDE4B2  is  a  short  form  that  is 
expressed in both humans and rat. PDEB5 is a super-short form expressed 
only in brain and its N-terminal region is identical to that of  PDE4D6 (Cheung 
et al; 2007), the first time, to date, this phenomenon has been noted. 
 
1.7.3.3  Phosphodiesterase-4C 
 
Three  isoforms have  been  reported  from  PDE4C  family  by  various  groups 
(Engels, et al; 1995 Owens et al, 1997 and Obernolte et al, 1997), all of which 
are long isoforms. It has been argued that it is unlikely for a PDE4C short form 
to exist because of the lack of space between long form exons (Sullivan et al; 
1999).  However,  other  studies  (Obernolte  et  al;  1997)  have  identified  four 
splice variants. Isoforms PDE4C-791 and 426 were isolated from foetal lung 
whereas PDE4C delta-54 and delta 109 were isolated from testis mRNA.  
 
1.7.3.4  Phosphodiesterase-4D 
 
PDE4D encodes 9 isoforms 4D1-4D9 (Bolger et al; 1997). PDE4D1 is a short 
form and PDE4D2 is super-short form (Nemoz et al; 1996). PDE4D3, 4D4 and 
4D5 are long forms (Bolger et al; 1997). PDE4D6 is a brain-specific super-
short  form  and  PDE4D7  is  a  long  form  (Wang  et  al;  2003).  PDE4D8  and 
PDE4D9 are long forms that are closely related to PDE4D3 (Richter et al; 
2005).  
 
1.7.4  Regulation of PDE4 isoforms 
 
1.7.4.1 Transcriptional regulation of PDE4 isoforms  
 
             Cyclic AMP sensitive promoters regulate cellular PDE4 activity at a 
transcriptional level. Follicle stimulating hormone (FSH)-mediated elevation of   27 
cAMP levels in sertoli cells were shown to elevate the mRNA transcripts and 
protein levels of PDE4D family enzymes particularly PDE4D1 and PDE4D2 
(Vicini and Conti; 1997) This elevation in protein levels was due to cAMP-
mediated activation of promoters of PDE4D1 and 4D2.  Similarly, Jurkart-T 
cells pre-treated with 8-bromo-cAMP or with Prostaglandin E2 increased the 
protein  levels  of  PDE4D1-D3,  PDE4A4  and  PDE3  in  a  protein  synthesis 
sensitive manner as confirmed by using Actinomycin D to inhibit transcription 
and Cycoheximide to inhibit translation suggesting that elevated cAMP levels 
directly impact cellular PDE4 expression (Seybold et al; 1998). Furthermore, 
Oxo-7-prostacyclin-treated  rats  exhibited  a  marked  change  in  expression 
profile of the PDE4 isoforms in heart tissue. Forty-eight hours post-treatment, 
levels  of  mRNA  transcripts  of  PDE4B3  were  elevated  while  the  levels  of 
mRNA transcript levels of isoforms D1, D2 and D3 Kosti et al; 1997). The 5` 
flanking  sequence  of  PDE4A10  exon-1  is  shown  to  have  cell  type-specific 
promoter-like activity (Rena et al; 2001). Furthermore, two regions upstream 
to  exon-1
4A10  identified  in  mouse,  namely  A  and  B,  were  shown  to  bind 
transcription  factors.  Region  B  has  binding  sites  for  transcription  factors 
CREB,  GATA,  Nuclear  factor-κB  and  H2O2-activated  USF  suggesting  that 
PDE4A10  might  be  involved  in  inflammatory  response  (Rena  et  al;  2001). 
Similar studies on PDE4A11 (Wallace et al; 2005) of a region 1 Kb upstream 
of exon-1
4A11 identified a potential transcription binding site as identified by an 
increase  in  luciferase  activity  in  reporter  construct  assays  The  PDE4D 
subfamily  has  also  been  shown  to  be  subject  to  transcriptional  regulation. 
Exons encoding isoform-specific N-terminal regions of PDE4D5 were shown 
to  exhibit  promoter  activity  (Le  Jeune  et  al;  2002).  This  transcriptional 
regulation is reported to be driven by cAMP due to the presence of a CRE site 
upstream  of  the  exon  (Le  Jeune  et  al;  2002).  Transcriptional  regulation  of 
PDE4D1 and PDE4D2 has also been noted (Vicini and Conti, 1997). 
 
1.7.4.2 Regulation by Protein Kinase A 
 
 In  1996,  Sette  and  Conti reported that  PDE4  isoforms  are  activated  upon 
phosphorylation by cAMP dependent protein Kinase (PKA) from observations 
of rat thyroid cells stimulated with TSH. PDE4D3 was the first studied isoform   28 
for  PKA  phosphorylation.  The  target  sites  were  mapped  within  two  PKA 
consensus sites at Ser
13 and Ser 
54. Ser
13 is located with PDE4D3’s unique N-
terminal  region  while  Ser 
54  is  in  the  UCR1  region  (Alvarez  et  al;  1995, 
Hoffmann et al; 1998, Sette and Conti, 1996). Although there are two PKA 
phosphorylation sites on PDE4D3 only Ser
54 is required for the activation of 
the enzyme (Sette and Conti 1996).   
 
PKA phosphorylation occurs at the R-R-E-S-F motif in UCR1 region, which is 
conserved in long PDE4 isoforms. PKA phosphorylation at this site activates 
the enzymes (MacKenzie et al 2002). The glutamate residue present in PKA 
consensus  site  is  highly  conserved  in  all  PDE4  long  forms  and  has  an 
inhibitory  affect  on  PKA  phosphorylation  (Hoffman  et  al;  1998).  Mutational 
analysis  of  the  glutamine  preceding  the  Ser  in  PKA  consensus  site  was 
shown  to  increase  PDE4  activity,  which  was  further  increased  by  PKA 
phosphorylation (Hoffmann et al; 1998).  
 
UCR1 and UCR2 bind with each other by electrostatic interactions between 
positively charged amino acids in UCR1 and negatively charged amino acids 
in UCR2, an interaction which is modulated by PKA phosphorylation (Beard et 
al;  2000). The  intramolecular  association  of  UCR1  and  UCR2  is  known  to 
form a module that has an inhibitory affect on catalytic unit. This inhibitory 
effect is abolished by phosphorylation of PKA on UCR1 region, which opens 
the module and thereby activates the enzyme (Lim et al, 1999).  
 
PKA phosphorylation is also known to have an affect on rolipram sensitivity of 
PDE4 long forms. PKA phosphorylation increases the rolipram-binding affinity 
of certain long-forms by switching on the HARBS conformation (Mackenzie et 
al; 2002 and Hoffman et al; 1999). 
 
1.7.4.3 Regulation by Extra-cellular signal regulated kinase 
 
            The ERK-MAP kinase family is a family of serine-threonine kinases 
and is one of the most important signalling cascades that can regulate the 
activity of the cAMP messenger system through crosstalk (Mackenzie 2000).   29 
ERK1  and  ERK2  are  members  of  MAP  Kinase  family.  Phosphorylation  by 
ERK requires three motifs, a kinase interaction motif (KIM), FQF domain and 
a  proline-directed  serine  consensus  motif  found  in  all  authentic  ERK 
substrates.  The KIM domain is located upstream of the target Ser/Thr and 
has  a  consensus  sequence  [Leu/Val]-Xaa-Xaa-  [Arg/Lys]-[Arg/Lys]-Xaa  (6)-
Leu-Xaa- [Leu/Ser]. FQF domain is downstream of the target Ser/Thr and has 
a consensus of Phe-Glu-Phe (Lynch et al; 2006, Houslay and Adams; 2003 
and Mackenzie et al, 2000).  
 
It  has  been  shown  that  PDE4  isoforms  are  substrates  for  the  ERK-MAP 
kinases.  ERK2  is  known  to  associate  with  the  PDE4  catalytic  subunit  by 
binding to the KIM domain and FQF site on an exposed β hairpin loop and α 
helix  respectively.  These  two  sites  flank  an  ERK  phosphorylation  site. 
Phosphorylation of long, short and super short forms of PDE4 enzymes by 
ERK  leads  to  either  the  activation  or  inhibition  of  the  particular  isoform 
depending  upon  the  presence  or  absence  of  UCR1/2  regulatory  modules 
(Hoffmann et al 1999 Mackenzie et al; 2000, Baillie et al; 2000, Baillie et al; 
2001) 
 
Ser
579 in PDE4D3 isoform is a target site of phosphorylation by ERK, which 
leads to the inhibition of the activity of PDE4D3. Interestingly, isoforms of the 
PDE4B,  4C  and  4D  subfamilies,  but  not  the  PDE4A  subfamilies,  are  ERK 
substrates. This is due the presence of a target Ser/Thr in a P-x-ser/Thr-P 
motif in the PDE4B, 4C and 4D families. In the PDE4A subfamily, one of the 
proline residues in the motif is replaced by and arginine. PDE4A subfamily of 
isoforms are therefore not inhibited by ERK2 (Baillie et al; 2000, Baillie et al; 
2001).  
 
As  mentioned,  PDE4D3  is  also  regulated  by  the  PKA-mediated 
phosphorylation at Ser
54 within UCR1, which leads to activation of the enzyme 
(Mackenzie  et  al;  2000).  The  phosphorylation  events  regulating  PDE4D3 
counteract  each  other  as  PKA-mediated  activation  is  ablated  by  the  ERK-
mediated inhibition of PDE4D3. This provides a regulatory system whereby 
ERK-mediated inhibition leads to an increase of cAMP levels which triggers   30 
the  subsequent  PKA-mediated  phosphorylation  and  activation  of  PDE4D3 
(Hoffmann R, 1999). PDE4D3 therefore provides a point of cross talk between 
the ERK MAP kinase pathway and cAMP pathway.  
 
Hill and coworkers (Hill et al, 2006) showed that PDE4D3 is activated rapidly 
and phosphorylated at Ser
579 and Ser
239 upon challenging RAW macrophages 
with hydrogen peroxide (H2O2). Phosphorylation at Ser
579 was revealed to be 
mediated  by  ERK  whereas  phosphorylation  at  Ser
239  occurred  by  as  yet 
unidentified  kinase  downstream  of  PI3  kinase.  Phosphorylation  at  Ser
239 
reverses the inhibitory effect caused by phosphorylation at Ser
579 by ERK. It is 
proposed that phosphorylation at Ser
239 might reverse the inhibitory effect of 
ERK  phosphorylation  by  inhibiting  the  interaction  of  UCR1-UCR2-catalytic 
region.  
 
1.7.4.4 Regulation by Phosphatidyl Inositol Kinase-3 
 
PDE4A5,  a  rat  homologue  of  human  PDE4A4,  is  activated  and 
phosphorylated by an unknown kinase downstream to PI3 kinase in F442-pre-
adipocytes  activated  by  Growth  hormone  stimulation  and  contributed  to 
differentiation of the pre-adipocytes into adipocytes (Mackenzie et al, 1998). 
Activation and differentiation were not seen when the cells were treated with 
PI3-kinase  inhibitors  such  as  wortmannin  and  Ly294002.  In  further  studies 
(Yarwood et al; 1999) differentiation was reported to be transduced through a 
Janus  Kinase–2  and  Signal  Transducer  and  activator  of  Transcription-5 
(STAT5) pathway.  
 
1.7.4.5 The action of Phospholipids 
 
It  has  been  suggested  that  certain  PDE4  long  forms  can  be  activated  by 
acidic  phospholipids.  This  activation  is  not  seen  in  short  and  super-short 
forms. Lysophosphatidic acid and phosphatidyl-serine, but not phosphatidyl 
choline, increase the activity of PDE4D3 activity up to 3-fold (Disanto et al, 
1995  and  Nemoz  et  al,  1997).  Subsequent  work  (Garange  et  al;  2000)   31 
showed that phosphatidic acid failed to activate a UCR1 deletion mutant of 
PDE4D3.  
 
Studies from our group (Baillie et al; 2002) identified a novel phosphatidic acid 
binding  domain  in  the  N-terminus  of  PDE4A1.  This  domain  was  named 
TAPAS1  (tryptophan  anchoring  phosphatidic  acid  selective  domain).  The 
sequence  of  the TAPAS  domain  is  LVXaaWWDXaaXaa  K/R,  where  residues 
LVXWW  are  needed  for  membrane  insertion  and  residues  DXXK/R  are 
needed  for  calcium  binding.  The  TAPAS  domain  uses  submicromolar  free 
calcium ions to bind to Asp21 in PDE4A1, allowing insertion of this isoform 
into membranes. This feature is analogous to that of annexin whereby calcium 
binding switches on a conformation that exposes the tryptophan residues in 
the protein such that they can be inserted into the membrane (Campos et al; 
1998).  
 
1.8  Targeting of PDE4 isoforms to signalling complexes 
 
It is now widely appreciated that cAMP signalling is compartmentalised within 
cells (Houslay et al; 2007, Zaccolo 2006, Zaccolo et al; 2006, Lissandron et 
al; 2006, Terrin et al; 2006, Houslay and Adams, 2003). Buxton and Brunton, 
in 1983, for the first time showed that ventricular myocytes challenged with 
isoprenaline and prostaglandin E1 produced different responses on glycogen 
phosphorylase  activity  suggesting  that  their  cAMP  responses  are 
compartmentalised. Recently, Zaccolo and Pozzan; 2002 have demonstrated 
the presence of distinct pools of cAMP in live neonatal cardiomyocytes using 
fluorescence resonance energy tranfer (FRET) technology.  
 
PDE4 isoforms have been shown to contain regions that confer a high degree 
of  specificity  in  allowing  them  to  interact  with  a  wide  variety  of  signalling 
complexes. This allows PDE4 isoforms to regulate the cAMP levels in specific 
intracellular  compartments (Lynch  et  al;  2006,  Houslay and  Adams,  2003). 
The following section discusses the various signalling PDE4 binding proteins 
which have been shown to regulate compartmentalisation of cAMP signalling. 
A schematic of cAMP signalling is shown in Figure 1.5.    32 
1.8.1 β-arrestins 
 
           Arrestins are ubiquitously expressed scaffold proteins and are of two 
types, visual arrestins and β-arrestins. Visual arrestins are expressed only in 
retinal tissue (Yamaki et al, 1987 and Shinohara et al 1987), whereas the β-
arrestins  are  expressed  in  all  tissues  particularly  in  the  brain  and  spleen 
(Attramadal et al; 1992). Visual arrestins play an important mechanistic role in 
the visual responses whereas β-arrestins are involved in complex signalling 
pathways including GPCR desensitisation (Lefkowitz and Shenoy; 2005 and 
Luttrell and Lefkowitz, 2002).  
 
           Recently,  it  has  been  demonstrated  that  PDE4D5  interacts  with  β-
arrestins  (Bolger  G.  B  et  al,  2003).  PDE4D  isoforms  are  ubiquitously 
expressed in a wide range of cell types and PDE4D3 and PDE4D5 are the 
most  predominant  isoforms  (Conti  M;  2003).  Specifically,  the  interaction 
appears to involve amino acid residues 70-88 within the unique N-terminal 
region of PDE4D5 (Bolger et al, 2006). Two hybrid assays show that both the 
unique N-terminal region and a portion of catalytic region are required for the 
interaction PDE4D5 with β-arrestins. Most probably the two different domains 
of βarrestins interact with the two interaction sites of PDE4D5. Indeed, the site 
within the conserved PDE4 catalytic region allows PDE4s from all subfamilies 
to interact with β-arrestin (Baillie et al; 2007 and Bolger G. B et al; 2003). β-
arrestins have two domains, N- and C- domains each of which are composed 
of seven-stranded β helix loops. Truncation experiments show that the amino 
terminal regions of both domains are required to interact with PDE4 isoforms. 
Also, residues K25 and R26 within a β helix loop of the N-terminus of arrestin 
have  been  shown  to  be  crucial  for  interaction  with  the  FXFELXL  and 
FQFELTLEED motifs present in the catalytic site of the PDE4 isoforms (Baillie 
et al; 2007 and Bolger et al 2003). It is through this site in the catalytic unit 
that all the PDE4 isoforms can potentially interact with β-arrestin. In case of 
PDE4D5,  an  additional  β-arrestin  binding  site  is  present  in  the  N-terminal 
region  of  the  isoform.  Whether  the  site  within  the  specific  amino  terminal 
region of PDE4D5 facilitates the binding of common binding site in catalytic   33 
site, or allows other proteins that interact with β-arrestin to bind is unknown. 
However, it is known that β-arrestin does not affect the enzymatic activity of 
the PDE4 enzymes (Bolger G. B et al, 2003).  
 
It has been recently reported that desensitisation of β2 adrenergic receptor 
involves  the  β-arrestin  mediated  recruitment  of  PDE4D5,  thus  leading  to 
decrease in cAMP levels around the receptor and eventually leading to re-
coupling of G proteins to the receptor. In contrast, the β1 adrenergic receptor 
shows  very  low  affinity  to  β-arrestins.  This  is  in  accordance  with  the 
observation that stimulation of cardiac contraction by β2-adrenergic receptor is 
transient  and  that  the  receptor  undergoes  desensitisation  very  quickly. 
However,  the  stimulation  of  cardiac  contraction  by  β1  adrenergic  receptor 
recovers very slowly. Furthermore, the activity of β1 adrenergic receptor is not 
affected by inhibiting PDE4D in β2-AR knockout murine myocytes, indicating 
that PDE4D is involved in regulating the activity of β2 AR, but not that of the 
β1-AR, thereby contributing to the differential regulation of cardiac contraction 
by adrenergic agonists (Xiang Y et al, 2005 and Lynch et al; 2005).  
 
Agonist-induced β2-AR desensitisation is also mediated by second messenger 
responses. PKA tethered to AKAP5 is constitutively bound to the receptor and 
subsequently phosphorylates the receptor upon ligand activation. Similarly, an 
agonist-mediated PKA-AKAP79 complex is recruited to the receptor inducing 
receptor  phosphorylation  eventually  leading  to  receptor  desensitisation 
(Willoughby et al; 2006, Houslay and Baillie; 2005, Lynch et al; 2005, Fraser 
et al; 2000, Tao et al; 2003). PKA-mediated phosphorylation of the receptor 
leads switching of receptor coupling from Gs to Gi. This Gs to Gi switching now 
allows for ERK1/2 activation through Src recruitment to the complex (Baillie et 
al; 2003).  
 
PKA (Cong et al; 2001) or PKC (Krasel et al; 2001) -mediated phosphorylation 
and activation of GRK2 leads to its increased interaction with Gαβγ subunits 
and desensitisation of the β2-AR receptor by GRK2 phosphorylation (Li et al; 
2006). This activation and recruitment of GRK2 to the β2 AR is reversed by   34 
ERK phosphorylation of GRK2, which decreases its affinity for Gαβγ. Li and 
coworkers (Li et al. 2006) showed that PKA phosphorylation of the receptor 
and  its  subsequent  switching  from  Gs  to  Gi  signalling  is  controlled  by 
recruitment of a β-arrestin-PDE4D5 complex to the receptor where PDE4D5 
regulates  the  levels  of  cAMP  and  thereby  PKA  activity  and  prevents 
inappropriate recruitment of GRK2 to the membrane.  
 
Abrahamsen  and  coworkers  (Abrahamsen  et  al;  2004)  showed  that  T  cell 
activation  is  initiated  in  lipid  rich  membrane  micro-domains  known  as  lipid 
rafts and leads to the production of cAMP within these lipid rafts. Concomitant 
stimulation of CD-28 (cluster of differentiation), induces β-arrestin dependent 
recruitment of PDE4 enzymes to the lipid rafts The long isoform PDE4A4, the 
short isoforms PDE4B2, and PDE4D1/2 were all found to rapidly recruited to 
lipid  rafts  in  a  β-arrestin  dependent  process.  This  recruitment  of  PDE4 
enzymes to lipid rafts offers a way to downregulate the inhibitory affects of 
cAMP elevation on T-cell activation, which is mediated by PKA through a Csk-
Lck pathway (vang et al, 2003). The process of cAMP elevation in lipid rafts 
and PDE4 recruitment achieved only by activation of the T-cell receptor (TCR) 
and concomitant activation of CD28 as upon TCR stimulation alone, there is 
insufficient PDE4 to reduce the cAMP levels and therefore maximal T- cell 
activation cannot be achieved due to the inhibitory effects of cAMP signalling 
(Abrahamsen et al; 2004).   
Apart  from GPCR  desensitisation,  β-arrestins  are  also  involved  in  receptor 
internalisation. After receptor activation and desensitisation, β-arrestins binds 
to  adaptor  protein-2  (AP-2),  which  concentrates  the  receptor–βarrestin 
complex  to  clathrin-coated  pits  (Laporte  et  al;  1999  and  Goodman  et  al; 
1996). Once the receptor-arrestin complex reaches the clathrin-coated pits, 
the  pits  will  be  pinched  off  by  the  Src-phosphorylated  G  protein  dynamin 
(Sever,  2002).    Arrestin  then  dissociates  from  the  internalised  receptor 
complex which will be either degraded via proteasomal/lysosomal complex or 
recycled back to membrane after dephosphorylation by phoshphatase PP2A 
(Vaughan et al; 2006 and Oakley et al; 1999).  
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1.8.2 RACK1 
 
RACK1-Receptor  of  Activated  C-kinase  is  a  36  KDa  protein  with  a  seven 
bladed propeller structure, each blade consisting of β sheets. RACK1 has Trp-
Asp 40 (WD40) repeats. These repeats are highly conserved in a range of 
species. RACK1 serves as a binding protein for Protein kinase C. However, 
other proteins like Src, integrin β subunits, and γ-aminobutyric acid (GABA) 
are  also  known  to  interact  with  RACK1  (McCahill  et  al,  2002).  RACK1 
associates  with  proteins  in  either  a  constitutive  or  stimulus-dependent 
manner.  RACK1  has  multiple  independent  protein  binding  sites,  which 
suggest the individual blades of RACK1 may be able to interact with specific 
protein classes. Similar to its interaction with the Gβ and Gα subunits, the 
RAID1 (RACK1 Interaction Domain) within the N-terminal region of PDE4D5 
interacts with WD repeats on RACK1 (Bolger et al; 2006 and Yarwood et al; 
1999).  Recent work (Bolger et al. 2006) showed that RACK1 has a further 
PDE4  binding  site  within  the  catalytic  unit  suggesting  that  RACK1  might 
interact  with  other  isoforms  of  other  PDE4  subfamilies.  The  functional 
consequences  of  RACK1-PDE4  interaction  are  not  yet  known  but  it  is 
predicted  that  PDE4D5  interacting  with  RACK1  controls  the  cAMP  levels 
within  its  immediate  surroundings  and  alter  the  sensitivity  of  the  RACK1-
interacting proteins to PKA phosphorylation (McCahill et al, 2002). In support 
of this, it has been reported that RACK1 has a role in regulating the PKA 
activity  of the defective  CFTR  chloride  channel  in  cystic  fibrosis.  However, 
The  regulatory  mechanisms  of  this  process  are  still  unknown.  Its  been 
showed  that  activation  of  adenylyl  cyclase  and  subsequent  production  of 
cAMP  by  forskolin  caused  the  translocation  of  RACK1  to  nucleus  without 
altering  the  location  of  PKC  βII  (McCahill  et  al;  2002).  This  indicates  that 
RACK1 might be involved in shuttling of proteins into nucleus.  It has also 
been shown that inhibition of ethanol-induced compartmentalisation of RACK1 
is  inhibited  by  cAMP  analogues  that  prevent  activation  of  PKA  by  cAMP 
(McCahill  et  al;  2002).  Thus  PDE4-RACK1  interaction  may  have  a  role  in 
regulating the PKA activity within the environment of this scaffold.  
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1.8.3 AKAPs 
 
A  Kinase  Anchoring  Proteins,  known  as  AKAPs  for  short,  are  a  family  of 
proteins that can bind directly to regulatory subunit II of PKA (McConnachie et 
al;  2006  and  Newlon  M.  G.  et  al,  1999)  and  thus  generate  a 
compartmentalized PKA response to various intracellular gradients of cAMP. 
Although all most all AKAPs have been shown to bind RII subunit of PKA, 
some  AKAPs  like  AKAPCE  bind  to  RI  subunit  (Angelo  et  al;  2000).  The 
interaction  of  AKAPs  with  PKA  is  disrupted  by  peptide  likes  Ht31 
(McConnachie et al; 2006, Carr et al; 1992). Interestingly, some AKAPs like 
AKAP250,  also  known  as  gravin,  are  PKA  phosphorylated.  PKA 
phosphorylation is crucial for association of gravin to β2 AR and subsequent 
resensitisation of the receptor (Tao et al; 2003). To date more than 50 AKAPs 
have been identified and they show sparse homology. However, they share 
some a common RII subunit-binding domain (Wong and Scott; 2004).  
 
PDE4 isoforms have been shown to interact with certain AKAPs (Dodge K. L., 
et al 2001 and Asirvatham A. L et al. 2004). PDE4D3 has been reported to 
bind mAKAP (muscle–selective) and AKAP 450. AKAP 450 interacts with the 
UCR2 of PDE4D3, whereas mAKAP interacts with the N-terminal region of 
PDE4D3 (Dodge K. L., et al 2001).  
 
As  mentioned  previously,  PDE4D3  can  be  phosphorylated  by  PKA  at  two 
sites,  namely  Ser
13  and  Ser
54  (Sette  and  Conti  1996).  Phosphorylation  of 
PDE4D3 at Ser
54 by PKA bound to mAKAP leads to activation of the enzyme. 
This results in increased activity of PDE4D3, which decreases the local cAMP 
levels. This in turn, leads to deactivation of the mAKAP bound PKA, leading to 
the  dephosphorylation  and  deactivation  of  PDE4D3  itself.  Thus  these 
components form a signalling complex with unique feedback control (Dodge 
K. L., et al 2001). PKA phosphorylation at Ser 
13 of PDE4D3 increases the 
affinity of the isoform for mAKAP (Carlisle Michel et al; 2004) but does not 
alter the activity of PDE4D3.   
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 It has been shown that mAKAP recruits PDE4D3 to the nuclear envelope 
where  the  isoform  is  shown  to  be  in  a  complex  with  PKA,  the  ryanodine 
receptor  (RyR)  and  protein  phosphatase  2A.  This  complex  is  believed  to 
regulate  the  function  of  RyR  by  modulating  PKA  phosphorylation  of  the 
receptor as shown by elevated PKA phosphorylation of the receptor in PDE4D 
deficient-mice cardiac tissue (Lehnart et al; 2005 and Kapiloff et al; 2001). 
 
PDE4A interacts with AKAP95 and AKAP149 in T lymphocytes (Asirvatham et 
al. 2004).  AKAP95 has been identified in the nucleus of T lymphocytes and is 
known to interact with c-Myc binding protein. AKAP149 is known to be present 
in cytoplasm of the T cells and binds to phosphatase PP1 (Asiravatham et al. 
2004).  Since these AKAPs are organelle-specific and they bind to PKA and 
specific forms of PDE4s, it is likely these interactions play an important role in 
regulating cAMP homeostasis in T cells. 
 
AKAPs have been shown to be involved in a wide range of functions. They 
are  involved  in  sperm  mobility;  aquaporin-mediated  water  reabsorption  in 
renal collecting ducts; cell cycle progression and gene regulation (Bajpai et al; 
2006, McSorley et al; 2006, Tasken and Aandhal; 2004).  
 
1.8.4  XAP2 immunophilin 
 
Immunophilins  are  key  targets  for  immunosuppressive  drugs  including 
cyclosporin  and  rapamycin.  Most  immunophilins  are  known  to  have  a 
characteristic  amino  acid  sequence  known  as  the  Immunophilin  Domain 
(Bolger  et  al;  2003).  This  domain  in  many  immunophilins  has  a  rotamase 
activity, which is targeted by the drugs. Rotamases are those enzymes that 
enhance  the  rate  of  protein  folding  (Avramut  and  Achim,  2002). 
Immunophilins are also known to have protein chaperone function (Bolger et 
al;  2003).  XAP2  (AIP/Ara9)  is  an  immunophilin  that  does  not  have  these 
general functions (Bolger, G.B. et al 2003). 
 
XAP2 or Hepatitis B virus X-associated protein, also known as ARA9 or Aryl 
hydrocarbon receptor (AhR) Interacting Protein (AIP), has been shown to form   38 
a complex with Hsp90 and the dioxin receptor regulating the stability of the 
complex (Meyer and Perdew; 1999 and Kuzhandaivelu et al; 1996). XAP2 is 
also associated with regulation of transcriptional activity of both X-HBV and 
AhR (Meyer et al; 2000 and Meyer et al; 1998). XAP2, along with Hsp90, 
regulates  the  transcription  of  other  proteins  such  as  the  peroxisome 
proliferator  in  association  with  peroxisome  proliferator-activated  receptor 
alpha (PPARalpha) (Sumanasekera et al; 2003).  
 
PDE4A5 is targeted to both insoluble and soluble fractions of the cell (Beard, 
M.B. et al, 2002). Bolger and coworkers (Bolger et al 2003) showed that XAP2 
specifically  interacts  with  PDE4A5.  This  interaction  requires  the 
tetratricopeptide  repeat (TPR)  within  the  N-terminal  region  of  XAP2,  which 
interacts,  with  the  unique  N-terminal  region  of  PDE4A5  and  a  motif  within 
UCR2.  Arg
271  within  XAP2  TPR  interacts  with  an  EELD  motif  in  UCR2  of 
PDE4A5. The functional significance of this interaction is inhibition of PDE4A5 
activity  by  XAP2  in  a  non-competitive  way.  This  is  mediated  through  a 
regulatory region extended to the cAMP-binding site in PDE4A5, presumably 
UCR2. This interaction also evokes a decrease in sensitivity of the isoform 
towards  inhibition  by  the  specific  PDE4  inhibitor,  rolipram.  Furthermore, 
binding of XAP2 acts to inhibit PKA phosphorylation of PDE4A5 at Ser
140 in 
UCR1.  This  indicates  that  XAP2  and  UCR2  bind  to  similar  regions  within 
UCR1 of PDE4A5. This suggests that XAP2 blocking of PKA phosphorylation 
of UCR1 leads to changes in the conformation in UCR1 thereby preventing it 
from interacting with UCR2. The functional significance this interaction and 
subsequent  effects  on  PDE4A5  activity  are  yet  to  be  fully  appreciated. 
However,  given  the  expression  profiles  of  PDE4  isoforms,  particularly  the 
PDE4A subfamily in inflammatory cells and the role of AhR and complexes 
containing AhR in inflammatory diseases like COPD, it could be argued that 
PDE4A  and  XAP2  might  play  an  important  role  in  mediating  inflammatory 
responses (Wallace et al; 2005, Teske et al; 2005, Matinez et al; 2002). In 
support  of  this,  the  PDE4A4  isoform  has  been  reported  to  be  significantly 
elevated in monocytes from smokers (Barber et al; 2004).  
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1.8.5  SH3 binding domains 
 
           Src,  Lyn  and  Fyn  are  Src  homology  3  (SH3)  domain  containing 
tyrosine  kinases  that  regulate  the  function  of  a  wide  variety  of  cellular 
proteins.    They  are  globular  proteins  and  can  be  divided  into  two  classes 
depending upon their binding consensus motifs. Class I SH3 binding domains 
have a P-X-X-P motif, and confer specificity to interaction with Src Kinases 
(Ramos-Morales et al; 1994). Class II SH3 binding sites are variable and bind 
to  motifs  such  as  X-P-X-X-P-R  and  confer  specificity  to  interactions  with 
proteins  including  Crk  and  abl  (Alexandropoulos  et  al;  1995).  In  some 
instances,  SH3  binding  domains  are  known  to  bind  proteins  that  do  not 
contain this consensus sequence but have positively charged sequences (Jia 
et al; 2005 and Pawson; 1994).   
 
           PDE4A5 and PDE4D4 have been shown to be able to bind to SH3 
domains of Lyn, Fyn and Src kinases. PDE4D4 has also been identified to 
bind the SH3 domains of fodrin and abl tyrosine kinases. PDE4A5 has a P-X-
X-P motif whereas PDE4D4 has polyproline stretches (Beard M.B et al, 1999, 
McPhee et al; 1999 and O’Connell, 1996). The interaction was mapped to the 
N-terminal  region  PDE4A5,  the  truncation  of  which  prevented  the  tyrosyl 
kinase interaction. The probable function of such an association may be is to 
provide a means of regulating the affinity of PDE4A5 for cAMP and PDE4 
inhibitors.  It  is  suggested  that  SH3  domains  bound  to  PDE4A5  initiate 
conformational  changes  in  LR2  region  of  the  enzyme  thus  increasing  its 
affinity to rolipram thereby converting it to the HARBS conformation (McPhee 
et al; 1999). The interaction of PDE4A5 with SH3 binding domains is also 
known to change the subcellular localisation of PDE4A5 (Beard et al; 2002 
and Huston et al; 2000).  
 
Caspases  are  enzymes  involved  in  initiating  apoptotic  cell  death  and  their 
substrates have a consensus motif Asp-Xaa-Xaa-Asp within which cleavage 
by  caspase  occurs.  Caspase-3  cleavage  of  PDE4A5  N-terminal  region 
prevents  its  interaction  with  Lyn  and  ablates  the  ability  of  the  isoform  to 
localise to the perinuclear region (Huston et al; 2000). Caspase cleavage is   40 
specific to PDE4A5 and is not seen in other PDE4A isoforms (Wallace et al; 
2005). 
 
Since PDE4A5 is localised to membranes, it is also possible that PDE4A5-Src 
interactions might contribute to a reduction of local concentrations of cAMP 
surrounding the tyrosyl kinase and other proteins recruited to complexes at 
the plasma membrane. This would provide local and specific control of actions 
of cAMP, possibly mediated through PKA action, on such tyrosyl kinases and 
their  associated  complexes.  The  association  of  PDE4A5  N-terminal  region 
with SH3 domains might also help in regulating the activity of the PDE4A5 
and  targeting  PDE4A5  to  membrane  and  cytoskeletal  fractions  of  the  cell 
(O’Connell, 1996). 
 
1.8.6  Myomegalin 
 
Myomegalin is a scaffold protein related to Drosohphila centrosomin protein. 
The  C-terminus  of  Myomegalin  interacts  with  UCR2  region  of  PDE4D3  in 
yeast-two hybrid assays (Verde et al; 2001). Myomegalin is composed of α-
helical  and  coiled-coil  structures  and  shares  domains  with  microtubule 
associated  proteins.  It  co-localises  with  PDE4D3  at  the  sarcoplasmic 
reticulum  in  cultured  skeletal  muscle  cells  and  is  though  to  anchor  the 
PDE4D3 to golgi/centrosomal regions in Cos cells (Verde et al; 2001).  
 
1.8.7  Disrupted in Schizophrenia-1 
 
Disrupted-in-Schizophrenia  1(DISC1)  was  first  reported  to  be  linked  to 
schizophrenia  upon  the  observation  that  the  DISC1  was  disrupted  by 
translocation,  leading  to  DISC1  haploinsufficiency  in  cases  of  familial 
schizophrenia  (Millar  et al;  2000). More  recently,  a  translocation  within  the 
PDE4B gene has been linked to instances of inherited schizophrenia (Millar et 
al; 2005).  
 
DISC1 is thought have as many as 5-7 isoforms that  differ from each other in 
their  C-termini  and  share  a  common  N-terminal  region  although  some   41 
isoforms  like  c-75kDa  lack  N-terminal  regions  that  are  shared  among  the 
isoforms  and  is  thought  to  exist  as  homodimer.  DISC1  expression  is 
cytoplasmic but can also be detected at the mitochondria and nucleus (James 
et al; 2004).  
 
The N-terminal region of DISC1 has been shown to interact with the UCR2 
region  of  isoforms  from  all  PDE4  subfamilies  with  subfamily-specific 
differences  in  sensitivity  to  dissociation  from  DISC1  in  the  presence  of 
elevated  cAMP  (Millar  et  al;  2005;  Murdoch  et  al;  2007).  An  N-terminal 
truncated DISC1 was found to interact with PDE4B1 dynamically whereby its 
interaction with PDE4B1 was attenuated by elevating cellular cAMP levels or 
by PKA activation (Murdoch et al; 2007). However, this dynamic interaction 
was  not  observed  for  full-length  DISC1,  where  cAMP  elevation  failed  to 
dissociate  the  PDE4B1-DISC1  whilst  allowing  for  the  release  of  isoforms 
PDE4D3  and  PDE4C2.  The  possible  reason  for  this  is  that  the  full  length 
DISC1 isoform has extra binding sites for PDE4B1 within its N-terminal region 
which is not present in the shorter–isoform, thus making it insensitive to the 
actions of cAMP/PKA (Murdoch et al. 2007).  
 
Missense  mutations  within  in  the  DISC1  gene,  which  were  found  to  elicit 
schizophrenia-like  phenotype  in  mice,  were  revealed  to  be  located  within 
DISC1’s PDE4B1-specific binding regions (Clapcote et al. 2007). This would 
suggest that alterations in PDE4B1-DISC1 interactions, and associated cAMP 
signalling, might confer susceptibility to schizophrenia (Millar et al; 2007).  
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Figure 1.5 - Schematic presentation of the cAMP signalling system 
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1.8.8 PDE4 oligomerisaton 
 
The  concept  of  PDE4  oligo/dimerisation  has  been  proposed  by  various 
studies (Richter and Conti, 2004, Richter and Conti; 2002 and Lee et al; 2002, 
Rocque et al; 1997).  Rocque and coworkers suggested that purified PDE4B2 
exists as a dimer and showed that it exhibited different affinity for rolipram 
compared to its monomeric form. Mutating the N-terminal region the isoform 
drastically reduced its ability to dimerise.  
 
PDE4  oligomerisation  was  further  characterised  by  Richter  and  Conti  who 
showed that UCR1 and UCR2 might also have a role in oligomerisation of 
PDE4  long  forms.    Studies  from  our  group  (Beard  et  al  2000)  originally 
showed that the C-terminal half of UCR1 and the N-terminal half of UCR2 of 
PDE4D3 interact with each other internally. Richter and Conti suggested that 
this interaction might be switched from internal to external allowing UCR1 to 
interact with UCR2 on a dimer and vice versa. Considering positively charged 
residues  Arg-98  and  101  contained  within  the  UCR1  domain  of  PDE4D3 
interact with negatively charged residues Glu
146, Glu
147, and Asp
149 present 
within the UCR2 domain of the same molecule (Beard et al 2000), Richter and 
Conti proposed that these interactions may also occur between two molecules 
of  PDE4  isoforms  thus  leading  to  dimerisation  (Richter  and  Conti,  2004). 
Richter  and  Conti  demonstrated  that  PDE4D3  can  dimerise  and  that 
disruption of dimerisation ablates the PDE activity of the isoform mediated by 
either  PKA  phosphorylation  or  by  phosphatidic  acid  binding  (Richter  and 
Conti; 2004).  
 
Others (Lee et al; 2002) have suggested that the PDE4 C-terminal region is 
necessary  for  oligomerisation.  It  was  shown  that  C-terminal  truncates  of 
PDE4D  failed  to  oligomerise  whereas  full-length  PDE4D  and  the  Catalytic 
domain were able to oligomerise. Arg
358 was identified as a crucial residue in 
dimer interface which when mutated, prevented dimerisation. This finding was 
also  supported  by  gel  filtration  chromatography  analysis,  where  full-length 
isoforms  existing  as  oligomers  eluted  first,  followed  by  the  Arg
358  mutant, 
which was present as a monomer. Mutational analysis identified key residues   44 
putatively  involved  in  dimerisation,  namely  Glu
315,  Asn
321,  Asp
322,  Asn
328, 
Arg
358, and Ile
362. These residues are highly conserved in PDE 1, 3, 4, 8 and 9 
subfamilies.  These  observations  are  contradictory  to  the  model  for  PDE4 
dimerisation  as  suggested  by  Richter  and  colleagues  (Richter  and  Conti; 
2002) in which it is argued that the upstream conserved regions are involved 
in dimerisation. Although further investigation is needed to confirm the sites of 
dimerisation, it is likely that UCR1, UCR2 and catalytic regions contribute to 
dimerisation of PDE4 isoforms. 
 
Functional  significance  of  PDE4  dimerisation  is  yet  unknown.  Beard  and 
coworkers  (Beard  et  al,  2000)  showed  that  UCR1  and  UCR2  interact  with 
each other to form a regulatory module, which has a role in the activation of 
PDE4 long forms upon PKA phosphorylation. The long form splice variants of 
PDE4  as  discussed  above  are  proposed  to  exist  as  dimers  due  to  inter-
molecular interaction of UCR1-UCR2 regions; they show higher sensitivity to 
inhibitors like rolipram after phosphorylation by PKA. This is in agreement with 
the  previous  findings  that  purified  PDE4B2  and  PDE4A  isoforms  show  a 
higher affinity to rolipram when present in oligomeric state (Rocque et al, 1997 
and Jacobitz et al 1996). The formation of this high affinity state for rolipram 
binding  has  been  shown  to  involve  residues  outside  the  catalytic  region 
towards  the  N-terminal  region  of  the  protein  (Rocque  et  al,  1997).   
Dimerisation helps in stabilising the PDE4 long forms, so that they exhibit a 
high affinity for rolipram binding state. However, it has been suggested that 
although dimerisation stabilises the long forms and helps in maintaining the 
high  affinity  rolipram  binding  state,  it  is  not  required  for  the  HARBS 
conformation as there are fewer rolipram binding sites in the monomeric state 
compared to the dimeric form (Richter and Conti 2004).  
 
It has been shown that dimerisation modulates the activity of long PDE4 forms 
upon  modifications  including  phosphorylation,  ligand  binding,  and  protein-
protein interaction (Richter and Conti 2004) and that dimerisation may be a 
requirement for enzyme activation.  
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1.8.9  Foci formation  
 
PDE4 isoforms PDE4A4B and to some extent PDE4A5, have been shown to 
undergo dynamic redistribution and form accretion foci after chronic treatment 
with the PDE4 selective inhibitor rolipram (Terry et al; 2003). This process is 
triggered by HARBS-sensing PDE4 inhibitors such as rolipram and RO 20-
1724 but not by LARBS-sensing inhibitors such as Ariflo®. Protein synthesis 
is  crucial  for  formation  and  maintenance  of  foci  (Terry  et  al;  2003).    It  is 
thought  PDE4A4  foci  formation  is  mediated  by  conformational  changes 
produced  upon  binding  of  the  inhibitor.    The  unique  N-terminal  region  of 
PDE4A4 is also thought to contribute to the process, as other isoforms of the 
PDE4A subfamily are not known to form foci.   
 
It  has  been  noted  that  the  triggering  of  HARBS  conformation  upon  PDE4 
inhibitor binding is associated with the side effects produced upon treatment 
with PDE4 inhibitors (Martin et al; 2002 and Souness et al; 1997). The ability 
of a PDE4 inhibitor to induce PDE4A4 foci formation may therefore serve as 
an important screen for identifying potentially therapeutic PDE4 inhibitors.  
 
1.9  PDE4 isoforms in diseases- PDE4 inhibitors as therapeutics agents 
 
PDE4 inhibitors may serve as therapeutic agents in diseased states. PDE4 
inhibitors  are  known  to  elicit  anti-inflammatory  effects  (Cheng  and  Grande; 
2007) and have also been used in the treatment of many CNS disorders such 
as depression (Cheng and Grande; 2007, Dastidar et al; 2007, Houslay et al; 
2005). The potential therapeutic value of selective PDE4 inhibitors has been 
assessed in PDE4 knockout studies. In mice the knock down of the PDE4B 
gene decreased production of tumour necrosis factor (TNF) upon exposure to 
lipopolysaccharide  (LPS)  (Jin  and  Conti;  2002).  However,  knockdown  of 
PDE4D in mice did not alter TNF production. However, PDE4D knockdown 
has been shown to attenuate the muscarinic-cholinergic response leading to 
the  loss  of  hyper-reactivity  of  the  airways  (Hansen  et  al  in  2000).  These 
studies indicate that there is little or no redundancy in the roles of the PDE4 
subfamilies and pave the way for development of PDE4 inhibitors that can   46 
selectively inhibit the activity of the isoforms in various inflammatory tissues 
thus  offering  a  promising  treatment  for  inflammatory  diseases  including 
arthritis and asthma. The sequence similarity of the catalytic sites for these 
enzymes will make it difficult to design sub-family or isoform specific inhibitors 
successfully.  However,  a  recent  study  (Wang  et  al;  2007)  has  shown  the 
PDE4  inhibitor  NVP  {4-[8-(3-nitrophenyl)-[1, 7]  napthyridin6-yl]benzoic  acid} 
binds the same conformation in the cAMP and inhibitor binding pocket of all 
PDE4 subfamilies but the PDE4A and PDE4C subfamilies show significant 
differences  in  key  residues  that  are  displaced  by  inhibitor  binding.  This 
indicates  that  there  is  a  possibility  to  design  subfamily-specific  PDE4 
inhibitors.  
 
It  has  been  reported  that  the  PDE4B2  isoform  inhibits  the  cAMP-induced 
apoptotic  cell  death  in  B  cells,  thus  leading  to  Diffuse  Large  Cell  B  Cell 
lymphoma (Smith et al; 2005). It is therefore possible that inhibition of this 
isoform may induce death of the malignant cells and serve as a therapeutic 
agent in the treatment of lymphomas.  
 
Follicle  stimulating  hormone  (FSH),  Human  chorionic  Gonadotropin  (hCG) 
and  Luteinizing  hormone  (LH)  are  the  principal  hormones  that  regulate 
ovulation. It was noted that PDE4 inhibition in FSH-primed rats, untreated with 
LH and hCG, stimulated ovulation indicating that PDE4 function modulates 
the signalling mechanisms involved in the ovulation (McKenna et al, 2005). 
The rat oocytes produced thus were found to be as equally fertile as oocytes 
produced  by  untreated  rats.  PDE4  inhibitors  may  therefore  be  useful  as 
therapeutic agents in infertility conditions with hCG and LH defects (McKenna 
et al 2005). 
 
It is now well established that smooth muscle contraction and relaxation is 
regulated  by  cyclic  nucleotides  cAMP  and  cGMP  which  act  as  secondary 
messengers  and  regulate  many  downstream  pathways  and  are  associated 
with many physiological responses (Abdel-latif AA 2001). Myometrial smooth 
muscle cells express five different types of PDEs (1-5), of which, PDE4 family 
is the most predominant with PDE4 activity comprising 75% of the cAMP -  47 
specific PDE activity in late pregnancy.  PDE4D and PDE4B are the most 
predominant  PDE4  isoforms  expressed  in  human  myometrium;  especially 
PDE4B2  is  selectively  induced  in  the  myometrium  at  the  late  stage  of 
pregnancy (Mehats et al; 2005). Elevation of cAMP levels led to increase of 
PDE4 activity due to induction of PDE4B2, PDE4D1 and PDE4D2.  β-agonists 
can relax a non-pregnant myometrium but not that of a pregnant myometrium, 
indicating  the  β  adrenergic  receptors  of  pregnant  myometrium  are 
desensitized. However, PDE4 inhibitors can reverse this effect and potentiate 
the relaxant functions of β-agonists. It is therefore likely that selective PDE4 
isoforms are  involved  in  regulating  the  contractile  functions  of  myometrium 
and altered PDE4 activity/expression within the myometrium may induce pre-
term labour (Méhats et al. 2004).  
 
Prostaglandin E2 (PGE2) induces PDE4B2, PDE4D1 and PDE4D2 expression 
in  a  cAMP-dependent  manner.  PGE2  also  mediates  heterologous 
desensitisation of β-adrenergic receptors inhibiting their relaxant functions, an 
effect which is reversed by the presence of PDE inhibitors. PDE4 inhibitors 
may therefore be of use to increase the tocolytic efficiency with β-mimetics so 
as to prevent premature births (Méhats et al, 2004). 
 
Bones  are  formed  through  the  action  of  three  important  cell  types, 
osteoblasts,  osetoclasts  and  osetocytes  respectively.  Osteoblasts  are 
involved  in  bone  formation.  Osteoclasts  are  involved  resorption  and 
osteocytes  comprise  the  ossified  part  of  the  bone.  Osteoblasts  when 
stimulated by factors such as 1, 25(OH)2D3, parathyroid hormone, interleukin-
6, prostaglandin E2 stimulate production of a cytokine known as TNF-Related 
Activation  Induced  Cytokine  (TRANCE).  TRANCE  then  activates  the 
signalling  pathways  leading  to  differentiation  of  osteoblasts  to  osteoclasts. 
This  process  is  inhibited  by  osteoprotergerin  (OPG),  a  decoy  receptor  for 
TRANCE,  which  is  also  produced  in  osteoblasts  (Takami  M  et  al,  2005).   
Recent studies have revealed that PDE4 enzymes are involved in regulating 
the expression of TRANCE, as determined by increased levels of TRANCE 
after  treatment  of  osteoblasts  with  PDE4  inhibitor  rolipram  (Takami  et  al;   48 
2005). The effect of PDE4 inhibition appears to be mediated through a PKA-
dependent pathway as PKA inhibitors were shown to attenuate IBMX-induced 
TRANCE expression in osteoblasts (Takami et al; 2005). Furthermore, it was 
shown that the PDE inhibitor-treated osteoblasts elicited increased activity of 
ERK and p38 MAPKand that treatment with ERK inhibitor PD98059 and p38 
MAPK  inhibitor  SB  203580  reduced  the  rolipram-induced  TRANCE 
expression  in  osteoblasts.  These  findings  are  indicative  of  a  cAMP-PKA-
PDE4  pathway  regulating  the  expression  of  TRANCE  via  ERK  and  p38 
activation (Takami M et al, 2005). PDE4 activity may therefore regulate bone 
cell differentiation induced by TRANCE.  
 
PDE4 genes have also been implicated in osteoporosis, a disease associated 
with  a  decrease  in  osteoblast  levels  (Reneland  et  al;  2005).  Rolipram-
mediated  inhibition  of  PDE4  leads  to  elevation  of  alkaline  phosphatase 
activity,  a  marker  for  the  differentiation  of  osteoblasts  to  osteoclasts 
(Reneland et al; 2005). Inhibition of PDE4 also induces increased expression 
of  osteopontin,  osteocalcin  and  collagen  type  I  which  mark  osteoblast 
differentiation suggesting a role of PDE4 enzymes in bone disorders including 
osteoporosis (Reneland et al; 2005). 
 
Glucocorticoids  and  Parathyroid  hormone  (PTH)  play  a  crucial  role  in 
regulating bone metabolism. PTH is known to decrease bone resorption (loss) 
by  reducing  osteoblastic  (bone  forming  cells)  apoptosis  via  a  cAMP-
dependent pathway (Ahlstorm, M. et al, 2005). Glucocorticoids, in contrast, 
decrease osteoblast levels, potentially leading to osteoporosis (Ahlstorm, M. 
et al, 2005).   
 
Evidence  also  suggests  that  PDE4  may  mediate  the  effects  of 
dexamethasone-regulated  cAMP  signalling  in  the  osteoblasts.  Synthetic 
glucocorticoid Dexamethasone is known to a decrease cAMP-specific PDE 
activity in MG-63 and SaOS-2 osteosarcoma cells (Ahlstorm, M. et al, 2005). 
Dexamethasone  treatment also  leads  to  reduced  rolipram  sensitivity of  the 
total cAMP-PDE activity (Ahlstorm, M. et al, 2005). The reduction in cAMP 
response and the decrease in sensitivity to rolipram indicate an altered PDE   49 
profile in the osteosarcoma cells. In support of this, it was noted that there is a 
massive  decrease  in  the  expression  of  PDE4A4  and  PDE4B1  isoforms  in 
these cells (Ahlstorm, M. et al, 2005).  
 
Glucocorticoids act as anti-inflammatory and immuno-suppressive agents by 
inhibiting prostaglandin biosynthesis (Ahlstorm, M. et al, 2005). They mainly 
inhibit  the  cyclo-oxygenase  activity  thereby  reducing  the  levels  of  PGE2 
whose functions are mainly anabolic. However, PDE4 inhibitors rolipram and 
denbufylline  have  been  shown  to  increase  the  PGE2-mediated  anabolic 
effects and subsequent bone formation in rat bone marrow cells (Ahlstorm, M. 
et  al,  2005).  All  these  studies  indicate  glucocorticoid-induced  bone  loss  is 
mediated through a PDE4-dependent pathway (Ahlstorm, M. et al, 2005).  
 
Rolipram  is  the  first  generation  PDE4  inhibitor  to  be  used  as  an  anti-
depressive agent (Scott et al; 1991). However, the side effects (e.g. nausea) 
associated with usage of rolipram have limited its role as a therapeutic agent 
(Scott  et  al;  1991).  However,  with  the  advent  of  second-generation  PDE4 
inhibitors such as roflumilast and cilomilast, which exhibit anti-inflammatory 
and  CNS  effects,  PDE4  inhibitors  are  emerging  as  potentially  useful 
therapeutic  agents  (Houslay  et  al;  2005).  However,  neither  of  these 
compounds successfully passed phase-II clinical trials, revealing side effects 
and  efficacy  problems  still  need  to  be  resolved  in  order  to  market  PDE4 
inhibitors successfully for therapeutic use (Geimbycz, 2006).  
 
1.10 SUMOylation 
 
Ubiquitylation is a post-translational modification involving the attachment of 
the  76-amino  acid  protein  ubiquitin  to  its  substrate  protein,  which  will  then 
mark its substrate for proteasomal-degradation (Zhao et al; 2007).   
 
Small Ubiquitin-related Modifier (SUMO) belongs to a family of ubiquitin-like 
proteins that are closely related to ubiquitin and are covalently attached to 
substrates as a part of their post-translational modification (Kerscher; 2007 
and Johnson; 2004). SUMO was first discovered in mammalian cells and has   50 
since  been  reported  in  all  eukaryotic  organisms  where  it  is  known  to  be 
involved in a wide range of functions. SUMO is also known as, Pmt2p, PIC-1, 
GMP-1, Ubl1 and sentrin (Johnson, 2004).  
 
1.10.1 Components of SUMO conjugation pathway 
SUMO conjugation pathway is very similar to ubiquitin pathway both in the 
process  and  in  the  components.  However,  many  functional  differences  do 
exist between the ubiquitin and SUMO (Kerscher, 2006). Please refer to figure 
3.1 
 
1.10.1.1 SUMO genes and isoforms 
 
In mammals SUMO is encoded by four SUMO genes, which encode SUMO 
molecules 1-4 (Geiss-Friedlander and Melchior, 2007). SUMO-2 and 3 share 
95%  sequence  homology  and  50%  sequence  homology  with  SUMO-1. 
SUMO-4  differs  from  the  other  three  SUMOs  in  that  it  can  form  covalent 
bonds with its substrate.  (Owerbach et al 2005, Bohren et al; 2004, Johnson; 
2004,  Melchior  et  al;  2003,  Hayashi  et  al;  2002,  Apionishev  et  al;  2001). 
SUMO-1 differs from SUMO-2 and SUMO-3 in that the latter two form poly 
SUMOylation chains whereas SUMO1 does not form poly SUMO chains. This 
unique ability of SUMO-2 and 3 is attributed to the presence of a consensus 
on  the  target  molecule  SUMO  modification  site  ΨKXXE  where  Ψ  is  an 
aliphatic residue and X is any amino acid. This consensus sequence is not 
present  in  SUMO-1  suggesting  that  the  differences  within  their  primary 
structures contribute to their distinct functions (Tatham et al; 2001). In support 
of this, it was shown that in plant cells SUMO-2 and SUMO-3 levels were 
elevated in response to stress whereas SUMO-1 levels were unaltered under 
similar conditions (Lois et al; 2003).  
 
1.10.1.2 SUMO-activating enzyme (E1) 
 
SUMO  molecules  exist  in  an  inactive  state  until  processed  by  SUMO-
activating enzyme. SUMO-activating enzyme is a heterodimer consisting of 
two Aos1 (SAE1) and Uba2 (SAE2) units. Aos1 is structurally analogous with   51 
the  N-terminus  of  ubiquitin  activating  enzyme  Ub  E1,  whereas  Uba2  is 
structurally similar to the C-terminus of Ub E1, which contains the enzyme’s 
active site (Johnson et al; 1997).  
 
1.10.1.3 SUMO-conjugating enzyme (E2) 
 
UBC9  is  the  universal  SUMO-conjugating  enzyme  in  all  organisms  with  a 
SUMO  conjugation  pathway  (Hayashi  et  al;  2002).  It  is  structurally  and 
functionally  similar  to  Ub  conjugation enzyme  Ub-E2  (Johnson  and  Blobel, 
1997).  
 
1.10.1.4 SUMO ligases (E3) 
 
There are three classes of E3 ligases, namely Protein inhibitor of Activated 
STAT (PIAS), RNBP2/NUP358 and polycomb group protein PC2 (Johnson; 
2004).  
 
PIAS  proteins  are  inhibitors  of  the  Signal  Transducer  and  Activator 
Transcription (STAT) class of proteins, which are involved in the JAK-STAT 
signalling  pathway.  There  are  four  different  PIAS  proteins  PIAS1,  PIAS3, 
PIASx and PIASy (Jackson; 2001 and Gross et al; 2001).  All PIAS proteins 
have  been  shown  to  possess  SUMOylation  (E3  ligase)  activity  and  show 
substrate-specificity. (Chun et al; 2003 and Miyauchi et al; 2001). All PIAS 
proteins  have  a  conserved  N-terminus  with  a  variable  C-terminus.  These 
proteins contain SAP, SP-ring and SIM domains from the N-terminus to the C-
terminus. The SAP domain (SAR, Acinus and PIAS domain), is involved in 
chromosomal organisation by interacting with DNA at AT-rich regions (Aravind 
et  al;  2000).  The  SP-ring  domain  contains  the  E3  ligase  activity.  The  SIM 
domain (SUMO interaction motif) contains an S/T-X-X-D/E consensus motif, 
which  is  thought  to  mediate  interaction  with  SUMO.  This  SIM  consensus 
sequence is also seen in SAE-2 and RanBP2 (Minty et al; 2000). 
 
RanBP2, also known as Nup358, is a nuclear GTPase that forms a complex 
with  chromatin-bound  guanosine  nucleotide  release  factor  RCC1.  This   52 
RanBP2-RCC1  complex  pore  protein  localises  to  the  cytoplasmic  side  of 
nuclear membrane. It possesses a leucine-rich N-terminal region and eight 
zinc  finger  motifs.  The  C-terminus  contains  regions  homologous  to 
cyclophilins (Yokoyama et al; 1995). RanBP2 was shown to have SUMO E3 
ligase activity similar to PIAS proteins. RANBP2 interacts with UBC9 bound 
SUMO-1 and transfers the SUMO to SP100. E3 ligase activity of the protein is 
evoked by two repeats of a unique 50-amino acid region known as internal 
repeat domain, IR0) which is not seen in any other E3 ligases (Pichler et al; 
2004 and Pichler et al; 2002).  
 
Pc2 is recently discovered E3 ligase and belongs to a class of proteins called 
polycomb groups that are known to be involved in gene repression. Pc2 does 
not share any homology with other E3 ligases (Kagey et al; 2003). 
 
1.10.1.5 SUMO deconjugating enzymes 
 
Seven genes encode various SUMO deconjugating enzymes that are known 
to cleave SUMO from SUMOylated proteins in mammals. Some cleave the 
SUMO precursor as well as SUMO from SUMOylated proteins (e.g.; Ulp1) 
while other members only function in latter process (Melchior et al; 2003). All 
SUMO cleavage enzymes have a conserved C-terminal domain named the 
Ulp  (Ubiquitin  like  protease)  domain,  which  has  isopeptidase  activity.  The 
enzymes have a variable N-terminal domain that is regulatory in function and 
targets  the  enzyme  to  specific  sub-cellular  compartments  (Johnson  et  al 
2004).  
 
1.10.2 SUMO conjugation pathway 
 
SUMOylation  conjugation  involves  three  enzymatic  steps.  In  summary,  a 
SUMO  molecule  is  activated  in  an  ATP-dependent  manner  by  SUMO 
activating enzyme 1, with the SUMO deconjugating enzymes contributing to 
this process. This activation leads to maturation of the SUMO molecule. The 
SAE1/SAE2  complex  then  transfers  the  matured  SUMO  to  conjugating 
enzyme  E2,  UBC9.  It  is  then  transferred  from  UBC9  to  its  substrate,  a   53 
process, which requires the substrate-specific E3 ligases (Kerscher; 2006). A 
more detailed explanation of this pathway is described in Chapter 3. 
 
1.10.3 Regulation of SUMO conjugation pathway 
 
The mechanisms regulating SUMO conjugation are poorly understood. There 
is  no  evidence  for  a  common  signalling  pathway  for  SUMOylation  of 
substrates. Most of SUMO consensus motifs in a vast number of proteins are 
sites  for  other  post-translational  mechanisms  such  as  acetylation  and 
ubiquitinylation.  For  example,  the  acetylation  sites  of  Sp3,  a  transcription 
factor,  are  also  a  part  of  SUMO  consensus  motif  thus  acetylation  and 
SUMOylation compete for the same sites and may have an inhibitory affect on 
each  other  (Braun  et  al;  2001).  Similarly,  ERK  phosphorylation  and 
SUMOylation of ELK-1 seems to elicit  opposing effects on each other as well 
as on the activity of the transcription factor (Yang et al; 2003).  
 
Gam1,  an  adenoviral  gene  product,  is  a  unique  protein  that  the  inhibits 
SAE1/SAE2  heterodimer  complex  both  in  vivo  and  in  vitro  thus  elevating 
unprocessed  SUMO  molecules  and  consequently  inhibiting  the  SUMO 
conjugation pathway and promoting loss of SUMO-1 from the nucleus (Boggio 
et  al;  2004  and  Colombo  et  al;  2002).  Gam1  forms  a  complex  with 
SAE1/SAE2  in  a  dose-dependent manner  and  inhibits  the  de  novo  SUMO 
conjugation of substrates. Furthermore, it has been shown to decrease the 
levels  of  both  SAE1/SAE2  and  UBC9  proteins  through  regulation  of 
transcription. Gam1 was found not to affect the conjugation pathway in the 
presence  of  preformed  SAE1/SAE2  heterodimer  complexes  suggesting  its 
inhibitory  function  is  partially  mediated  through  its  ability  to  prevent  the 
formation of heterodimer complexes in cells (Boggio et al; 2004).  
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1.11 Small GTPases  
 
Rho  GTPases  belong  to  Ras  superfamily  of  GTPases  along  with  other 
subfamilies  including  Ras,  Rab,  Ran  and  Arf.  Rho  GTPases  are  small 
GTPases  that  regulate  actin  cytoskeletal  system  in  all  eukaryotes 
(Aspenstrom  et  al;  2004).  So  far,  22  different  Rho  GTPases  have  been 
identified that can be divided into 8 groups, of which Rho, Cdc42 and Rac1 
are the most studied (Jaffe and Hall; 2005). Classification and groups of Ras 
and Rho GTPases are shown in Table 1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3 Groups of Ras and Ras like GTPases 
 
 
 
 
 
 
Cdc42 
TC10 
TCL 
Chp 
Wrch1 
 
Ras Superfamily of GTPases 
Ras           Rab          Ran             Rho            Arf              Rap            Sar 
   Rho          Rac           Rnd     RhoD & Rif    RhoH/TFF    Rho BTB       Miro    RhoG    Cdc42 
   (A-C)         (1-3)         (1-3)                                    (1 & 2)       (1 & 2)          55 
1.11.1 GTPase cycle and regulation of Rho GTPases  
 
Rho GTPases cycle between a GTP-bound active and GDP-bound inactive 
state.  Rho  GTPase  cycle  is  regulated  by  various  proteins  including  GEFs 
(Guanine  exchange  factors),  GAPs  (GTPase  activating  proteins)  and  GDIs 
(Guanine  nucleotide  dissociation  inhibitors). GEFs  exchange  GDP  for  GTP 
thereby activating Rho; GAPs switch on the intrinsic GTPase activity of Rho 
thereby inactivating Rho. GDIs block the dissociation of GDP from Rho thus 
blocking their activation (Jaffe and Hall; 2005, Aspenstrom; 2004, Luo; 2000 
and Olofsson; 1999). In resting cells, Rho exists in a complex with GDI, which 
can be dissociated from Rho upon appropriate stimulation (Saski and Takai; 
1998).  Two  regions  called  switch-I  and  switch-II  play  a  crucial  role  in 
activation, inactivation and protein interactions of Rho GTPases (Dvorsky and 
Ahmadian,  2004).  Figure  1.5  is  a  diagrammatical  representation  of  the 
GTPase cycle of RhoGTPases.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Schematic of GTPase cycle. Rho GTPase cycle is regulated by 
GAPs, GEFs and GDIs. 
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1.11.2 Guanine exchange factors (GEF) 
 
Guanine  exchange  factors  or  GEFs,  act  by  nucleotide  exchange  and 
GTPases  are  subsequently  activated  by  the  virtue  of  the  higher  levels  of 
cellular  GTP.  GEFs  lack  preference  for  GDP  or  GTP  and  modify  the 
nucleotide-binding site of G-proteins, thereby accelerating the release of the 
nucleotide  from  the  G-protein  so  that  GTP  can  replace  it.  The  guanine 
nucleotide  and  GEF  also  compete  for  binding  to  the  G  protein  thereby 
promoting the binding of the nucleotide to the G-protein (Bos et al; 2007).   
 
GEF activity is regulated by various mechanisms including protein-protein/lipid 
interactions,  secondary  messengers  and  Post-translational  modifications 
(Garcia-Mata and  Burridge;  2006,  Bos  et  al;  2007  and  Ebinu  et  al;  1998).  
Most  Rho-GEFs  have  been  shown  to  contain  a  putative  PDZ  domain 
(Postsynaptic density protein PSD95; the Drosophila septate junction protein 
Discs-large;  tight  junction  protein,  ZO-1).  PDZ  domains  mediate  protein 
targeting and allow for the formation of multi-protein complexes thus providing 
a  mechanism  to  limit  individual  GEF  activity  to  various  sub-cellular 
compartments.    This  has  been  reported  for  GEFs  including  Kalirin-7  and 
betaPIX exchange factor (Liu and Horowitz; 2006, Garcia-Mata and Burridge; 
2006).  
 
Second messengers including cAMP, calcium and DAG have all been shown 
to modulate the function of various GEFs as discussed previously in 1.5.2, 
cAMP is a regulator of EPAC; Ca
+2 and DAG regulate Ras GEFs, Ras GRP1 
and 2, which activate golgi-localised Ras in response to elevated levels of 
either of these second messengers (Bos et al; 2007 and Ebinu et al; 1998).  
 
Tyrosine phosphorylation of the RhoGEF Vav by Lck and Src kinases within 
its Dbl homology (DH) domain is shown to disrupt the auto-inhibitory effect of 
the intra-molecular interaction of the Ac-DH domain leading to activation of 
the GEF (Aghazadeh et al; 2000).  
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1.11.3 GTPase activating proteins 
 
GTPase  activating  proteins  (GAPs)  are  regulators  of  G-protein  signalling 
(RGS) and contain a 120 amino acid homologous RGS domain (Willars; 2006 
and  Popov  et  al;  1997).  Approximately,  70  putative  GAPs  specific  for 
RhoGTPases have been identified, 30 for Ras GTPases, five for Rap and one 
for Ran-GTPases (Bernards and Settleman; 2005).  
 
The  catalytic  domains  of  GAPs  from  any  two  families  are  very  different 
although  GAPs  of  same  subfamily  share  similar  sequences  (Boguski  and 
McCormick; 1993).  GTP hydrolysis by GTPases is very slow and requires a 
GAP  to  hasten  the  process.  GAP-assisted  GTP  hydrolysis  has  been 
explained by two different models; in the first model, GAPs help stabilise the 
catalytic machinery of a GTPase that otherwise performs the hydrolysis at a 
slower  rate  (Moore  et  al;  1993  and  Eccleston  et  al;  1991).  In  the  second 
model, GAPs provide GTPases with an arginine finger residue (Arg
789), which 
stabilises the transition states of the active site (Scheffezek and Ahmadian, 
2005 and Scheffezek et al; 1997).  
 
RasGAPs  contain  a  catalytic  domain,  PH  domain  and  a  C-2  domain 
(Conserved domain 2 in PKC). Some RasGAPs, like P120GAP, also contain 
SH2 and SH3 domains (Bernards and Settleman; 2004). Various regulatory 
mechanisms  have  been  reported  for  individual  RasGAPs.  Serth  and 
coworkers (Serth et al; 1991) showed that p21 is inhibited by lipid micelles in 
vitro. The PH domain of some RasGAPs, including GAP1m and GAPIP4BP, 
has been reported to induce translocation of the GAPs to plasma membrane 
(Lockyer et al; 1997).  
 
RhoGAPs possess a conserved catalytic domain. Different RhoGAPs have 
various  regulatory  domains  such  as  a  BCR  (Breakpoint  Cluster  Region) 
domain.  RhoGAPs  including  RasGAPs  can  be  regulated  by  phospholipids 
such  as  phosphotidylserine.  In  case  of  p190,  a  RhoGAP  as  well  as  a 
RacGAP,  phospholipid  binding  has  been  shown  to  switch  the  GTPase 
preference  with phospholipid  binding  inhibiting  theRhoGAP  activity of  p190   58 
and subsequently activating its RacGAP activity (Ligeti and Settlemen, 2006 
and Ligeti et al; 2004).  
 
RhoGAPs and other Rho proteins have been shown to play a significant role 
in pathogen invasion. Bacterial toxins pumped into host cell cytoplasm modify 
the Rho proteins and alter the dynamics of actin cytoskeleton to aid pathogen 
uptake into host cells (Scheffzek and Ahmadian; 2005).  
 
RapGAPs contain RapGAP domain and differ from GAPs of other families in 
that they do not use arginine finger residue in regulating GTPase activity and 
utilise two lysine residues (Daumke et al; 2004 and Brinkmann et al; 2002). 
Some RapGAPs contain PDZ domains, which may serve to target this protein 
to specific subcellular locations like cytoskeleton as well as to other signalling 
molecules (Schefzek and Ahmadian, 2005) 
 
RabGAPs are involved in vesicle trafficking. All Rabs identified share similar 
primary sequence but exhibit different substrate specificities. They function to 
regulate  the  activity  of  Rab  GTPases  within  the  same  sub-cellular  location 
(Bernards; 2002).  
 
Arf GAPs are GAPs for ADP ribosylation factors (ARF). One of the major roles 
of ARFs is in regulating vesicle/endosomal trafficking in conjunction with the 
Rab  proteins  (Gaynor  et  al;  1998).  ArfGAP  activity  is  regulated  by 
phosphorylation and phospholipid interaction (Menetrey et al; 2007).  
 
RanGAP  is  a  GAP  for  the  Ran  G  protein,  which  is  involved  in 
nucleocytoplasmic shuttling of proteins. RanGAP1 is one of the first proteins 
identified  to  become  SUMOylated.  RANGAP1  associates  with  the  nuclear-
pore complex upon SUMOylation (Mahajan et al; 1998).  
 
1.11. 4 Guanine dissociation inhibitors (GDI) 
 
Guanine  dissociation  inhibitors  (GDI)  bind  to  GTPases  and  prevent  the 
dissociation of GDP from the inactive GTPase. GDIs in turn, are regulated by   59 
GDI  dissociation  factors  (GDFs)  (Dermardrossian  and  Bokoch;  2005, 
Olofsson; 1999). So far, three Rho GDIs have been identified that function to 
regulate the activity of Rho GTPases (Olofsson; 1999), RabGDIs function in a 
similar manner in regulating the RabGTPase cycle (Olofsson; 1999). It has 
been shown that RhoGDI is a substrate for phosphorylation by p21-activated 
kinase 1 (Pak1) leading to the dissociation of RhoGDI from RacGTPase. Pak1 
action  therefore  indirectly  promotes  Rac  activation  (Dermardrossian  et  al; 
2004).   
 
1.12 Thesis Aims 
 
The data presented in this thesis is divided into three distinct chapters. Each 
chapter focuses on different aspects of PDE4 function. Previous unpublished 
work  from  our  group  has  shown  that  certain  PDE4  isoforms  can  be 
SUMOylated  in  vitro.  Chapter  3  aims  to  characterise  the  SUMOylation  of 
PDE4  isoforms  both  in  vitro  and  in  vivo  and  to  examine  the  effects  of 
SUMOylation  on  PDE4  signalling  and  compartmentalisation  of  PDE4 
signalling.  
PDE4A4  has  been  shown  to  form  accretion  foci  reversibly  only  in  the 
presence of rolipram and its analogues and that this process is dependent 
upon  protein  synthesis  (Terry  et  al;  2003).  Considering  that  only  PDE4 
inhibitors that cause emesis lead to PDE4A4 foci formation and not the non 
emetic ones, PDE4A4 foci formation may be important in understanding the 
side-effects  elicited  upon  treatment  with  PDE4  inhibitors.  Chapter  four 
therefore aims to indentify the signalling pathways involved in foci formation 
and maintenance. 
PDE4 isoforms and their interacting partners like β-arrestins have been shown 
to play an important role in cell migration and stress fibre formation (Flemming 
et al; 2004 and Barnes et al; 2005). Chapter 5 describes the preliminary work 
in  characterising  the  interaction  of  novel  RhoGAP  ARHGAP21/10  with 
PDE4D5 and β-arrestin.    61 
Chapter 2 Materials and Methods 
 
2.1 Materials 
 
Throughout the following methods the names of the companies used for the 
purchase of specific reagents are given in parentheses. Where no company is 
mentioned, the reagent was purchased from Sigma-Aldrich. All reagents were 
of analytical grade.  
 
2.2 Methods 
 
All molecular biology techniques were undertaken in DNAase and RNAase 
free environment  using  sterilised  equipment  and  aseptic  technique.  Buffers 
were  of  molecular  biology  grade  and  were  sterilised  by  autoclaving  or 
sterilised filtration. 
 
2.2.1 Large scale production of plasmid DNA 
 
A sample of E.coli bacteria carrying a plasmid containing the DNA of interest 
was taken from a frozen glycerol stock and transferred to a 2 L flask of culture 
medium (LB broth- 1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 
1%  (w/v)  NaCl  distilled  H20)  supplemented  with  antibiotic  ampicillin  or 
kanamycin  (100µg/ml  final  concentration)  depending  upon  the  antibiotic 
resistance  of  the  plasmid  by  means  of  a  sterile  pipette.  The  culture  was 
incubated at 37ºC overnight in an orbital shaking incubator. The cells were 
harvested the next day by centrifugation at 6000 x g for 15 minutes using the 
JA-14  rotor  in  a  Beckman  refrigerated  centrifuge.  The  plasmid  DNA  was 
extracted from the cell pellet using the Wizard maxi-prep kit (Promega
®, UK) 
according to manufacturer’s instructions. The principle of the method involves 
precipitating of DNA from cell lysates by isopropanol treatment followed by its 
purification using a silica resin.  
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DNA  was  precipitated  from  the  eluted  solution  by  addition  of  room 
temperature  isopropanol  followed  by  centrifugation  at  15000  x  g  for  30 
minutes at 4ºC. DNA pellet was then washed with 5 ml of room temperature 
70% ethanol and air dried for 5-10 minutes before resuspended in 500 µl of 
distilled H2O.  
 
2.2.2 Small-scale production of DNA 
 
QIAprep
® Spin miniprep kit was used for this procedure. The principle of this 
method involves alkaline lysis of bacteria followed by adsorption onto a silica 
resin  from  which  the  DNA  will  be  extracted  by  water.  A  sample  of  E.coli 
bacteria carrying a plasmid containing the DNA of interest was taken from a 
frozen glycerol stock was cultured in 5 ml of LB broth containing appropriate 
antibiotic was incubated at 37ºC overnight in an orbital shaking incubator. The 
cells were harvested the next day by centrifugation at 3000 x g for 10 minutes 
using  a  Jouan  tabletop  centrifuge.  Pelleted  cells  were  resuspended  and 
subjected to alkaline lysis by lysis buffer provided by the manufacturer. DNA 
was adsorbed onto a silica spin column followed by a wash with ethanol. The 
column was air-dried and the DNA was eluted into sterile distilled H2O.  
 
2.2.3 Quantification of DNA 
 
Both DNA and RNA concentrations were measured using a WPA lightwave 
spectrophotometer. 5 µl of DNA was diluted into 1ml distilled H2O and the 
absorbance measurements were taken at 260 and 280 nM against distilled 
water as blank.  
 
The  concentration  of  nucleic  acid  was  calculated  using  the  following 
approximations: 
An absorbance of 1 at 260 nM corresponds to 50 µg/ml double stranded DNA, 
37 µg/ml single stranded DNA, 40 µg/ml single stranded RNA.  
 
The  ratio  between  the  absorbance  measurements  at  260nM  and  280nM 
provided an indication of the purity of the nucleic acid. In solution RNA and   63 
DNA have A260: A280 ratios of 1.8 or 2.0 respectively. If the absorbance ratio 
is significantly less than this it indicates that the nucleic acid may be impure. 
 
2.3 Site-directed mutagenesis                
 
2.3.1 Primer designs     
 
Site-directed mutagenesis is altering parental DNA by incorporating designed 
changes  using  engineered  primers  and  polymerase  chain  reaction.  While 
designing  the  5’-primer  the  nucleotide  bases  that  encode  new  amino  acid 
were kept as close to the original sequence as possible. Depending upon the 
length of each primer varied between 45-50 nucleotides in length containing 
both desired mutation and flanked unmodified sequence in total. A melting 
temperature of 75ºC was considered good. 3’ primer is reverse complement of 
5’ primer to amplify the other strand. G or C was always chosen for the first 
and last nucleotide of the primer as it ensures efficient bonding.  
 
The  following  formula  is  commonly  used  for  estimating  the  melting 
temperature Tm of the primers: 
 
Tm (°C) ≈ 2 (NA+NT) + 4 (NG+NC) 
 
 N equals the number of adenine (A), thymidine (T), guanidine (G), or cytosine 
(C) bases in the primer. 
 
The  5’  and  3’primers  are  designed  for  PDE4D5  SUMO  K  mutant 
(PDE4D5K323R) are shown below. 
 
5’-primer CCCAAGGTTTGGAGTTCGAACTGAACAAGAAGATGTCC 
3’-primer GGACATCTTTCTTGTTCAGTTCGAACTCCAAACCTTGGG 
 
The base substitutions made to the K323R mutation are shown underlined.  
 
2.3.2 Mutant strand synthesis reaction    64 
 
Site directed mutagenesis was performed using the Quickchange site-directed 
mutagenesis  kit  according  to  manufacturer’s  instructions  (Stratagene,  UK). 
Primers designed in section 2.3.1 were custom synthesised and purified by 
HPLC by Thermo scientific®. The sample reactions then prepared in thermo-
tubes (Abgene, UK) as below: 
 
5 µl of 10x reaction buffer (supplied with the kit); 
x µl (5-50 ng)of dsDNA template (See below); 
x µl (125 ng) of oliconucleotide primer #1 (sense primer); 
x µl (125 ng) of oligonucleotide primer #2 (antisense primer); 
1 µl of dNTP mix (supplied with the kit); 
Sterile, deionised H2O to a final volume of 50µl                                                                
 
A  series  of  sample reactions  were  set  up with  various amounts  of dsDNA 
template  while  the  primer  concentration  was  kept  constant.  Once  the 
reactions were set up 1µl of pfu turbo DNA polymerase (2.5U/µl) was added 
into each tube and mixed by vortexing. The reactions were cycled in a PTC-
200 Peltier thermo cycler PCR machine using the parameters indicated below 
in table 2.1 
Segment  Cycles  Temperature  Time 
1  1  95°C  30 seconds 
95°C  30 seconds 
55°C  1 minute 
2  12 
68°C  2  minutes/kb  of 
plasmid length 
 
Table  2.1  Cycling  Parameters  for  the  QuickChange  Site-Directed 
Mutagenesis Method.  
 
Following temperature cycling, the reactions were placed on ice for 2minutes 
to cool the reaction to below 37°C.  
2.3.3 Dpn I digestion of parental plasmid    65 
 
1µl  of  the  Dpn  I  restriction  enzyme  (1U/µl)  (Stratagene,  UK)  directly  was 
added to each amplification reaction and the samples were thoroughly mixed 
by  pipetting  the  solution  up  and  down.  Then  the  reaction  mixtures  were 
centrifuged  at  18,000  x  g  in  a  Heraeus  microcentrifuge  for  1  minutes  and 
immediately  incubated  at  37°C  for  1  hour  to  digest  the  wild  type  parental 
super coiled ds DNA.  
 
2.3.4 Transformation of XL1-Blue supercompetent cells 
 
The XL1-Blue supercompetent cells (Stratagene, UK) were gently thawed on 
ice. For each transformation 50µl of the supercompetent cells were aliquoted 
to a pre-chilled Falcon
 polypropylene tube. 1µl of each DpnI treated DNA 
was  then  added  to  separate  aliquots  of  the  supercompetent  cells,  swirled 
gently  to  mix  and  were  incubated  on  ice  for  30  minutes.  Transformation 
reactions were then heat shocked by incubating the samples at 42°C for 45 
seconds in a water bath with and the samples were immediately transferred 
on to ice for 2 minutes.  0.5 ml of LB broth preheated to 37°C was added to 
transformation reactions and then incubated at 37°C for 1 hour. 250µl of each 
transformation reaction was spread onto an agar plate containing 100 ug/ml 
final concentration of ampicillin and incubated at 37°C for 16 hours. A number 
of single colonies were selected for analysis by plasmid preparation followed 
by DNA sequencing to verify successful mutagenesis.  
 
2.3.5 Sequence analysis 
 
Samples  of  DNA  obtained  from  mutagenesis  were  sent  to  Baseclear
® 
sequencing centre, The Netherlands. Routine DNA and deduced aminoacid 
sequence analysis were performed on the Genejockey II programme. 
 
 
 
2.3.6 Glycerol stocks   66 
 
A single colony was picked from an agar plate and for long term storage of 
E.coli containing a plasmid of interest was used to inoculate 5 ml of LB broth 
supplemented with appropriate antibiotic. The culture was grown overnight at 
37°C overnight in an orbital shaking incubator. 1 ml of the overnight culture 
was transferred into a sterile eppendorff
® tube with 500µl of sterile glycerol 
(Riedel-DeHaën, Germany). The glycerol stock was immediately frozen to  
-70°C using dry ice and then stored at -80°C until required. To revive the cells, 
cells from glycerol stock were picked using a nichrome wire near a Bunsen 
flame and were streaked onto an LB plate and incubated at 37°C over night. 
Single colonies from the picked plate were used in further experiments.  
 
2.3.7 Agarose Gel analysis of DNA 
 
DNA  was  visualised  using  agarose  gel  electrophoresis.  1%  agarose  was 
dissolved in 1 x TBE buffer (9M Tris base, 20mm EDTA, 0.9M Boric acid) by 
heating in the microwave with occasional swirling to reduce air bubbles in the 
solution. To agarose solution, 0.01% Ethidium bromide was added to enable 
the visualisation the DNA under UV light. A comb and end stoppers were set 
up into the gel apparatus and the agarose solution was poured into it. Once 
the gel was set, the comb and end stoppers were removed and the gel tank 
was filled with 1 x TBE buffer until the gel was immersed in the buffer. 5µl of 1 
Kb DNA ladder (Roche
®, UK) was added to the first lane to enable prediction 
of size of the DNA fragments. All the samples were then diluted 5:1 by adding 
6 x DNA blue/orange loading dye (Promega
®, UK). The samples were then 
loaded onto the gel which was then run at 50V until the dye front migrated 
along the gel to ensure sufficient separation of the fragments. The gel was 
then carefully removed from the tank and examined under UV light.  
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2.4 Expression and purification of proteins 
 
2.4.1 Maltose Binding Proteins (MBP) fusion proteins 
 
E.coli BL21 pLys (DE3) cells transformed with the appropriate pMAL plasmid, 
as described in Table 2.2 were grown in 30ml of LB broth supplemented with 
100 ug/ ml ampicillin, overnight in an orbital shaking incubator at 37°C. 450ml 
of sterilised LB broth supplemented with 100 ug/ ml ampicillin, was inoculated 
with overnight culture and grown in the orbital shaker at 37°C for 1-2h. A 1 ml 
sample of culture was removed to a plastic cuvette and the optical density 
measured at 600nm (OD600) against a rich media control. Expression of the 
fusion protein was induced with 0.2mM isopropyal-β-D-thiogalactopyranoside 
(IPTG) when an OD600 of 0.6-1 was achieved. An OD600 at this level ensured 
that  the  culture  was  in  the  logarithmic  phase,  where  bacteria  will  grow 
exponentially. Expression of the target protein was undertaken for 4h in an 
orbital shaker set at 30°C. 1 ml samples of culture were removed hourly to 
monitor  protein  expression.  These  samples,  including  the  sample  used  for 
OD600 measurement  were  centrifuged  at  13000  x  g  and  the  pellet  was  re-
suspended in 100 µl 1x SDS sample buffer for analysis by SDS-PAGE and 
Coomassie
® staining, as described in section 2.10. Four hrs post-induction 
the cells were harvested by centrifugation at 4000 x g for 10 minutes. The 
cells  were  re-suspended  in  resuspension  buffer  (50mm  Tris-HCl;  pH  8.0, 
10mM  NaCl  and  10mm  β-mercaptoethanol).  The  re-suspended  cells  were 
then  frozen  at  -80°C  and  thawed  on  ice.  Lysozyme  was  added  at  a  final 
concentration of 1mg/ml and the cell suspension was subjected to sonication 
three times for 30 seconds each with an interval of 30 seconds in between to 
achieve cell lysis. NP-40 was added to a final concentration of 0.05% to aid 
cell lysis and the subsequent cell debris removed by centrifugation at 13000 x 
g for 15 minutes. 1 ml of amylose resin (New England Biolabs, UK) was pre-
equilibrated  with  re-suspension  buffer  containing  0.05%  NP-40.  The  fusion 
protein  was  eluted  from  the  amylose  resin  with  500  µl  of  10mM  maltose, 
50mM Tris-HCl; pH 8.0 by incubating end-over-end for 20 minutes at 4°C.   68 
This was repeated up to three times, if necessary. The eluted fractions were 
pooled and dialysed using a slide-A-lyser dialysis cassettes (Pierce Rockford, 
USA) against three 650ml volumes of dialysis buffer (100mM NaCl, 50mM 
Tris-HCl, pH 8.0, 5% glycerol) for 1h each at 4°C. The purified fusion protein 
was frozen in aliquots on dry ice and stored at -80°C. The expression time 
course and final purification to homogeneity was analysed by SDS-PAGE and 
Coomassie
® staining, described in section 2.10.  
 
2.4.2 Glutathione-S-Transferase (GST) Fusion proteins 
 
Recombinant GST fusions proteins were expressed and purified from E.coli 
essentially as described for MBP fusion proteins (section 2.4.1). Competent 
E.coli  BL21  pLys  (DE3)  cells  were  transformed  with  appropriate  pGEX 
plasmid  (Table  2.2).  GST  fusions  proteins  were  purified  using  glutathione 
sepharose  resin  (Amersham  Biosciences,  UK)  and  eluted  using  10mM 
glutathione following the sample protocol as described in section 2.4.1.  
 
2.4.3 In vitro transcription and translation (TnT
®) of recombinant proteins 
 
TnT
®, Promega kit is a system designed for expression of proteins through in 
vitro  transcription and  translation of  PCR  generated  templates  using rabbit 
reticulocyte  lysates.  The  reactions  were  performed  as  described  in 
manufacturer’s  instructions  (Promega
®  TB126).  Briefly,  40µl  of  rabbit 
reticulocyte TnT Sp6
® quick master mix, 0.5ug of DNA template, 2µl of amino 
acid mixture were mixed in an eppendorff
® tube and the total volume was 
made upto 50µl with nuclease free water. Reaction tubes were incubated at 
30°C for 2 hours. Transferring the tubes to 4°C terminated the reactions and 
the resulting recombinant proteins were stored at -80°C.  
 
2.4.4 Purification of TnT
® yields 
 
Reaction samples from TnT
® were mixed with equal volumes of 4M saturated 
ammonium sulphate in TE buffer (10mM Tris, pH 7.5, 1mM EDTA) at room   69 
temperature. Samples were then incubated in ice water for 20 minutes and 
then centrifuged for 20 minutes at 14,000 x g at 4°C. The supernatant was 
removed and the pellets were washed with ice-cold TE buffer containing 2M 
ammonium sulphate and 2mM Dithiothreitol. The samples were centrifuged 
and the pellets were resuspended in modified TE buffer.  
 
2.5 Maintenance of cell lines  
 
2.5.1 COS1 and COS7 cell lines  
 
Cos1 and Cos7 cell lines are derived from African green monkey kidney cells 
and have been transformed with SV40 virus. The cells were propagated in 
complete DMEM (DMEM supplemented with 10% FBS, 0.1% Penicillin and 
Streptomycin (10000U/ml), 2mM Glutamine). The cell line was maintained at 
37°C in an atmosphere of 95% air and 5% CO2. The cells were passaged 
when approximately 90% confluence was reached. This was carried out in a 
laminar flow hood to maintain sterility. To passage the cells the growth media 
was removed and 5 ml of pre-warmed sterile phosphate buffered saline (PBS) 
was added. The cells were washed by gentle agitation with sterile PBS, which 
was then aspirated. 1 or 2ml of Trypsin-EDTA solution was added and cells 
were incubated for 5min at 37°C. The cells were vigorously agitated and then 
analysed under a microscope to check for efficient cell detachment. Once this 
state was achieved, 10ml of growth media was added to inactivate the trypsin-
EDTA solution. The cells were collected by centrifugation at 1000 x g for 3 
minutes. The growth media supernatant was removed and the cell pellet re-
suspended in the appropriate volume of fresh media. Cells were routinely split 
1:5 into fresh media in sterile flask. The cells were returned for incubation at 
37°C in atmosphere of 95% air and 5% CO2 until confluent.  
 
2.5.2 HEK293 cells 
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The  human  embryonic  kidney-293  cell  line  has  epithelial  cell  morphology. 
These  cells  were  maintained  as  described  in  section  2.5.1  for  COS1  and 
COS7 cells 
2.5.3 CHO cells  
 
CHO  cells  were  cultured  in  HAM’s  F12  nutrient  mix  with  Glutamax-1  10% 
foetal bovine serum (FBS) plus 0.1% Penicillin / streptomycin (10,000U/ml).  
 
2.5.4 HEK293 cells with inducible (Flp-In-T-Rex) At1a receptor 
 
HEK293 cells stably expressing At1a receptor were maintained in complete 
DMEM  supplemented  with  200  ug/ml  Hygromycin  (Calbiochem,  UK).  Cells 
were treated with 1 ug/ml doxycycline 24-96 hours before assays to induce 
expression of receptors cloned into Flp-In- locus.  
 
2.5.5 Freezing and Thawing of cell lines 
 
The storage of cells with a low passage number at -200°C in liquid nitrogen 
vats ensured the long-term integrity of the specific cell line. To revive cells 
from  this  temperature  the  individual  vial  was  quickly  thawed  and  added 
directly to 10ml of pre-warmed fresh growth media, under sterile conditions. 
Once the cell line was established and confluent, further 1ml aliquots of cells 
were  re-suspended  in  freezing  media.  These  were  initially  frozen  at  -80°C 
before being transferred to -200°C for long-term storage.  
 
2.6 Transfection of mammalian cell with plasmid DNA 
 
Transfection is a process of introducing foreign DNA into mammalian cells to 
allow the expression of recombinant proteins.  
A list of DNA plasmids used for the transfection of mammalian cell lines is 
described in table 2.2 
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2.6.1 DEAE-dextran transient transfection 
 
This method of mammalian cell transfection was used for the transfection of 
COS1 and COS7 cell lines only. Flasks of confluent cells were passaged the 
day prior to transfection and plated to ensure 70% confluence on the day of 
transfection. These plates were incubated overnight at 37°C in an atmosphere 
of 95% air and 5% CO2.  The amount of DNA required for each transfection 
plate is dependent on the number of cells to be transfected and should be 
scaled  accordingly.  This  protocol  is  accurate  for  100mm  plates  of  70% 
confluent cells in 10ml of growth media. 10ug of desired plasmid DNA was 
diluted in 10mM Tris-Cl, pH 7.6, 0.1mM EDTA to a final volume of 250 µl. 
200µl of 10mg/ml DEAE-Dextran was added to the DNA solution, mixed and 
incubated for 15 min at room temperature. Where co-transfection of two DNA 
plasmids was required 10ug of each plasmid in final 250 µl of 10mM Tris-Cl, 
pH 7.6, 0.1mm EDTA was added to 200µl of 10mg/ml DEAE-Dextran. During 
the  incubation  period  the  growth  media  was  removed  from  the  plates  and 
replaced with 10ml of fresh growth media supplemented with 100µM sterile 
chloroquine.  The  DNA-DEAE-Dextran  solution  was  added  directly  to  the 
appropriate transfection plate and incubated for 3-4hrs at 37°C. The growth 
medium was removed from the plates and 10ml of sterile PBS containing 10% 
Di-methyl sulphoxide (DMSO) added and aspirated immediately. The plates 
were washed twice with 10ml of sterile PBS before the introduction of 10ml of 
fresh growth media. The plates were incubated for approximately 2 days at 
37°C in an atmosphere of 95% air and 5% CO2 prior to any cell treatments 
and harvesting.  
 
2.6.2 Polyfect
® transient transfection 
 
The Polyfect
® method of mammalian cell transfection from QIAGEN
® U.K, was 
used  for  transfection  of  COS1,  COS7,  and  HEK293  cell  lines.  Cells  were   72 
cultured and prepared for transfection essentially as described in section 2.6.1. 
4ug of the desired plasmid DNA for the transfection was mixed with 25µl of 
Polyfect for HEK 293 cells (80µl for COS cells) and the final volume of the 
mixture was made up to 300 µl with serum free growth media. The reaction 
mixture was incubated at room temperature for 5-10 minutes to allow complex 
formation.  During  incubation  growth  medium  was  removed  from  the  plates 
and  replaced  with  7ml  of  fresh  complete  DMEM.  Post-incubation,  1  ml  of 
complete DMEM was added to reaction mixture, which was then gently mixed 
and  added  to  the  appropriate  trasnfection  plate.  The  plates  were  then 
incubated for approximately 2 days at 37°C as described in section 2.6.1 
 
2.6.3 FuGENE
® 6 transient transfection  
 
The  FuGENE
®6  method  of  mammalian  cell  transfection,  from  Roche
® 
diagnostics,  Germany  was  used  for  the  trasnfection  of  COS1,  COS7  and 
HEK293 cell lines that were used for confocal microscopy analyses for better 
morphology. Cells were grown and prepared as described in section 2.6.1. 
This  protocol  is  accurate  for  one  well  of  a  6-well  plate  containing  70% 
confluent cells in 2ml of growth media. 5µl of FUGENE
®6 transfection reagent 
was  added  to  95µl  of  serum  free  growth  media  and  incubated  at  room 
temperature for 5minutes. 1ug of the desired plasmid DNA for cell transfection 
was added to reaction mixture and were further incubated for 15-45 minutes 
allowing the complex formation. The transfection reagents were then added 
directly  to  the  appropriate  well  of  the  transfection  plate.  The  plates  were 
incubated as described in section 2.6.1 prior to harvesting.  
 
2.6.4 Generation of stable cell lines 
 
Chinese hamster ovarian cells (CHO) and HEK293 cells were transfected with 
plasmids as described in Table 2.2 using the transfection agent FUGENE
® 6 
(Roche
®  diagnostics,  USA).  Cells  were  allowed  to  grow  for  further  48-72 
hours before starting the selection system.  
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After transfection, cells were split to 1:10, 1:20, and 1:50 into 15 cm dishes 
and were selected by growing them in media containing selection antibiotic. 
The choice of selection antibiotic was determined by the plasmid DNA used 
for transfection. For example, G418 was used for all plasmid DNAs cloned 
into pcDNA. An appropriate concentration (lowest concentration) of drug that 
gave  massive  cell  death  within  3  days  was  used.    Cells  were  left  in  the 
selection medium for a week with occasional topping of selection medium. 
After  the  first  week,  any  dead  floating  cells  were  removed,  fresh  selection 
media  was  added  and  the  cells  were  replaced  in  the  incubator  for  further 
selection.  The  process  was  repeated  for  2-4  weeks  until  single  isolated 
colonies started appearing. Single colonies were scraped carefully into 1ml of 
fresh medium with a micropipette. Cells were then plated into a 24-well plate 
and 1 ml of fresh selection media was added to them. Once the cells reached 
70% confluency, they were trypsinised and then they were plated into a 6-well 
plate.  Once the cells were confluent, they were split into a 75-cm
2 flask. Once 
confluent, cells were tested for protein expression and were stored at -200°C.  
 
2.7 Immunocytochemistry 
 
COS1 or COS7 cells were plated on to cell culture treated cover slips and 
transfected in 6-well plates with the appropriate plasmid DNA using FUGENE
® 
6  (Roche
®  diagnostics,  USA)  as  described  in  2.6.3.  Following  protein 
expression for 24h and any subsequent cell treatments the cells were fixed in 
sterile PBS containing paraformaldehyde (4% Paraformaldehyde with 10mM 
MgCl2 and 150mM NaOH pH 7.5). The cells were then washed three times 
with 2ml of sterile PBS. Cells were then permeabilised with 200µl of 0.2% 
TritonX-100.  This  was  repeated  three  times  and  the  excess  TritonX-100 
removed by blotting with napkins. The proteins were then blocked using 10% 
goat serum (dependent upon the primary antibody) and 2% BSA diluted in 
20mM  Tris-HCl,  pH  7.5  and  150mM  NaCl.  The  protein  of  interest  was 
detected using specific primary anti-serum. If staining for two different proteins, 
the cells were first stained for the protein with monoclonal anti-sera followed 
by polyclonal. Appropriate dilution of 200µl of primary anti-serum in 1:1 TBS   74 
and blocking solution was added to cover slips for 2h at room temperature. 
The cover slips were washed three times with 200µl of blocking solution and 
incubated  with  200µl  of  secondary  antibody  conjugated  to  Alexa
®  594/495 
from Molecular Probes (Eugene, OR, USA). The cells were then fixed to a 
microscopic  slide  using  immuno-mount  and  observed  using  Zeiss
®  Pascal 
laser-scanning microscope (Jena, Germany).  
 
2.8 Preparation of cell extracts 
 
2.8.1 Preparation of nuclear extracts 
 
Cells were grown and transfected using appropriate methods as described in 
section 2.6. Forty-eight hours post-transfection, cells were washed with cold 
sterile PBS and they were scraped into 500µl of hypotonic buffer (1M HEPES 
pH  7.0,  1M  KCl,  1M  MgCl2,  1M  DTT,  10%  Triton  X-100,  100%  Glycerol, 
500mM  PMSF,  1mg/ml  Aprotinin,  1mg/ml,  Leupeptin).  The  cells  were 
disrupted with 10-20 strokes of a Dounce homogeniser (Wheaton #357542, 
USA) and centrifuged at 3000-x g for 5 minutes. The supernatant was the 
cytoplasmic  fraction.  The  pellet  was  resuspended  in  100µl  cold  extraction 
buffer  (Hypotonic  buffer  with  5M  NaCl).  Resuspended  pellets  were  then 
incubated on an end over end rotating wheel for 20 minutes at 4°C. Cells 
were then centrifuged at 13,000 x g, for 10 minutes. The supernatant was 
used as nuclear extract and the pellet or nuclear matrix was resuspended in 
100µl extraction buffer. The fractions were all subjected to SDS-PAGE and 
immunoblotting as described in section 2.10 
 
2.8.2 Sub-cellular fractionation 
 
Cells were grown and transfected using appropriate methods as described in 
section 2.6. Post-transfection, cells were washed with sterile PBS and they 
were scraped into 500µl of KHEM buffer (50mM KCl, 50mM HEPEs; pH7.2, 
10mM  EGTA,  1.92mM  MgCl2,  and  1mM  DTT)  and  1x  protease  inhibitors 
(Roche
®  Diagnostics,  Germany).  Cells  were  then  passed  through  brown   75 
gauge needle for 10 minutes and were centrifuged at 2000 x g for 10 minutes.  
The  pellet  was  P1  fraction  and  supernatant  was  removed  into  another 
eppendorff
® tube and was centrifuged at 75000 x g for 30 minutes at 4°C. The 
supernatant obtained was S fraction and the pellet was resuspended in 750µl 
of KHEM buffer and centrifuged at 75000 x g for 30 minutes at 4°C. The pellet 
was retained as P2 fraction. P1 and P2 fractions were resuspended in the 
same volume of buffer as that of S fraction.  The fractions were all subjected 
to SDS-PAGE and immunoblotting as described in section 2.10.  
 
2.8.3 Whole cell lysate 
 
Confluent cells were harvested at temperatures less than 4°C using buffers 
that had been previously chilled to minimise protein degradation in the whole 
cell extract. The cell culture media was aspirated and the cells were washed 
twice with ice cold sterile PBS. The cell plates were drained thoroughly and 
the appropriate volume of cell lysis buffer added. For a 6-well plate 100µl of 
cell lysis buffer was added whereas a 100mm plate received 500µl of cell lysis 
buffer. For the production of whole cell lysate, 3T3 lysis buffer (25mM HEPES, 
pH  7.5,  50mM  NaCl,  10%  glycerol,  1%  triton,  50mM  NaF,  30mM  Na 
pyrophosphate,  5mM  EDTA)  and  1x  protease  inhibitor  cocktail  (Roche
® 
diagnostics, Germany) was used.  
 
2.9 Determination of protein concentrations  
 
The protein concentration of purified recombinant proteins or cell lysates was 
determined  using  bovine  serum  albumin  (BSA)  as  a  standard  in  a 
spectrophotometric  assay.  The  assays  were  undertaken  in  a  clear  96-well 
micro-titre  plate.  A  standard  curve  of  known  proteins  concentrations  was 
generated using a series of BSA standards of 0-5 ug in a final volume of 50µl.   
Protein assay reagent (BioRad
®, UK) was diluted 1:5 with sterile water and 
200µl of diluted reagent was added to each well of 96-well micro-titre plate. 
The intensity of the colour change (Brown to blue) was directly proportional to 
the protein concentration of the sample.   The 96-well plate was analysed with   76 
a  590nm  test  filter  using  Dynex  MRX  micro-titre  plate  reader  controlled 
through Dynex Revelation, version 3.04-computer software. A standard curve 
was generated by plotting A590 of the BSA standards against their protein 
concentrations, with least squares regression used to obtain the best-fit line. 
The protein concentration of cell lysates was determined by comparison of 
their A590 with the standard curve.  
 
2.10 Protein analysis 
 
2.10.1 SDS-PAGE 
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is 
a  method that  is  routinely employed  to  separate  proteins  by  virtue  of  their 
molecular  weight  (Schägger  and  von  Jagow,  1987).  Protein  samples  of  1-
100ug were denatured and reduced by dilution in 1x SDS sample buffer (10% 
SDS, 300mM Tris-HCl; pH 6.8, 0.05% bromophenolblue, 50% glycerol and 
10% β-mercaptoethanol).  The samples were boiled for 5 minutes and the 
loaded  directly  to  an  appropriate  well  of  an  Invitrogen™  UK  protein  gel. 
NuPAGE
®  4.12%  Bis-Tris  polyacrylamide  gel  immersed  in  Invitrogen™ 
NuPAGE
®  MES  or  MOPS  SDS  running  buffer.  5µl  of  Bio-Rad
®,  UK  pre-
stained molecular weight protein marker was also loaded to an appropriate 
well of the gel to allow the molecular weight of the proteins within the sample 
to  be  estimated.  The  gels  were  run  at  200V  for  1  hr.  For  more  detailed 
description  of  Invitrogen  NUPAGE
®  pre-cast  gels and  associated  Xcell  II™ 
apparatus please consult the manufacturer’s instructions.  
 
2.10.2 Visualisation of electrophoreses proteins by Coomassie
® staining 
 
Proteins separated by SDS-PAGE can be visualised by a variety of methods. 
The limit of coomassie
® staining is approximately 0.1-0.5ug of proteins per 
band on a polyacrylamide gel and detects all proteins within a sample. Gels 
that  required  Coomassie
®  staining  were  removed  from  the  pre-cast  gel 
cassette  and  washed  with  sterile  water  to  remove  residual  running  buffer.   77 
Coomassie
® stain (1.25g (w/v) of Brilliant blue R250, 44.4% Methanol, 5.6% 
acetic  acid)  was  added  to  the  gel  with  gentle  shaking  for  2h  at  room 
temperature.  The  gel  was  transferred  from  Coomassie
®  stain  into  de-stain 
(44.4%  Methanol,  5.6%  acetic  acid).  De-stain  removed  all  background 
staining with Coomassie
® stain remaining bound to the proteins resulting in 
the detection of all proteins present in the sample. The gels was then washed 
with sterile water and incubated with sterile water plus 10% glycerol to prevent 
the gel cracking during drying.  
 
2.10.3 Western Immuno-blotting  
 
Proteins separated by SDS-PAGE can be visualised by a variety of methods. 
Western immunoblotting allows the detection of the individual proteins with 
specific anti-sera. The proteins separated by SDS-PAGE were transferred to 
nitrocellulose membrane using the XCell
™ blotting apparatus and NuPAGE
® 
transfer buffer containing 20% methanol. The proteins were transferred with 
an applied voltage of 30V for 1h. For a more detailed description of XCell
™ 
blotting  apparatus  setup  and  buffer  compositions  please  consult  the 
manufacturer’s instructions. Following the transfer of the sample proteins, as 
indicated by successful transfer of the pre-stained molecular weight markers, 
the nitrocellulose membrane was incubated or blocked in 5% milk (Marvel
®, 
UK), reconstituted in TBST (20mM Tris-Cl pH 7.6, 150mM, NaCl and 0.1% 
Tween20)  for  1h  at  room  temperature  with  gentle  agitation.  The  primary 
antibody was added at the appropriate dilution to a solution of 1% milk powder 
in  TBST.  Details  of  the  primary  antibodies  used  in  the  experiments  are 
indicated  throughout  the  text  where  they  have  been  used.  The  blocked 
nitrocellulose  membrane  was  then  sealed  in  an  airtight  hybridisation  bag 
containing the primary antibody solution and this was incubated for 1h at room 
temperature, or overnight at 4°C, with vigorous agitation. The membrane was 
then  washed  several  times  with  TBST  before  the  application  of  the 
appropriate  horseradish  peroxidase  (HRP)  conjugated  anti  immunoglobulin 
secondary antibody diluted 1:5000 in 1% milk powder in TBST in a sealed bag 
as  before.  Similarly,  this  was  incubated  for  1h  at  room  temperature,  or   78 
overnight at 4°C, with vigorous agitation. The membrane was again washed 
several times with TBST before employing the Amersham Biosciences, UK 
enhanced chemiluminiscence (ECL) western blotting-kit as the visualisation 
protocol  for  detecting  bound antibodies.  Briefly,  the  bound  antibodies  were 
detected by exposure of the membrane to lumionol, a substrate for HRP that 
oxidises luminol in the presence of hydrogen peroxide. Luminol is converted 
to an excited stated which emits light that is received by blue-light sensitive X-
ray film and developed using the Kodak
® X-Omat model 2000 processor.  
 
2.11 Fusion protein interactions 
 
2.11.1 GST-MBP pull-downs assays 
 
Appropriate amounts of MBP fusion proteins were mixed with 100µl of slurry 
50% (v/v) PBS-washed amylose resin (Amersham Biosciences, UK) for 2h at 
4°C. The beads were pelleted by centrifugation at 14,000 x g for 1 min and 
washed twice with PBS containing 1% Triton X-100 before the addition of 50 
ug of the required GST fusion protein in a 1ml solution of PBS and Triton x-
100 containing 5mM Dithiothreitol. After 2h incubation at 4°C, the beads were 
collected  and  washed  three times  with  PBS  and  Triton  x-100  solution  and 
eluted in 100 µl of 1 x SDS sample buffer. Eluates were resolved by SDS-
PAGE and the bound GST fusion proteins were detected by immunoblotting 
as described in section 2.10.  
 
2.11.2 Peptide arrays 
 
Peptide  arrays  are  Whatmann
®50  cellulose  membranes  on  which  peptide 
sequences are directly synthesised (Reineke et al; 2001 and Frank; 2002). 
Each spot on a peptide array contains an overlapping 25mers spanning the 
entire  protein  sequence.  These  peptide  arrays  are  able  to  bind  purified 
recombinant proteins and provide evidence for direct protein interaction and 
the elucidation of the critical domains and the residues involved (Espanel and 
Hooft  van  Huijsduijnen;  2005  and  Bolger  et  al;  2006).  Substitution  alanine   79 
scans were also made where a particular amino acid is substituted by alanine 
to identify the critical residues involved in binding.  The peptide arrays used in 
the  experiments  detailed  in  the  thesis  were  kindly  produced  by  Dr.  E. 
Klussmann  (Forschungsinstiut  FÜr  Molekulare  Pharmakologie,  Berlin, 
Germany)  using  the  Intavis  Bioanalytical  instruments  (Köhn,  Germany) 
Autospot-Robot  ASS  222  and  utilising  Fmoc-Chemistry.  Recombinant  GST 
fusion  proteins  were  produced  homogeneity  as  described  in  section  2.4.2. 
The peptide arrays were activated by immersion in 100% ethanol and then 
washed in TBST for 10min at room temperature on an orbital shaker. The 
peptide arrays were then incubated or blocked with 5% milk powder (Marvel
®), 
reconstituted  in  TBST  for  1h  at  room  temperature  with  vigorous  agitation. 
Recombinant GST fusion protein or GST alone as control was then added to 
1% milk powder in TBST to a final concentration of between 3-10ug/ml and 
incubated with the peptide array in a hybridisation bag overnight at 4°C with 
vigorous  agitation.  The  peptide  array  was  then  subjected  to  three  10  min 
washes in TBST. Binding of the GST fusion protein to the peptide array was 
detected by incubation of the membrane with protein or GST specific primary 
antibody, followed by a HRP conjugated secondary antibody followed by ECL 
as described in section 2.10.3. As a general rule the primary antibody was 
used at two-fold less than the recommended dilution for immuno-blotting. The 
resolution of spots, distinct from the GST control peptide array, on the blue 
light  sensitive  X-ray  film  were  indicative  of  positive  interaction  of  the 
recombinant fusion protein with the peptide array and the critical sequences 
were  analysed  for  putative  consensus  or  binding  motifs  using  sites  like 
Scansite (Scansite.mit.edu).  
 
2.11.3 GST-Rhotekin pulldown assays 
 
GST-Rhotekin  beads  were  prepared  as  per  manufacturer’s  instructions 
(Millipore,  UK)  and  as  described  by  Barnes  et  al;  2005.  Following  the 
necessary cell treatments, cells were lysed in 1x ice-cold Mg
2+ lysis buffer 
(125mM  HEPES,  pH  7.5,  750mM  NaCl,  5%Igepal  CA-630,  50mM  MgCl2, 
5mM EDTA, 10% glycerol, 10ug/ml aprotinin and 10ug/ml leupeptin). Lysed 
cells were then incubated on ice for 10 min and then scraped into prechilled   80 
1.5 ml eppendorff
® tube. Lysates were centrifuged at 15000 x g for 5 min. 
Supernatant was then removed into a fresh tube and protein concentration 
was determined as described in section 2.9. A volume of lysate containing 
70ug of protein was then pipetted into a fresh prechilled 1.5 ml eppendorff
® 
tube and mixed with 30ug of GST Rhotekin beads in a final volume of 300µl. 
Lysates with beads were allowed to rotate for 1h at 4°C before the beads 
were washed 3 times with 1 x Mg
2+ lysis buffer. Following the last wash the 
majority  of  the  supernatant  was  removed  by  pipette  and  the  beads  were 
aspirated to dryness with a flat gel-loading tip followed by SDS-PAGE and 
immuno-blotting to determine the Rho activity of the samples.  
 
2.12 Co-immunoprecipitation  
 
Mammalian cell lines were co-transfected, as described above in section 2.6 
and cell lysates were produced by sub-cellular fractionation as described in 
2.8. The protein concentrations of the samples were determined as described 
in  section  2.9  and  the  concentrations  equalised  for  all  samples  to  contain 
approximately 250ug of protein in a 500µl volume of ice-cold KHEM. A 30µl 
sample  of  the  diluted  lysate  was  removed  for  western  immunoblotting  to 
determine he relative immuno-reactive inputs of the co-expressed proteins for 
the co-immunoprecipitation experiment. Anti-Flag or anti-VSV agarose beads 
pre-equilibrated in ice-cold KHEM to produce 50% slurry. 60µl of the slurry 
was added to each 500µl protein sample and these were incubated end-over-
end wheel for 2 h at 4°C. The samples were centrifuged at 13,000 x g for 1 
min at 4°C. Bound proteins were then eluted in 1x SDS sample buffer and 
subjected to SDS-PAGE and western immunoblotting as described in section 
2.10.2  and  2.10.3  respectively.  The  quantification  by  densitometry,  of  the 
immuno-reactive amounts of the co-expressed proteins, in both the initial cell 
lysate  and  following  co-immunoprecipitation,  was  determined  using  the 
Discovery series Quantity one
® software, version 4.4.0. These data were used 
to compare the interaction efficiency of the two proteins and assess conditions 
that may facilitate the specific interaction. Control immuno-precipitations were 
undertaken in a similar manner with cell lysates produced from cells singly   81 
transfected  with protein  that  was  co-immunoprecipitated  to  screen  for  non-
specific binding to the chosen agarose bead conjugate.  
2.13 Phosphodiesterase activity assay  
 
To measure PDE activity a radioactive cAMP hydrolysis assay was employed. 
This  procedure  has  been  described  previously  (Marchmont  and  Houslay, 
1980) and is a modification of a historical two-step procedure (Thomson and 
Appleman,  1971).  PDE  enzymes  hydrolyse  cAMP,  which  results  in  the 
formation of 5’AMP. In this assay, both [8-
3H] adenosine 3’, 5’-cyclic mono-
phosphate  from  Amersham  Biosciences,  UK  and  adenosine  3’,  5’-cyclic 
mono-phosphate are hydrolysed.  
 
2.13.1 Activation of Dowex 1x8-400 anion exchange resin 
 
Dowex  1x8-400  was  prepared  and  activated  by  dissolving  400g  of  dowex 
resin in 4 litres of 1M NaOH. The solution was stirred for 15 min at room 
temperature and the resin was allowed to settle down. The supernatant was 
removed and the dowex resin extensively washed 30 times with 4 litres of 
distilled water and allowed to settle after each wash. After thirty washes the 
resin was washed with 4 litres of 1M HCl for 15 min at room temperature and 
allowed to settle. The resin was then washed a further 5 times with distilled 
water  and  stored  at  4°C  as  1:1  slurry  with  distilled  water.  This  procedure 
generally produced approximately 1 litre of Dowex slurry. This Dowex slurry 
was utilised in the PDE assay as a 2:1 solution of slurry to 100% ethanol.  
 
2.13.2 Assay procedure 
 
The  assay  was  performed  1.5ml  eppendorff
®  tubes.  The  cAMP  substrate 
solution for the assay was composed of 2µl of 1mM 3’, 5’ cyclic adenosine 
mono-phosphate  3µl  of  740GBq/mM  [8-
3H]  adenosine  3’,  5’-cyclic  mono-
phosphate per millilitre of PDE substrate buffer (20mM Tris Cl; pH 7.4, 10mM 
MgCl2). The appropriate volume of purified protein or cell extract was diluted 
to a final volume of 50µl in PDE assay buffer (20mM Tris Cl; pH 7.4). 50µl of 
PDE assay buffer was used as a blank control. The exact volume of purified   82 
protein or cell extract required in the assay was predetermined in a pilot assay 
using  increasing  concentrations  of  protein  samples  to  ensure  activity 
measurements  were  within  detection  range.  50µl  of  cAMP  substrate  was 
added  to  50µl  of  PDE  containing  sample,  mixed  and  these  were  then 
incubated in a water bath at 30°C for 10 min to allow hydrolysis. The samples 
were then placed in a boiling bath for 2 min to inactivate the PDE and stop the 
reaction. The tubes were then cooled on ice for a minimum of 15 min. 25µl of 
1mg/ml snake venom of Ophiphagus hannah was then added to the reaction 
tubes,  mixed  and  incubated  for  a  further  10min  at  30°C.  400µl  of  Dowex-
ethanol mixture was added to each reaction tube, mixed and incubated on ice 
for a further 15min. Snake venom prevents re-circularisation of uncharged 5’ 
AMP by further hydrolysis to adenosine and the dowex slurry binds charged, 
unhydrolysed cAMP. Following incubation the tubes were then mixed again 
and centrifuged at 13000 x g for 3 minutes at 4°C in a refrigerated bench-top 
centrifuge. 150µl of supernatant from each reaction was added to 1ml of Opti-
Flow SAFE1 scintillant in a fresh 1.5ml eppendorff
® tube and mixed well. The 
extent of cAMP hydrolysis by PDE was determined by measuring the 8-
3H 5’-
AMP in 150µl of each supernatant using a Wallac
® 1409 liquid scintillation 
counter. 50µl of cAMP substrate solution was also added to 1ml of Scintillant 
and counted to provide a total count for the calculation of PDE activity.  
 
2.13.3 Determination of phosphodiesterase activity 
 
To  determine  specific  PDE  activity  contained  within  any  reaction  tube  the 
following formula was applied 2.61x (value-blank/average total) x10
11X10
12 x 
(1000/ug protein) resulting PDE activity in pmoles/min/mg protein. To assess 
the effect of PDE inhibition, the activities of samples containing inhibitor were 
directly compared to an uninhibited control reaction and were expressed as 
the percentage of the aforementioned uninhibited control.  
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2.14 In vitro phosphorylation assays 
 
2.14.1 In vitro PKA phosphorylation assay  
 
All  PKA  phosphorylation  assays  were  undertaken  using  Promega
®  purified 
PKA catalytic subunit. The expression and purification of MBP or GST fusion 
proteins  in  E.coli  was  undertaken  as  described  in  section  2.4  and  the 
concentration of the purified protein determined as described in 2.9. 1ug of 
fusion protein and 10 units of Promega
® recombinant protein kinase A were 
diluted in phosphorylation buffer (100mM Tris-HCl pH 7.5, 0.2mM ATP, 10mM 
MgCl2, 30mM β-mercaptoethanol, 20% glycerol, 10mM Calyculin A) (One unit 
of  PKA  is  defined  as  an  amount  of enzyme  required  to  incorporate  1pmol 
phosphate into casein in one minute).  The reaction was incubated at 30°C for 
30 min to allow phoshphorylation. A control was set up without PKA catalytic 
unit.  The  reaction  stopped  by  the  addition  1  x  SDS  sample  buffer.  The 
samples were then analysed by SDS-PAGE and immunoblotting. The extent 
of PKA phosphorylation was determined by using a PKA phosphosubstrate 
antibody that specifically recognises phosphorylated PKA substrates.  
 
2.14.2 In vitro ERK phosphorylation assay 
 
 All ERK phosphorylation assays were undertaken using purified recombinant 
MAPK-2  from  Upstate  cellular  signalling
®.  The  procedure  was  same  as 
described in section 2.14.1.  
 
2.15 Foci-Plate reader assays 
This  procedure was followed as described in Terry et al. 2003  
CHO cells stably transfected with PDE4A4GFP were plated overnight onto 
96-well plates (Costar, UK) at a density of 1x10
6 cells/ml. Cells were then 
treated for 1-24h with a range of signalling inhibitors either with or without 
rolipram.  PDE4A4-GFP  accretion  foci  were  quantified  by  measuring  GFP 
fluorescence using a Packard Fusion Plate Reader equipped with appropriate 
filter set (GFP: exc 485nm, emi 527nm; Hoescht: exc 355nm, emi 460 nm).   84 
Total GFP per well was measured first from live cells in full growth media, 
then cells were treated with an extraction buffer (0.4% formaldehyde in PBS 
with  1%  tritonX-100)  for  10  min  at  room  temp.  Full  fixation  and  nuclear 
staining  was  completed  with  fixation  buffer  (4%  formaldehyde  with  10  uM 
Hoescht in PBS) and the cells were washed three times in PBS. PDE4A4 
accretion foci were quantified by calculating immobile GFP as percentage of 
the total GFP (mobile and immobile). Hoescht values were used to monitor 
cell numbers.  
 
2.16 In vitro SUMOylation assay  
 
GST  or  MBP  fusion  proteins  were  expressed  and  purified  as  described  in 
section  2.4.  The  purified  proteins  were  used  in  the  in  vitro  SUMOylation 
assays (Biomol, UK) according to the manufacturer’s instructions. Briefly, the 
SUMOylation  buffer,  SUMO  ligases,  Mg-ATP  mixture  and  5ug  of  purified 
recombinant proteins were mixed in an eppendorff
® tube and were incubated 
at 30°C for an hour. The SUMOylation assays were quenched using 25µl of 1 
x  SDS  sample  buffer  and  the  samples  were  analysed  by  SDS-PAGE  and 
immunoblotting as described in section 2.10. The extent of SUMOylation was 
determined using a SUMO specific antibody as well as by band shift caused 
by SUMOylation.  
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Plasmid   Antiobiotic 
resistance 
Expression  Description 
pcDNA 3.1 UBC9  Ampicillin  Mammalian  UBC9 
PcDNA3.0His SUMO  Ampicillin  Mammalian  SUMO-1 
pKW HA PIASy  Ampicillin  Mammalian  PIASy 
pcDNA3.1VSV 4D5   Ampicillin  Mammalian  PDE4D5 VSV tag 
pcDNA3.1VSV  4D5 
FQF mutant 
Ampicillin  Mammalian  PDE4D5  VSV  tag-
FQF mutant 
pcDNA3.1VSV  4D5 
K323R mutant 
Ampicillin  Mammalian  PDE4D5  VSV  tag-
K323R mutant 
pcDNA3.1FLAG 
βarrestin1  
Ampicillin  Mammalian  β-arrestin-1 Flag tag 
pEGFP RACK1  Kanamycin  Mammalian  RACK1 GFP fusion  
MycEXV3 ERK2  Ampicillin  Mammalian  ERK2 myc tag 
pEGFP AKAP18δ  Kanamycin  Mammalian  AKAP18δ GFP 
pS462 4A4GFP  Kanamycin  Mammalian  GFP PDE4A4 
pGEX3 UBC9  Ampicillin  E.coli  GST UBC9 
pGEX4 4D5  Ampicillin  E.coli  PDE4D5 with GST 
pGEX-4D5  K323R 
mutant 
Ampicillin  E.coli  K323R  mutant  of 
PDE4D5  
pGEX6 Arrestin  Ampicillin  E.coli  β-arrestin-1 GST 
pGEX4T3 AKAP18δ  Ampicillin  E.coli  AKAP18δ GST 
pGEX4T3 RACK1  Ampicillin  E.coli  RACK1 GST 
pGEXEV3 ERK2  Ampicillin  E.coli  ERK2 GST 
pGEX4T ARHGAP21 
1064-1346 
Ampicillin  E.coli  ARHGAP21(1064-
1346 a.acids) GST  
pGEX4T ARHGAP21 
1042-1346 
Ampicillin  E.coli  ARHGAP21(1042-
1346 a.acids) GST 
pGEX4T ARHGAP21 
929-1346 
Ampicillin  E.coli  GST  of  ARHGAP21 
fragment  929-1346 
a.acids 
pGEX4T ARHGAP21 
929-1096 
Ampicillin  E.coli  ARHGAP21(929-
1096 a.acids) GST 
pGEX4T ARHGAP21 
885-1096 
Ampicillin  E.coli  ARHGAP21(885-
1096 a.acids) GST 
pGEX4T ARHGAP21 
885-1052 
Ampicillin  E.coli  ARHGAP21(885-
1052) GST 
pGEX4T ARHGAP21 
929-1052 
Ampicillin  E.coli  ARHGAP21(929-
1052 acids) GST   86 
 
pGEX4.0 UCR1  Ampicillin  E.coli  PDE4D UCR1 GST 
pGEX4.0 UCR2  Ampicillin  E.coli  PDE4D UCR2GST 
pGEX4.0  Catalytic 
region 
Ampicillin  E.coli  PDE4D  Catalytic 
region GST 
pMALN Arrestin  Ampicillin  E.coli  β-arrestin-1 MBP 
pMAL 4D5   Ampicillin  E.coli  PDE4D5 MBP 
pMAL 4A4B  Ampicillin  E.coli  PDE4A4 MBP 
pMALC2 4B1  Ampicillin  E.coli  PDE4B1 MBP 
 
 
Table 2.2 cDNA plasmid constructs used for protein over-expression in 
either E.coli or mammalian cells.  
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Chapter 3 SUMOylation of PDE4 isoforms in HEK293 cells 
 
3.1 Introduction 
 
3.1.1 SUMO modification   
 
Small Ubiquitin-like Modifier proteins modulate the structure and subsequently 
the function of its target protein by covalently attaching to a lysine residue 
within the consensus motif ΩKXE/D, where Ω is a hydrophobic amino acid 
and X is any residue (Johnson, 2004).  
 
SUMO modification of proteins is known to regulate various cellular processes 
ranging from transcriptional activity (Motter and Castronovo, 2007, Yang et al; 
2003  and  Zhao  et al;  2005)  to  cell  signalling  such  as regulation  of mitotic 
check points (Bischof and Dejean; 2007, Gutierrez and Ronai 2007), Kerscher 
et al; 2006).  
 
3.1.2 SUMO conjugation pathway  
 
The SUMO conjugation pathway is very similar to ubiquitin pathway both in 
structure and function (summarized in Figure 3.1). The components of SUMO 
pathway are highly conserved in all eukaryotes. There are four different kinds 
of  SUMO  molecules  1-4,  which  are  conjugated  to  various  substrates  by 
specific ligases (Johnson, 2004). 
 
Initiation of the SUMO conjugation pathway involves activation of a SUMO 
molecule by SUMO proteases. So far, six mammalian SUMO proteases have 
been  identified  and  they  have  all  been  classed  under  ulp  (Ubiquitin  like 
protease) family. Human SUMO proteases SENP 1, 2, 3 and 5 are closely 
related  to  ulp1  in  yeast  whereas  SENP  6  and  7  are  related  to  ulp2  (Hay, 
2007).  SUMO  proteases  have  dual  functions.  Firstly,  their  C-terminal 
hydrolase  activity  processes  the  SUMO  molecule  leading  to  its  maturation 
such that the two C-terminal diglycine residues are exposed. They also    89 
function to cleave SUMO molecules from SUMO-conjugated proteins by their 
isopeptidase activity thus contributing to SUMO turnover in the cells (Li and 
Hochstrasser, 2003). 
 
SUMO  maturation  also  involves  the  enzyme  complex,  SUMO  activating 
enzyme E1 complex. Unlike ubiquitin E1, SUMO E1 enzyme is a heterodimer 
complex comprising the Aos1 and Uba2 proteins also known as SAE1 (SUMO 
Activating  enzyme  and  SAE2  respectively.  Both  E1  subunits  possess  a 
nucleotide-binding motif, GXGXXG, which is able to form a thio-ester bond 
with the C-terminal glycine residue in SUMO molecules. This process is ATP-
dependent and is inherent for activation of the enzyme complex (Desterro et 
al;  1999).  Activated  SUMO-E1  enzyme  subsequently  transfers  the  SUMO 
molecule  to  a  C-terminal  cysteine  residue  of  UBC9,  a  SUMO  conjugating 
enzyme; this transfer involves the formation of thio-ester bond between the 
SUMO molecule and UBC9. To date, UBC9 is the only SUMO conjugating 
enzyme to be identified (Hayashi et al; 2002).  
 
Transfer of SUMO molecule from UBC9 to the target protein is achieved by 
E3 ligases. There are three different classes of E3 ligases as described in 
section 1.10.1.4. All classes of E3 ligases share three functional properties. 
Firstly,  they  all  bind  to  E2  enzyme(UBC9).  Secondly,  they  all  bind  to  the 
SUMOylating target protein and thirdly, they all transfer SUMO from SUMO-
UBC9  complex  to  the  ε-amino  group  of  the  lysine  residue  within  SUMO 
consensus motif present on the substrate (Johnson, 2004). Interestingly, only 
the E1 and E2, but not E3, enzymes are required for SUMO conjugation in 
vitro. However, E3 enzymes have been shown to enhance the SUMOylation 
efficiency of their substrates both in vitro and in vivo (Okuma et al, 1999). 
Furthermore,  the  E3  SUMO  ligase  is  essential  for  the  SUMO  conjugation 
pathway in yeast (Takahashi et al; 2003).  
 
Availability of SUMO molecules for conjugation is under stringent control as 
almost all of SUMO is present as protein conjugates (Desterro et al; 1999). 
The pathway is summarized in fig 3.1 and in the first paragraph of section 
3.1.2.    90 
 
3.1.3 PDE4 isoforms and SUMO pathway  
 
Research  within  our  group  has  shown  that  PDE4  enzymes  can  be 
ubiquitylated (unpublished data). Given the similarity of SUMO and Ubiquitin 
conjugation pathways a SUMOPLOT
® analysis of PDE4 isoform sequences 
identified  potential  SUMOylation  sites  within  members  of  the  PDE4  family 
(www.abgent.com.cn/doc/sumoplot).  This  chapter  focuses  on  the 
SUMOylation of PDE4 sub-familes.  
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Figure 3.1 Schematic of SUMO conjugation pathway 
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3.2.1 SUMOylation of PDE4 isoforms in HEK 293 cells  
 
Earlier work from our group and collaborators (unpublished data) had shown 
that PDE4D5 is SUMOylated on lysine 323 in vitro (unpublished results). In 
order  to  examine  the  effects  of  SUMOylation  of  PDE4D5  in  vivo,  HEK293 
cells  were  co-transfected  with  plasmids  encoding  an  HA  epitope-tagged 
PIASy E3 ligase and a VSV epitope tagged wild type PDE4D5 or a mutant of 
PDE4D5 in which residue K323 had been mutated to arginine by site-directed 
mutagenesis  as  described  in  section  2.3..  Expression  of  the  transfected 
constructs in lysates was confirmed by SDS-PAGE and Western blotting. In 
figure 3.2 a 1,  immunoblotting with anti-VSV antibody identified two species 
of  wild-type  PDE4D5  migrating  at  ~100  and  125  kDa  corresponding  to 
unmodified  PDE4D5  and  SUMOylated  PDE4D5  respectively (upper  panel). 
However,  the  PDE4D5  K323R  mutant  migrated  as  a  single  species  of 
~100kDa. Co-expression of PIASy E3 ligase was confirmed by probing with 
anti-HA antisera (lower panel). In a separate experiment, probing for SUMO-1 
using an antibody against SUMO-1 identified a single band of ~125 kDa in the 
lysates expressing wild type PDE4D5 but not the K323R mutant (figure 3.2 a 
2).  
 
Since the lysine of PDE4D5 which undergoes SUMO modification is located 
within  a  region  of  the  catalytic  domain  of  PDE4D  which  is  moderately 
conserved between the PDE4 subfamilies, sequence alignment of each PDE4 
subfamilies was performed which revealed the SUMO consensus site to be 
present  in  only  the  PDE4A  and  4D  sub-families  but  not  the  PDE4B  and 
PDE4C  subfamilies  (Figure  3.2  b).To  test  the  ability  of  other  PDE4  sub-
families  to  serve  as  SUMOylation  substrates  plasmids  expressing  PDE4 
isoforms  from  the  other  three  sub-families  namely,  PDE4A4,  PDE4B1  and 
PDE4C2 were co-expressed with or without PIASy E3 ligase in HEK293 cells. 
Immunodetection  of  transfected  lysates  showed,  as  predicted,  PDE4A4 
migrated as two species when co-transfected with PIASy E3 ligase with the 
higher molecular weight band corresponding to SUMOylated PDE4A4 (Figure 
3.2 C 1).  In contrast, the migration of immunodetected PDE4B1 and PDE4C2   93 
isoforms was unaltered by PIASy co-expression (Figure 3.2 C 2, 3) indicative 
of their inability to serve as SUMOylation substrates.  
 
3.2.2 Interaction of UBC9 with PDE4D5 
 
Work from our group has indicated that PDE4D5 interacts with UBC9 SUMO 
conjugating  enzyme  E2  (unpublished  data).  To  identify  putative  sites  of 
interaction, a peptide array strategy was used. Indeed our group has exploited 
this  technique  to  identify  interaction  sites  that  define  the  interaction  of  the 
PDE4D5 isoform with the signalling scaffold proteins, ￿ arrestin and RACK1 
(Bolger  et  al.,  2006;  Baillie  et  al.,  2007).  PDE4D5  peptides  (25-mers) 
sequentially shifted by 5 amino acids across the entire sequence of PDE4D5, 
were immobilized on cellulose membranes. This was then probed with GST-
UBC9, a recombinant fusion protein of UBC9 with Glutathione-S-transferase 
and  expressed  in  E.  coli  prior  to  purification  for  use  as  a  probe.  Positive 
interactions  were  evident  as  dark  spots  on  the  PDE4D5  array.  The  probe 
identified  an  interaction  site  within  the  C-terminal  portion  of  the  PDE4D5 
catalytic domain. This site is called FQF ERK docking site (Mackenzie et al; 
2000) and is present in the catalytic region that maps to amino acids 661-685 
(Spot 133, figure 3.3 a). Each amino acid of the interaction peptide was then 
sequentially mutated to alanine to identify key residues for interaction. On the 
alanine scanning substitution array mutation of either phenylalanine residue 
within the sequence “F670A/Q671/F672A” severely ablated the interaction of 
UBC9 with PDE4D5 (Figure 3.3 a). To further support of these findings, a 
peptide  with  N-terminal  stearoyl  group  representing  the  PDE4D5  25-mer 
(Spot  133,  figure  3.3a)  shown  to  interact  with  UBC9  was  generated  in  an 
effort to disrupt this interaction in vivo. Stearated peptides have been shown 
to enter cells and specific species have been used to disrupt protein-protein 
complexes by competing for binding partners (Hundsrucker et al; 2006, Baillie 
et  al;  2007,  Murdoch  et  al;  2007).  HEK293  cells  transiently  expressing 
PDE4D5-VSV and UBC9 were treated with a non-related control stearated 
peptide or the PDE4D5 peptide containing “FQF” motif for 3 hours. PDE4D5-
VSV  was  immunoprecipitated  from  lysates  using  VSV-conjugated  agarose 
beads  and  co-precipitating  UBC9  was  detected  using  anti-UBC9  antisera.   94 
PDE4D5 interaction with UBC9 in cells treated with the control peptide was 
unaltered from non-treated cells. However, in the cells treated with PDE4D5 
“FQF”  containing  peptide,  interaction  of  UBC9  with  PDE4D5  was  then 
abolished (Figure 3.3 b).  
 
3.2.3 Interaction of PIASy SUMO E3 ligase with PDE4D5 
 
Having determined an interaction of PDE4D5 with UBC9, interaction of PIASy 
E3 ligase with PDE4D5 was also studied. HEK293 cells transiently expressing 
wild type PDE4D5-VSV and PIASy-HA were harvested and the complexes 
were  immunoprecipitated  using  VSV-  and  HA-conjugated  agarose 
respectively.  Control  immunoprecipitation  experiments  were  performed  with 
Protein  G-sepharose.  Non-SUMOylated  PDE4D5-VSV  species  showed 
interaction  with  immunoprecipitated  PIASy  (Figure  3.4  a1).  In  order  to 
determine  if  PIASy  interacts  within  the  same  region  as  UBC9,  an 
“F670A/Q671/F672A” mutant of PDE4D5 was used. The F670A/Q671/F672A 
mutant of PDE4D5, which is unable to interact with UBC9, was still able to co-
precipitate  with  PIASy  E3  ligase.  However,  the  PDE4D5-VSV 
“F670A/Q671/F672A”  mutant  migrated  as  a  single  band  indicative  the 
PDE4D5  was  not  SUMOylated  (Figure  3.4  a2).  Furthermore,  the  PDE4D5 
mutant K323R, which is not a SUMOylation substrate, was also able to co-
precipitate with PIASy (Figure 3.4 a3).  
 
To further characterise the interaction of PDE4D5 with PIASy, purified GST-
fusion  proteins  of  PDE4D5  and  its  individual  domains  (UCR1,  UCR2  and 
catalytic regions) were used in pull-down assays to test their ability to interact 
with  PIASy-HA  from  transfected  HEK293  cell  lysates.  The  purified  PDE4D 
GST fusion proteins were immobilised on glutathione sepharose beads and 
then  incubated  with  PIASy-HA  lysates  for  2  hours.  The  complexes 
immobilised were then analysed for pull-down of PIASy. PIASy was shown to 
interact  with  only  full-length  PDE4D5  and  not  with  any  of  the  individual 
PDE4D domains of PDE4D5 (Figure 3.4 b). Expression and pull-down of the 
GST fusion proteins was visualized by Ponceau S staining of the membrane 
(Figure 3.4 b)   95 
 
To study this interaction in greater detail, a scanning peptide array analysis 
was used. A peptide array spanning the full length PDE4D5 was incubated 
with  PIASy-HA  purified  from  an  in  vitro  protein  expression  system  as 
described in sections 2.4.3 and 2.4.4 and probed with a monoclonal anti-HA 
antibody.  PIASy  showed  interaction  with  spots  B8-10  and  G2-G5,  which 
correspond to PDE4D5 residues 111-140, which lie within the UCR1 region, 
and residues 486-530 within the catalytic domain (Figure 3.4 C2).  
 
3.2.4 Affect of signalling pathways on SUMOylation of PDE4D5 
 
In an attempt to determine the stimulus for SUMOylation of PDE4D5, HEK293 
cells  expressing  PDE4D5-VSV  and  PIASy-HA  were  subjected  to  various 
treatments  as  indicated  that  would  modulate  various  cellular  signalling 
cascades  including  cAMP  signalling  (forskolin/IBMX,  EPAC,  Rolipram), 
oxidative stress pathway (H2O2)and ERK signalling (EGF, PMA, Anisomycin). 
SUMOylated PDE4D5 was immunoprecipitated using the SUMO-1 antibody 
and  immunodetected  with  VSV  antisera.  SUMOylation  of  PDE4D5  did  not 
appear to be affected by any of these stimuli (Figure 3.5). 
 
3.2.5 Affect of SUMOylation on Sub-cellular localisation of PDE4D5 
 
SUMO modification of various substrate proteins is shown to alter their sub-
cellular localisation (Wies, 2003 and Zhao 2007). Nuclear extraction analysis 
was used to elucidate the effect of SUMOylation on sub-cellular localisation of 
PDE4D5. HEK293 cells transiently expressing PDE4D5 VSV with and without 
PIASy were treated with hypotonic buffer and extraction buffer to separate 
cytoplasmic and nuclear fractions respectively. Lysates were then analyzed 
by  SDS-PAGE  and  immunoblotted  for  PDE4D5-VSV.  SUMOylated  and 
unmodified  forms  of  PDE4D5  localised  exclusively  to  cytoplasmic  fractions 
and not to nuclear fractions of the cell (Figure 3.6). Lysates were re-probed for 
C-Jun, a nuclear protein, and p70S6 Kinase, a cytoplasmic protein as positive 
controls.  To  further  evaluate  the  role  of  SUMOylation  in  determining  sub-
cellular  localisation,  fraction  studies  were  carried  out  by  differential   96 
centrifugation.  HEK293  cells  expressing  PDE4D5  before  and  after 
SUMOylation were subjected to sub-cellular fraction as described in section 
2.9. The fractions were analysed by SDS-PAGE and immunoblotting (figure 
3.6).  
 
3.2.6 Affect of SUMOylation on PDE4 activity 
 
Various  interacting  partners  have  been  shown  to  change  the  activity  and 
rolipram  sensitivity  of  PDE4  isoforms  (Houslay  and  Adams;  2003).  A  PDE 
assay  was  performed  to  determine  the  potential  role  of  SUMOylation  in 
regulating PDE4 activity. Purified GST-PDE4D5 was in vitro SUMOylated as 
described  in  section  2.16.  The  SUMOylated  pool  of  GST-PDE4D5  was 
selectively isolated upon incubation with SUMO-1 antibody complexed with 
Protein G-sepharose beads. The precipitates were then used for PDE assays 
as described in section 2.13.  SUMOylation did not affect the PDE4 activity in 
comparison to nonSUMOylated PDE4D5. A similar assay was performed with 
GST alone and GST incubated with SUMO ligases as controls (Figure 3.7 a). 
 
PKA  phosphorylation  is  known  to  increase  PDE4  activity  by  activating  the 
enzyme (Sette and Conti; 1996, Hoffmann et al; 1998, Mackenzie et al, 2002, 
Ekholm et al; 1997). In order to evaluate the role of SUMOylation in regulating 
the PKA-mediated activation of PDE4D5, SUMOylated and un-SUMOylated 
PDE4D5-GST  was  in  vitro  PKA  phosphorylated  as  described  in  2.14.1. 
Samples  then  immobilised  on  glutathione  sepharose  were  washed  and 
subjected to PDE assay as described in 2.13. PKA phosphorylated PDE4D5 
showed a 2.5-fold increase in PDE activity compared to non-phosphorylated 
PDE4D5 whereas PKA phosphorylated SUMO PDE4D5 showed a five-fold 
increase in activity compared to its non-phosphorylated form (Figure 3.7 b). In 
similar  experiments  looking  at  the  effects  of  ERK2  phosphorylation,  un-
SUMOylated PDE4D5 showed a decrease in activity by ~60% whereas ERK 
phosphorylation  did  not  have  any  effect  on  SUMOylated  PDE4D5  activity 
(Figure 3.7 c) with the PDE activity the same as the non-GRK phosphorylated 
PDE4D5-SUMO protein. 
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3.2.7 Affect of SUMOylation on rolipram sensitivity of PDE4D5 
 
Interaction of SRC tyrosyl kinases through its SH3 domains is known to affect 
the rolipram sensitivity of PDE4 isoforms (McPhee et al, 1999). A rolipram 
dose response curve of in vitro SUMOylated and nonSUMOylated PDE4D5 
was therefore performed to determine the effect of SUMOylation on rolipram 
sensitivity.  PDE4D5  had  an  IC50  of  3.8  +/-  0.2uM  for  rolipram  whereas 
SUMOylated PDE4D5 had an IC50 of 0.45 +/- 0.03uM, thus showing more 
sensitivity to rolipram. As anticipated, a mixed population of nonSUMOylated 
PDE4D5 and SUMOylated PDE4D5 exhibited an IC50 of 1.5 +/- 0.01uM for 
rolipram, a value intermediary with the two previous observations (figure 3.8 
top panel). A further dose response assay was performed with the K323R 
SUMO mutant of PDE4D5, which similar to findings with the nonSUMOylated 
wild-type form had an IC50 of 3.9 +/- 0.027uM for rolipram in vitro (Figure 3.8 
bottom panel).  
 
3.2.8 Affect of SUMOylation and PKA phosphorylation on rolipram sensitivity 
of PDE4D5 
 
Since  SUMOylation  was  found  to  augment the  increase  in  activity  of  PKA 
phosphorylated PDE4D5, whilst not having a direct effect itself on activity, a 
dose  response  assay  for rolipram  was  carried  out  to  examine  the  conjoint 
effects  of  PKA  phosphorylation  and  SUMOylation  on  rolipram  sensitivity  of 
PDE4D5. PKA-phosphorylated PDE4D5 was shown to have an IC50 of 0.5 +/-
0.01uM whereas the non-phosphorylated PDE4D5 exhibited an IC50 of 3.8 +/- 
0.2uM. The PKA phosphorylated and SUMOylated PDE4D5 form had an IC50 
of  0.15  +/-0.009uM  compared  to  0.47  +/-  0.03uM  for  the  non-PKA 
phosphorylated SUMOylated PDE4D5 protein (figure 3.9).  
 
 
 
3.2.9 Affect of SUMOylation and PKA phosphorylation on rolipram sensitivity 
of PDE4D5 
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Mackenzie et al, 2000 showed that ERK2 phosphorylation has an inhibitory 
effect on PDE4D5 activity. To analyse the effect of SUMOylation on ERK-
mediated inhibition of PDE4D5 activity a PDE assay was performed as shown 
in figure 3.7. To investigate the subsequent role of SUMOylation and ERK 
inhibition on rolipram sensitivity, a dose response curve was performed on 
SUMOylated  and  non-SUMOylated  PDE4D5  proteins  after  in  vitro  ERK 
phosphorylation  as  described  in  2.14.2.    Non-SUMOylated  PDE4D5  was 
totally  inhibited  by  ERK  phosphorylation.  In  contrast  to  this,  ERK 
phosphorylation of SUMOylated PDE4D5 did not alter its rolipram sensitivity 
as compared to non-phosphorylated, SUMOylated PDE4D5 (figure 3.10). 
 
3.2.10 Affect of SUMOylation and RACK1 binding on rolipram sensitivity of 
PDE4D5  
 
RACK1 is an identified binding partner of PDE4D5 and is shown to change 
the sensitivity of PDE4D5 for rolipram by 3-4 fold (Yarwood et al; 1999). Given 
these findings, a dose response curve was performed to ascertain the effect 
of  RACK1  binding  on  the  rolipram  sensitivity  of  SUMOylated  and  non-
SUMOylated PDE4D5 in vitro. As the only fusion protein we have for RACK1 
is  a  GST  species,  here  I  investigated  the  interaction  of  RACK1-GST  with 
PDE4D5-MBP, instead of PDE4D5-GST. Purified RACK1-GST was incubated 
with  immobilised  SUMOylated  and  non-SUMOylated  PDE4D5-MBP 
recombinant proteins and assayed for PDE activity. RACK1-bound PDE4D5 
showed a 1.5 fold decrease in rolipram sensitivity with a shift in IC50 from 3.8 
+/-  0.2uM  (wild  type)  to  5.6  +/-  0.03uM.  Similarly,  the  IC50  of  rolipram  for 
RACK1-bound, SUMOylated PDE4D5 increased from 0.45 +/- 0.03uM to 1.2 
+/-  0.009uM.  A  control  experiment  was  performed  concomitantly  in  which 
GST-RACK1 was substituted with GST alone. GST alone did not affect the 
rolipram  sensitivity  of  either  SUMOylated  or  non-SUMOylated  species  of 
PDE4D5 (Figure 3.11).  
 
3.2.11 Affect of SUMOylation on affinity of PDE4 isoforms for β-arrestin 
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All PDE4 isoforms are known to bind to β-arrestin at a site within the catalytic 
region (Bolger et al; 2003), an interaction which is critical for the recruitment of 
PDE4 isoforms to the β2-AR and mediating receptor desensitisation (Perry et 
al;  2002).  As  SUMOylation  of  proteins  is  known  to  change  the  affinity  of 
proteins for their interacting partners (Zhao, 2007), the role of SUMOylation in 
regulating  the  affinity  of  PDE4  isoforms  for  their  interacting  partners  was 
assessed using in vitro pull-down assays. Purified MBP- PDE4A4 and 4B1 
were  incubated  with  β-arrestin-GST  before  and  after  SUMOylation.  The 
complexes immobilised on amylose resin were washed and analysed by SDS-
PAGE  and  subsequent  immuno-detection  for  bound  β-arrestin  was  carried 
using  a  polyclonal  GST  antibody.  The  amount  of  β-arrestin  bound  to 
SUMOylated 4A4 and 4B1 was determined by densitometric analysis using 
Quantity  one  software
.  It  was  shown  that  the  level  of  immonodetected  β-
arrestin bound to SUMOylated PDE4A4 was ~50% more than the β-arrestin 
bound  to  non-SUMOylated  PDE4A4.  However,  in  assays  with  recombinant 
PDE4B1  no  change  in  affinity  for  β-arrestin  binding  was  detected  upon 
incubation with SUMO ligases (Figure 3.12 b). A control experiment to rule out 
any  non-specific  interactions  was  performed  by  incubating  PDE4A4  and 
PDE4B1  with  GST  alone.  Neither  PDE4A4  nor  PDE4B1  showed  any 
interaction with GST alone (Figure 3.12 a).  
 
3.2.12 Affect of SUMOylation on interaction of PDE4D5 with its partners in 
vitro 
 
PDE4  isoforms  interact  with  a  plethora  of  signalling  proteins  that  have 
multifarious functions (Lynch et al 2006). Pull-down assays were performed in 
order to understand the effects of SUMOylation on PDE4D5 interactions with 
partner proteins. Purified GST fusion proteins of PDE4 interacting partners 
including β-arrestin-1; AKAP18 δ, ERK2, UBC9 and RACK1 were incubated 
with PDE4D5-MBP or MBP alone. Complexes immobilised on amylose resin 
were analysed by SDS-PAGE and immunodetected using a GST antibody. All 
the partners showed an interaction with PDE4D5 MBP but not with MBP alone 
(Figure 3.13 I). Purified GST- partner proteins (β-arrestin-1; AKAP18 δ, ERK2,   100 
UBC9 and RACK1) were incubated with SUMOylated and non-SUMOylated 
PDE4D5-MBP and also with the K323R PDE4D5-MBP SUMO mutant. It was 
found that all partner proteins examined exhibited an increased association 
for  SUMOylated  PDE4D5  compared  to  the  non-SUMOylated  form  with 
association for β-arrestin-1, AKAP18δ, ERK2, RACK1 and UBC9 increased by 
2.5-, 1.5-, 2.5-, 1.5- and 1.5-fold respectively. As anticipated, there was no 
change in partner association upon incubation with the K323R PDE4D5-MBP 
mutant even in the presence of SUMO ligases (Figure 3.13 ii a-e).  
 
3.2.13 Affect of SUMOylation on interaction of PDE4D5 with its partners in 
HEK293 cells 
 
The effect of SUMOylation of PDE4D5 on its interactions with binding partners 
was further assessed in vivo. HEK293 cells were transfected with plasmids 
encoding PDE4D5 partner proteins as described along with PDE4D5-VSV or 
the  K323R  PDE4D5-VSV  SUMO  mutant  construct.  Cells  were  also 
transfected with or without the PIASy expression vector. PDE4D5-VSV was 
immunoprecipitated  using  VSV-agarose  and  probed  for  individual  partners 
proteins as indicated in figure 3.14 (a-e). Blots were then re-probed with a 
VSV  monoclonal  antibody.  The  association  for  SUMOylated  PDE4D5 
compared  to  the  non-SUMOylated  form  for  AKAP18δ,  β-arrestin  1,  ERK2, 
RACK1 and UBC9 was increased 1.5-, 1.5-, 5-, 5-, and 2-fold respectively. No 
change in association was detected in cells expressing the K323R PDE4D5 
mutant with or without PIASy overexpression (Figure 3.14 a-e lanes three and 
four  bottom  and  top  panels).  Membranes  were  re-probed  for  tubulin 
expression as a loading control.  
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Post-translational modifications have long been known to regulate the function 
of  proteins  in  distinct  ways  (Hasselgren,  2007).  Modifications  like 
myristoylation are known to be involved in membrane targeting (Frame, 2002) 
whereas  ubiquitylation  is  known  to  recruit  proteins  for  proteasomal 
degradation (Kaiser et al; 2000).  
 
SUMO  modification  of  proteins  is  a  relatively  newly  identified  and  poorly 
characterised  post-translational  modification  (Johnson  et  al;  2004). 
Components of SUMO modification are closely related to the Ubiquitin family 
in structure (Zha, 2007 and Krescher 2006). Of the PDE4 family of enzymes, 
sub-families  4A  and  4D,  but  not  4B  and  4C,  have  a  conserved  SUMO 
consensus site near their catalytic region (Figure 3.2 b). SUMO plot analysis 
of  PDE4D5  sequence  (www.abgent.com.cn/doc/sumoplot),  using  high 
stringency parameters, revealed a SUMOylation site at lysine 323. Previous 
work from our group has shown that PDE4D5 is SUMOylated in vitro. It was 
shown that only E1 and E2 components of the SUMO conjugation pathway 
but not E3 ligases were required for SUMOylation in vitro (Okuma et al; 1999). 
In similar studies in HEK293 cells which were co-transfected with UBC9 and 
PDE4D5,  no  SUMOylated  PDE4D5  species  were  immunodetected  in  cell 
lysates.  Furthermore,  in  HEK293  cells  overexpressing  PDE4D5  and  E3 
ligases,  PIAS1  and  PIAS2,  no  detectable  levels  of  SUMOylated  PDE4D5 
were  noted.  However,  in  cells  co-transfected  with  PIASy  E3  ligase, 
SUMOylation of PDE4D5 (migrating at ~125KD) that could be readily detected 
by both SUMO-1 and PDE4D5 antibodies (Figure 3.2 a). Immunblot analysis 
revealed that not all the PDE4D5 cellular pool was SUMOylated as shown by 
two distinct PDE4D5 migration bands on the gel. Non-SUMOylated PDE4D5 
migrated at ~100 KD as opposed to SUMOylated PDE4D5 that migrated at 
~125 KD. Consequent analysis of PDE4A4 transfected into HEK293 cells with 
PIASy  E3  ligase  yielded  similar  results.  SUMOylated  PDE4A4  migrated  at 
~150KD and the non-SUMOylated species at 125KD (Figure 3.2 c).  
 
PIASy  E3  ligase  is  a  complex  molecule  possessing  a  Chromatin  binding 
domain, SUMO ligase domain and an acidic domain from its N-terminus to 
variable C-terminus in the same order (Sachdev et al; 2001). PIASy is known   102 
to conjugate SUMO substrates such as LEF1 with SUMO-2 molecules and 
exhibits a preference for SUMO-2 over SUMO1 (Sachdev et al; 2001). In this 
study,  PDE4D5  conjugates  with  SUMO-1  as  confirmed  by  probing  lysates 
transfected with PDE4D5 and PIASy for SUMO-1. However, probing same 
lysates  for  other  SUMO  species  did  not  show  any  SUMOylated  forms  of 
PDE4D5.  Overexpression  of  SUMO-2  in  HEK293  cells  in  the  presence  of 
PIASy and PDE4D5 did not result in conjugation of PDE4D5 with SUMO-2 nor 
was  PDE4D5  conjugation  with  SUMO-2  detected  in  vitro.    The  underlying 
preference  of  PIASy  for  SUMO-1  in  conjugation  with  PDE4  isoforms  is 
unclear.  Mutation  of  the  predicted  SUMO  site,  Lys
323  to  Arg
323  ablated 
SUMOylation of PDE4D5 (Figure 3.2 a).  
 
Having  confirmed  SUMOylation  of  PDE4  isoforms  in  vivo,  PDE4D5  was 
chosen  for  further  characterisation  due  to  its  high  expression  levels  and 
relatively  known  biochemistry.  However,  where  appropriate,  other  isoforms 
were are also analysed in this study. To further understand the mechanism of 
SUMOylation of PDE4D5, interaction of the isoform with various components 
of SUMO conjugation pathway was investigated. 
 
Although UBC9 did not directly lead to SUMOylation of PDE4D5 in vivo, it 
interacted with PDE4D5 both in vitro and in vivo (figure 3.3 and 3.13 ii e). 
UBC9 interacts at a multi-functional docking site on PDE4D5. This region is 
the  FQF  region  located  near  the  catalytic  region  of  all  PDE4s  and  is  well 
known  for  it  ability  to  act  as  a  docking  site  for  ERK2  for  all  isoforms 
(Mackenzie et al 2000). Other PDE4 binding partners such as β-arrestin and 
AKAP18δ  are  also  known  to  interact  with  the  FQF  region  (McSorley  et  al, 
2006 and Bolger et al 2003). Although the FQF region plays an important role 
as  a  docking  site  for  many  PDE4-interacting  partners,  most  partners  bind 
PDE4s  at  multiple  sites;  for  β-arrestin  interaction  at  N-terminal  region  of 
PDE4D5 as well as the FQF region has been shown (Bolger et al; 2006) 
Alanine mutagenesis of the F670A/Q671/F672A region severely ablated the 
interaction of UBC9 with PDE4D5 in peptide array analysis and incubation 
with a cell permeable disruption peptide comprising the FQF region produced   103 
similar  effects  on  PDE4D5:UBC9  interaction  in  HEK293  cells  (Figure  3.3). 
Since UBC9 interacts at FQF region of PDE4D5, which conserved in all PDE4 
isoforms,  it  could  be  postulated  that  UBC9  can  potentially  interact  with 
members  from  all  PDE4  subfamilies.  However,  the  functional  outcome  of 
UBC9 interaction with the PDE4 subfamilies which cannot be SUMOylated 
remains unclear, as UBC9 is required for recognition of the SUMO consensus 
motif  in  substrates  of  SUMO  conjugation  pathway  (Johnson  and  Blobel, 
1997). The roles of UBC9 in functions other than SUMOylation have not been 
determined. 
 
PDE4D5 was shown to interact with PIASy E3 ligase both in vitro and in vivo 
(Figure 3.4). E3 SUMO ligases exert functions that are independent of their 
ligase activity. For example, Pc2 is an E3 ligase that is known to regulate 
histone  methylation  (Kagey  et  al;  2003).  Similarly,  the  PIAS  class  of  E3 
ligases are inhibitors of transcription factors STATs (Jackson 2001, Chung et 
al; 2003 and Chun et al; 2003). PIASy interaction with PDE4D5 in HEK293 
cells led to SUMOylation of the isoform. In order to confirm the role of UBC9 
in PIASy-mediated SUMOylation of PDE4D5, an F670A/Q671/F672A mutant 
of  PDE4D5  was  co-transfected  with  PIASy-HA  into  HEK293  cells.  The 
F670A/Q671/F672A mutant immunoprecipitated with PIASy but PIASy did not 
SUMOylate the F670A/Q671/F672A mutant (Figure 3.4 a2). It could therefore 
be suggested that since UBC9 cannot be recruited to the FQF mutant, PIASy 
is unable SUMOylate the isoforms. In support of this; previous studies have 
shown that UBC9 is critical in identifying the SUMO consensus site on the 
substrate (Okuma et al, 1999, Johnson and Blobel, 1997).  
 
Experiments showed that PIASy was able to interact with the K323R PDE4D5 
mutant  although  it  did  not  SUMOylate  PDE4D5  due  to  the  loss  of  lysine 
residue within the SUMO consensus site. These results also confirmed the 
prediction that only one consensus site for SUMOylation in PDE4 isoforms is 
present (Figure 3.4 a3). Partial pull-down assays were used to identify the 
binding regions of PIASy on PDE4D5. PIASy from HEK293 cell lysates failed 
to interact with purified GST fusion proteins of the UCR1, UCR2 and catalytic 
regions  of  PDE4D.  PIASy  only  interacted  with  purified  full  length  GST-  104 
PDE4D5  (Figure  3.4  b).  Further  investigation  of  the  interaction  sites  using 
scanning  peptide  array  analysis  identified  two  potential  binding  regions  for 
PIASy on PDE4D5 (Figure 3.4 c). Region 1 included amino acids 111-140, 
which correspond to beginning of UCR1 region of PDE4D5. Region 2 included 
amino acids 486-530 that correspond to catalytic region of PDE4D5 (Figure 
3.4 C). From these results it could be inferred that PIASy requires binding to 
more  than  one  region  on  PDE4D5  for  interaction  and  subsequent 
SUMOylation of the isoform in vivo.  
 
Cell  conditions  like  oxidative  stress  are  known  to  activate  certain  post-
translational modifications including phosphorylation of PDE4 isoforms (Hill et 
al; 2006). Similarly, various stress conditions such as heat shock, oxidative 
stress and ethanol are known to upregulate SUMOylation of target proteins 
(Kurepa et al; 2003). Furthermore, ERK phosphorylation is known to modulate 
SUMOylation of transcription factors including Elk-1 (Yang et al, 2003). On the 
basis  of  these  observations,  various  signalling  pathways  which  modulate 
PDE4  activity  were  examined  to  determine  their  effect  on  SUMOylation  of 
PDE4D5.  SUMOylation  of  PDE4D5  in  HEK293  cells  was  unaltered  by 
activation of ERK, elevation of cAMP, or oxidative stress (Figure 3.5). It may 
be that SUMOylation of PDE4D5 in this cellular environment is regulated by 
factors that are independent of the pathways studied in this investigation.  
SUMOylation sites of certain substrates also act as sites for ubiquitylation as 
is  reported  for  IΚBα  (Hay  et  al;  1999).  In  some  instances  SUMOylation  is 
known  to  protect  the  substrate  from  being  ubiquitylated  and  consequently 
targeted for proteasomal-degradation as has been shown for smad4 (Lin et al; 
2003).  Research  from  our  group  has  shown  that  PDE4D5  is  ubiquitylated 
within its N-terminus and that SUMOylation has no affect on ubiquitylation of 
PDE4D5 (unpublished findings).   
 
SUMOylation  is  known  to  regulate  or  alter  the  sub-cellular  localisation  of 
substrates  and  most  of  the  known  SUMO  substrates  are  nuclear  proteins 
(Zhao,  2007  and  Rodriguez  et  al;  2001).  Analyzing  PDE4D5  sequence 
reveals  that  the  isoform  does  not  have  any  nuclear  localisation  sequence. 
However, to confirm the role of SUMOylation and subsequent modulation of   105 
PDE4D5  structure  and  function  on  sub-cellular  localisation,  nuclear 
translocation studies were carried out. Nuclear extracts were prepared and 
probed for the presence of PDE4D5. The purity of the subcellular fractions 
were confirmed using nuclear protein C-jun and cytosolic p70S6 Kinase as 
controls.  In  resting  cells  transiently  expressing  PDE4D5,  the  isoform  was 
found to be exclusively localised to cytoplasmic fractions and excluded from 
the nucleus in both its non-SUMOylated and SUMOylated states (Figure 3.6). 
However, it has yet to be determined if modulators of cellular signalling would 
induce  redistribution  of  SUMOylated  PDE4D5  with  cell.  Furthermore,  the 
possible role of SUMOylation in altering the localisation of PDE4D5 to various 
subcellular organelles including golgi and endoplasmic reticulum is yet to be 
determined.  This  would  involve  extensive  microscopic  analysis  using 
organelle markers. 
   
PDE activity is critical in regulating the cAMP levels in various compartments 
of cell. PKA and ERK phosphorylation are known to activate and inhibit the 
cellular PDE4 activity respectively (Mackenzie et al, 2000, Baillie et al 2001, 
Baillie  et  al;  2000,  Sette  and  Conti,  1996  and  Ekholm  et  al;  1997).  It  was 
therefore of interest to examine the effect of SUMOylation on PDE4 activity 
before  and  after  PKA/ERK  phosphorylation  of  the  enzyme  (Figure  3.7). 
SUMOylation did not affect non-PKA phosphorylated PDE4 activity. However, 
SUMOylation  had  an  additive  effect  on  PKA  phosphorylation.  Non-
SUMOylated  PDE4D5  showed  a  2-fold  increase  in  its  activity  after  PKA 
phosphorylation  whereas  PKA  phosphorylation  of  SUMOylated  PDE4D5 
exhibited  a  4-fold  increase  in  its  activity.  In  contrast  to  this,  ERK 
phosphorylation of non-SUMOylated PDE4D5 led to a decrease in activity by 
75%  whilst  the  activity  of  SUMOylated  PDE4D5  was,  rather  remarkably, 
unaffected by ERK phosphorylation (Figure 3.7).  
 
Upstream  conserved  regions  (UCR)  1  and  2  as  the  name  indicates  are 
regulatory regions of PDE4 isoforms and associate with each other forming a 
regulatory module that interacts with catalytic region thereby regulating the 
catalytic activity of the PDE4 isoforms (Beard et al; 2000) . It is proposed that 
PKA  phosphorylation  at  UCR1  region  of  PDE4  isoforms  causes  a   106 
conformational change that leads to the disruption of binding between UCR1 
and  UCR2  region  which  in  turn  activates  the  enzyme  activity  (Richter  and 
Conti 2002).  ERK phosphorylation within the catalytic region of PDE4 long-
isoforms is thought to promote the interaction of UCR1 and UCR2 regions and 
stabilise the isoform in a conformation that leads to inhibition of the PDE4 
enzymes (Mackenzie et al; 2000). It is possible that SUMOylation stabilises 
the conformational changes initiated by PKA phosphorylation in PDE4D5 thus 
leading to elevated catalytic activity of the isoform. At the same time these 
conformational  changes  induced  and  or  stabilised  by  SUMOylation  of 
PDE4D5  may  have  an  antagonistic  effect  on  the  conformational  changes 
initiated by ERK phosphorylation thus keeping the isoform catalytically active. 
Considering the data so far, it could be postulated that since only a small 
fraction of the total intracellular pool of PDE4D5 is SUMOylated, SUMOylated 
PDE4D5 might contribute to differential regulation of the cAMP levels within 
the  sub-cellular  regions  to  which  it  is  localised  due  to  its  inability  to  be 
inhibited in response to ERK signalling. SUMOylation of PDE4 enzymes may 
therefore  serve  to  tailor  cAMP  signalling  within  distinct  intracellular 
compartments. 
 
To  further  elucidate  the  role  of  SUMOylation  on  affecting  PDE4  catalytic 
activity, rolipram dose-response curves were carried out to study the kinetics 
of inhibition. Rolipram is a competitive inhibitor specific for PDE4 isoforms. 
Non-SUMOylated  PDE4D5  elicited  a  50%  inhibition  (IC50)  in  its  activity  in 
response  to  3.8+/-0.2  µM  rolipram  whereas  purified  SUMOylated  PDE4D5 
had an IC50 of 0.45 +/- 0.03µM. When an equimolar amount of SUMOylated 
and non-SUMOylated PDE4D5 were used the mixed population exhibited an 
IC50 of 1.5 +/- 0.01 µM whereas the K323R SUMO-null PDE4D5 mutant had 
an IC50 of 3.9 +/- 0.027 uM, a concentration similar to that of non-SUMOylated 
PDE4D5 suggesting that the change in rolipram sensitivity is a direct result of 
SUMOylation (Figure 3.8). PDE4 isoforms are known to exist in two different 
affinity states for rolipram, HARBS (High affinity rolipram binding state) and 
LARBS (Low affinity rolipram binding state) (Rocque et al; 1997). HARBS is 
promoted  by  PKA  phosphorylation  and  the  binding  of  interacting  partner 
proteins including SRC family tyrosyl kinase LYN (Sette and Conti, 1996 and   107 
McPhee et al, 1999). Given the observed effect of SUMOylation on rolipram 
sensitivity  of  PDE4D5,  it  could  be  argued  that  SUMOylation,  like  PKA 
phosphorylation,  promotes  the  HARBS  conformation  in  PDE4D5  thereby 
increasing  its  sensitivity  to  rolipram.  This  is  evident  from  the  unaltered 
rolipram sensitivity of PDE4D5 SUMO-null mutant as compared to the wild-
type. Furthermore, a mixed population of PDE4D5 and SUMOylated-PDE4D5 
exhibited  a  rolipram  sensitivity  that  could  be  roughly  placed  between  the 
values of the non-SUMOylated and SUMOylated PDE4D5 species.  
 
Having determined the effect of PKA phosphorylation on PDE4 activity, the 
effect  of  the  same  on  rolipram  sensitivity  of  SUMOylated  and  non-
SUMOylated PDE4D5 was determined. PKA phosphorylation increased the 
rolipram sensitivity of PDE4D5 by 7-fold whilst that of SUMOylated PDE4D5 
was elevated only 3-fold (Figure 3.9).  Increase in rolipram sensitivity after 
PKA phosphorylation is reflective of a switch to the HARBS conformation. It is 
likely most of the SUMOylated PDE4D5 pool exists in a HARBS conformation 
and therefore the effects of PKA phosphorylation on rolipram sensitivity are 
not as significant as those observed in non-SUMOylated PDE4D5. In order to 
evaluate the inhibitory effect of ERK phosphorylation on PDE4D5 activity and 
its  rolipram  sensitivity,  dose  response  curves  were  performed  with  in  vitro 
ERK-phosphorylated  recombinant  PDE4D5.  As  anticipated,  wild  type 
PDE4D5  activity  was  inhibited  by  ERK  and  rolipram  sensitivity  was  lost 
whereas SUMOylated PDE4D5 exhibited no change in rolipram sensitivity in 
response  to  ERK  phosphorylation  as  compared  to  the  non-phosphorylated 
form. It is possible that SUMOylated PDE4D5 is able to counterbalance the 
conformational  switches  initiated  by  the  ERK  phosphorylation  within  the 
catalytic  site  thus  overriding  ERK’s  inhibitory  effects  on  PDE4D5  (Figure 
3.10). The SUMO consensus site on PDE4 isoforms is located proximal to the 
catalytic  region  and  the  presence  of  a  SUMO  molecule  near  the  catalytic 
region  may  hinder  the  conformational  changes  induced  by  ERK 
phosphorylation. To confirm that the activity of SUMOylated PDE4D5 is non-
responsive to ERK action, in vitro ERK phosphorylated purified fractions of 
both  PDE4D5  and  SUMOylated  PDE4D5  were  immuno-blotted  using  a 
phosphor-serine  antibody  to  show  that  SUMOylated  PDE4D5  is  able  to   108 
undergo ERK phosphorylation (Figure 3.7 c). Similar analysis was performed 
using a phospho-PKA antibody to show that the recombinant proteins are able 
to serve as PKA substrates (Figure 3.7 b). The mechanism by which SUMO 
exerts these changes in structure and function of PDE4D5 is not understood. 
These  structural  effects  would  be  best  studied  by  X-ray  crystallography 
analysis of the SUMOylated and non-SUMOylated PDE4D5 proteins in both 
the absence and presence of rolipram.  
 
RACK1 is a scaffolding protein known to recruit activated PKC to different 
locations in cells. It has been reported that RACK1 selectively interacts with 
PDE4D5 through its unique N-terminal region thus preventing RACK1 binding 
other PDE4 isoforms (Yarwood et al; 1999). As it had also been shown that 
an  in  vitro  PDE4D5-RACK1  complex  displayed  a  decreased  affinity  for 
rolipram compared to PDE4D5 alone similar experiments were performed to 
determine  the  effect  of  RACK1  on  rolipram  sensitivity  of  PDE4D5  and 
SUMOylated-PDE4D5.  In  accord  with  the  findings  of  Yarwood  and  co-
workers,  a  recombinant    MBP  fusion  of  PDE4D5  protein  incubated  with  a 
RACK1-GST fusion protein showed a slight increase in its rolipram  IC50 value 
(5.6µM for the complex compared to 3.8µM for PDE4D5 alone). SUMOylated 
recombinant PDE4D5 incubated with RACK1-GST showed a similar shift in 
IC50 value with an increase from 0.45 µM to 1.2 µM. To rule out any effect of 
the GST moiety, both SUMOylated and non-SUMOylated species of PDE4D5 
were incubated with GST alone. This had no effect on the rolipram sensitivity 
of either PDE4D45 species (Figure 3.11). The effect of RACK1 on rolipram 
sensitivity of PDE4D5 may be due to the conformational changes elicited by 
RACK1 interaction with the N-terminal region of PDE4D5, leading to a slight 
destabilisation of the catalytic region thereby affecting its rolipram sensitivity. 
SUMO-1 is an 11-KD molecule and is conjugated to a region close to catalytic 
domain at the C-terminal region of PDE4D5 whereas 37-KD RACK1 binds at 
the N-terminal region as well as the catalytic region (Bolger et al, 2006). The 
binding of these two molecules at either end of the PDE4D5 protein could 
restrict it and induce a conformation change that is somewhat between the 
conformational states produced by binding of either of the these molecules   109 
individually. This “new” conformation may change the rolipram sensitivity of 
the isoform.  
 
SUMOylation of several substrates is known to change their binding affinity for 
their various interacting partners. However the underlying mechanism for this 
phenomenon  is  not  known  (Zhao,  2007).  The  modifications  of  histone 
acetylation  and  de-acetylation  are  processes  which  have  been  shown  to 
regulate transcription with acetylation promoting and de-acetylation repressing 
transcriptional  activity  (Motter  and  Castronovo,  2007).  SUMOylation  of 
transcription  factors  including  ELK1  and  MEF2  inhibits  their  transcriptional 
activity  by  altering  their  affinity  for  their  binding  partners.  However,  ERK 
phosphorylation of ELK-1 and deSUMOylation of MEF2 by SENP3 leads to 
their eventual activation and prevents further SUMOylation (Yang et al; 2003 
and Zhao et al; 2005). In case of p53, Arf targeted to nucleus increases the 
SUMOylation of p53 and its interaction with mdm2, which further promotes 
SUMOylation of p53 and prevents it from being ubiquitylated (Chen and Chen 
2003).  In  light  of  these  studies,  similar  experiments  were  performed  to 
evaluate the affinity of PDE4 binding partners for SUMOylated PDE4 isoforms 
compared to non-SUMOylated forms. Beta arrestin 1 interacts with all PDE4 
isoforms at site within their catalytic region (Figure 3.12 a) although it shows a 
preferred binding to PDE4D5 due to an extra interaction site present within 
the unique N-terminal region of isoform (Bolger et al, 2003 and Perry et al; 
2002). For in vitro β-arrestin binding assays, recombinant PDE4D5 was not 
used  as  its  β-arrestin  binding  is  supplemented  by  this  extra  binding  site. 
Instead,  PDE4A4  and  PDE4B1  were  selected  for  the  competition  assays. 
SUMOylated and non-SUMOylated purified MBP-PDE4A4 and PDE4B1 were 
incubated  with  purified  equal  amounts  of  β-arrestin  (Figure  3.12  b).  As 
discussed  earlier,  PDE4B1  cannot  be  SUMOylated  due  to  the  lack  of 
conserved lysine within the SUMO consensus motif (Figure 3.2) SUMOylated 
PDE4A4  showed  an  increased  binding  to  β-arrestin  compared  to  the  non-
SUMOylated form. However, PDE4B1 did not show any difference in its ability 
to  bind  β-arrestin  before  and  after  incubation  with  SUMO  ligases.  This 
observation also eliminates the possiblity of SUMO ligases in mediating any   110 
increase in partner association directly. SUMOylated PDE4A4 showed a 50% 
increase in binding to β-arrestin1 compared to non-SUMOylated PDE4A4 and 
PDE4B1 (Figure 3.12). Similar in vitro and in vivo binding assays with PDE4 
binding partners, AKAP18δ, ERK, RACK1 and UBC9, were performed. In all 
instances,  the  binding  partners  of  PDE4D5  showed  varying  levels  of 
increased  association  to  SUMOylated  PDE4D5  compared  to  the  non-
SUMOylated form in both in vitro and in vivo assays whereas association of 
partner proteins to the K323R SUMO mutant of PDE4D5 were unchanged in 
the presence of the SUMO ligases; There were significant differences in the 
association observed for each PDE4D5 partner proteins between in vitro and 
in vivo analyses. The binding affinities determined from in vivo experiments 
may  differ  from  those  of  in  vitro  studies  as  other  cellular  components  are 
known to influence SUMOylation. Factors including the SUMO cycle of PDE4 
isoforms  and  the  cell  cycle  which  is  known  to  be  affected  by  the  SUMO 
(Bischof and Dejean; 2007, Gutierrez and Ronai 2007) may contribute to the 
observed disparities. It could also be suggested that the competition between 
binding partners for SUMOylated species of PDE4D5 might also affect the 
partners’  binding  affinities  for  PDE4D5.  The  functional  outcome  of  such 
increased binding can only be interpreted based on the existing evidence of 
function of their interaction. Increased binding of scaffolding proteins such as 
AKAPs,  β-arrestins  and  RACK1  to  SUMOylated  PDE4D5  might  result  in 
sequestration  of  the  isoform  to  various  sub-cellular  locations  where  the 
isoform would play a key role in regulating the cAMP levels in and around 
various protein complexes whose function is under stringent control of local 
cAMP  levels.  Such  functioning  of  SUMOylated  PDE4D5,  which  cannot  be 
inhibited by ERK and is extremely sensitive to PKA phosphorylation, would 
only  add  more  to  the  complexity  of  compartmentalised  cAMP  signalling. 
Furthermore,  the  ability  of  only  certain  PDE4  sub-families  to  become 
SUMOylated, a modification which would subsequently alter enzyme activity 
would  allow  a  further  means  for  regulating  cAMP-associated  signalling 
pathways within cells. SUMOylation of PDE4 isoforms may help maintain the 
cAMP levels within various cellular compartments of cells thereby specifically 
regulating the localised functions of various PDE4 associated proteins.    111 
 
In conclusion, SUMOylation is novel post-translational modification of PDE4 
isoforms, a discovery which increases the complexity of compartmentalised 
cAMP signalling. Further investigations are required to identify the pathways 
involved in regulating the SUMOylation of PDE4 isoforms. Also, considering 
the SUMO consensus site is semi-conserved among the PDE4 families, and 
the consequences of SUMOylation on PDE4 structure and function deserve 
further study.  250 KD
150 KD
100KD
75 KD
50 KD
25 KD
10 KD
SUMOylated
PDE4D5 (125KD)
PDE4D5 (105KD)
  Wt      K323R
IB: PDE4D5
IB: PIASy
(1)
SUMOylated
PDE4D5
(125KD)
  Wt      K323R
IB:  SUMO1
 (2)
SUMOylation consensus site is semi-conserved in PDE4 subfamilies
PDE4A: IPFRGV K TD QEELL
PDE4B: ISFRGV N TE  NEDH
PDE4C: VPFRGVQ TD QEEQ
PDE4D: IPFRGV K TE QEDVL
b)
a) SUMOylation of PDE4D5 at K323 in HEK 293 cells
250 KD
150 KD
100KD
75 KD
50 KD
25 KD
10 KD
75KD
   1121)
C) SUMOylation in other PDE4 subfamilies
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Figure 3.2  SUMOylation of PDE4 isoforms in HEK293 cells co-transfected  with
PIASy  E3 ligase.
a) Wild type and K323R mutant of PDE4D5 VSV were co-transfected with PIASy-HA
E3 ligase and blotted for 1)PDE4D5  2)SUMO1(top panel) and PIASy HA (bottom
panel) respectively.
b) Sequence  alignment  near  the  semi-conserved  SUMOylation  site  of  PDE4
subfamilies  A, B, C and D respectively.
c) PDE4A4,  4B1  and  4C2  were  co-transfected  with  PIASy-HA  E3  ligase  and  the
lysates were blotted for 1)PDE4A4 2) PDE4B1 and 3)PDE4C2 respectively. All the
blots  were  then  reprobed  for  PIASy-E3  ligase  with  an  HA  antibody.  The  results
shown are examples of experiments done from three separate transfections
150 KD
100KD
75 KD
50 KD
25 KD
10 KD
 75KD IB: PIASy-HA
IB: PDE4B1
2)
IB: PIASy-HA
IB: PDE4C2
3)
150 KD
100KD
75 KD
50 KD
25 KD
10 KD
75KD
IB: PIASy-HA
SUMO- PDE4A4
PDE4A4
250 KD
150 KD
100KD
75 KD
50 KD
25 KD
10 KD
75KD666 690
           Spot 130      131    132   133  134    135   136
a)  Interaction of UBC9 on PDE4D5 Peptide array
Unique N-terminal region
UCR1 UCR2   Catalytic region
C-terminal region
Spot 130: STIPQSPSPADDPEEGRQGQTEKF (646-670)
Spot 131: SPSPADDPEEGRQGQTEKFQFELT (651-675)
Spot 132: PDDPEEGRQGQTEKFQFELTLEEDG (656-680)
Spot 133: EGRQGQTEKFQFELTLEEDGESDTE (661-685)
Spot 134: QTEKFQFELTLEEDGESDTEKDSGS  (666-690)
Spot 135: QFELTLEEDGESDTEKDSGSQVEED (671-695)
Spot136:  LEEDGESDTEKDSGSQVEEDTSCSD (676-700)
Control: E-G-R-Q-G-Q-T-E-K-F-Q-F-E-L-T-L-E-E-D-G-E-S-D-T-E
Spot2:   E-G-R-Q-G-Q-T-E-K-A-Q-F-E-L-T-L-E-E-D-G-E-S-D-T-E
Spot3:   E-G-R-Q-G-Q-T-E-K-F-Q-A-E-L-T-L-E-E-D-G-E-S-D-T-E
Spot4:   E-G-R-Q-G-Q-T-E-K-A-Q-A-E-L-T-L-E-E-D-G-E-S-D-T-E
Spot 5:  E-G-R-Q-G-Q-T-E-K-F-A-F-E-L-T-L-E-E-D-G-E-S-D-T-E
 Cont       2       3      4       5
UBC9 GST
b) Alanine scan of key residues from the parent peptide
   114Figure 3.3 Interaction of UBC9 SUMO E2  ligase with PDE4D5 in vitro and in vivo.
A)  PDE4D5  is  shown  schematically  as  unique  N-terminal  region,  Upstream  conserved
regions, catalytic domain and C-terminal region. Results show immobilized peptide ‘spots’ of
overlapping 25-mer peptides each shifted along by five amino acids in the entire PDE4D5
sequence  probed  for  interaction  with  either  UBC9  GST  or  GST  and  detection  by
immunoblotting. Positively interacting peptides generate dark spots, while those that do not
interact leave white (blank) spots. In all other sections of the array, spots were blank with
either probe. Spot numbers relate to peptides in the scanned array and whose sequence is
given as indicated. Arrays probed with purified GST did not yield any positively interacting
spots..
b) PDE4D5peptide arrays were probed for UBC9-GST binding based upon the indicated 25-
mer  ‘parent’  PDE4D5  peptide,  where  the  indicated  amino  acids  were  sequentially  and
individually replaced by alanine. Ct refers to the native peptide and all other spots reflect
alanine substitutions of individual amino acids in the native spot. GST alone did not give any
spots.
c) HEK293 cells were co-transfected with PDE4D5 VSV and UBC9. Cells were subjected to
no treatment, control peptide treatment or FQF peptide treatment for 3hrs in an incubator
and the lysates were used to immunoprecipitate PDE4D5 and the precipitate were blotted for
UBC9  using  an  UBC  antibody  (Santa  cruz)  and  VSV.  All  western  blots  shown  are
representative of the results obtained from three separate experiments. The peptide arrays
interaction data are from experiments done once.
b) Interaction of UBC9 at FQF region of PDE4D5 in HEK293 cells
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         Expression and purification of PIASy in vitro (TnT®)
PIASy       Control
75 KD
IB: HA
1)
Unique N-terminal region
UCR1 UCR2   Catalytic region
C-terminal region
 B8  B9  B10
Spot B8: GLILQANFVHSQRRESFLYRSDSDY  (111-135)
Spot B9: ANFVHSQRRESFLYRSDSDYDLSPK (116-140)
Spot B10:SQRRESFLYRSDSDYDLSPKSMSRN (121-145)
Spot G2:IFQNLTKKQRQSLRKMVIDIVLATD  (486-510)
Spot G3:TKKQRQSLRKMVIDIVLATDMSKHM (491-515)
Spot G4:QSLRKMVIDIVLATDMSKHMNLLAD (496-520)
Spot G5:MVIDIVLATDMSKHMNLLADLKTMV (501-525)
Spot G6:VLATDMSKHMNLLADLKTMVETKKV (506-530)
 G2  G3 G4 G5 G6
PIASy HA
PIASy HA
2)
Figure 3.4 Interaction of PIASy  SUMO E3 ligase with PDE4D5 in vitro and in vivo
a) HEK 293 cells were co-transfected with wt PDE4D5-VSV, FQF mutant of PDE4D5
VSV,  K323R  mutant  of  PDE4D5-VSV  and  PIASy-HA  respectively.  Lysates  were
used to immunoprecipitate  using HA and VSV tags and Detection of bound proteins
was  performed  by  immunoblotting  using  monoclonal  antibodies  for  VSV  and  HA
tags. Protein G sepharose was used as a control.
b) HEK293 cell lysates transiently expressing PIASy-HA were incubated with purified
GST (lane 1) or various truncates of purified GST PDE4D5 (UCR1 region, UCR2
region,  catalytic  region  and  full  length  4D5).  Complexes  were  immobilised  on
glutathione  sepharose  beads  washed  and  analysed  by  SDS-PAGE.  Detection  of
bound proteins was carried by immuno-blotting with monoclonal HA antibody. Later
the membranes were ponceau-S stained to show the presence of GST proteins. Cell
lysates expressing PIASy were loaded on to the gel as a standard.
c) Mapping  the  binding  sites  of  PIASy  interaction  on  PDE4D5  using  peptide  array
analysis.  PIASy-HA  DNA  was  used  to  express  the  protein  in  vitro  TnT  ®  kit  as
described in section 2.4.3 and 2.4.4. PDE4D5 is shown schematically as unique N-
terminal region, UCR1 and UCR2, conserved catalytic region  and sub-family specific
C-terminal region. Results show immobilized peptide ‘spots’ of overlapping 25-mer
peptides  each  shifted  along  by  five  amino  acids  in  the  entire  PDE4D5  sequence
probed for interaction with purified PIASy and detection by immunoblotting. Positively
interacting peptides generate dark spots, while those that do not interact leave white
(blank) spots. In all other sections of the array, spots were blank with either probe.
Spot numbers relate to peptides in the scanned array and whose sequence with
a.acids  in  parentheses  is  given  as  indicated.  Arrays  probed  with  lysates  without
PIASy  did  not  yield  any  positively  interacting  spots.  All  western  blots  shown  are
representative of the results obtained from three separate experiments. The peptide
arrays interaction data are from experiments done once.
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Figure 3.5 Effect of PDE4 activity on SUMOylation of PDE4D5
HEK293  cells  co-transfected  with  PDE4D5  VSV  and  PIASy-HA  were    treated  as
indicated above and the lysates were then incubated with SUMO1 antibody (Cellular
signalling). The complexes immobilised on to protein G sepharose were washed and
analysed  by  SDS-PAGE.    Detection  of  bound  proteins  was  carried  out  by
immunoblotting  using  a  monoclonal  VSV    antibody.  All  western  blots  shown  are
representative of the results obtained from three separate experiments.
   118Figure 3.6  Effect of SUMOylation on sub-cellular localisation and of PDE4D5
a)  HEK293  cells  co-transfected  with  PDE4D5-VSV  with  and  without  PIASy-HA  were
subjected  to  nuclear  extraction  as  described  in  section  2.8.3.  The  extracts  were  then
normalised for protein by Bradford’s assay and were analysed by SDS-PAGE. Detection of
the  proteins  was  performed  by  immunoblotting.  C-jun  and  p70  S6  kinase  were  used  as
positive controls for nuclear and cytosolic proteins respectively.
b)  HEK293  cells  co-transfected  with  PDE4D5-VSV  with  and  without  PIASy-HA  were
subjected  to  sub-cellular  fractionation.  The  extracts  were  the  normalised  for  protein  by
bradford’s assay and were analysed by SDS-PAGE followed by immunoblotting. All western
blots shown are representative of the results obtained from three separate experiments.
IB : C-Jun
 (Nuclear protein control)
IB : p70 S6 Kinase
(Cytoplasmic protein control)
IB : SAPU 4D
4D5VSV SUMO
4D5 VSV
Cytoplasmic extract
Nuclear extract
         4D5                       4D5 SUMO
Cytoplasmic extract
Nuclear extract
a)
   4D5-SUMO         4D5
       P1   P2  S        P1   P2  S
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4D5 VSV 4D5 VSV
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Figure 3.7 The effect of SUMOylation on PDE4 activity
a) Purified GST, GST PDE4D5, SUMOylated GST PDE4D5 and SUMOylated GST were used
to perform PDE4 activity assay with 1µM cAMP.
b) Purified GST PDE4D5 and SUMOylated GST PDE4D5 were in vitro PKA phosphorylated
and  the  samples  immobilised  on  glutathione  sepharose  were  washed  and  used  for  PDE4
activity assay with 1µM cAMP. A fraction of the samples were analyzed on SDS-PAGE and
phosphorylation  was  detected  by  immunodetection  using  a  monoclonal  phospho  PKA
substrate antibody (Upstate).
C) Purified GST PDE4D5 and SUMOylated GST PDE4D5 were in vitro ERK2 phosphorylated
and  the  samples  immobilised  on  glutathione  sepharose  were  washed  and  used  for  PDE4
activity assay with 1µM cAMP. A fraction of the samples were analyzed on SDS-PAGE and
phosphorylation  was  detected  by  immunodetection  using  a  conjugated  phospho  serine
antibody  (Abcam).  All  experiments  are  representative  of  the  results  obtained  from  three
different experiments Paired t-test statistical analysis of the PDE activity data were undertaken
where p<0.05 indicates significant difference in PDE activity    120Figure 3.8 The effect of SUMOylation on rolipram sensitivity of PDE4D5
Inhibition of PDE4D5, SUMOylated PDE4D5, and an equimolar mixture of PDE4D5
and  SUMOylated  PDE4D5  by  rolipram.  Dose  response  curves  for    inhibition  of
purified recombinant PDE4D5 before and after SUMOylation and assayed with 1µM
cAMP  for  rolipram.  These  data  are  given  as  IC50  values  in  micro-molar(µM)
concentrations  and  are  mean  values  +/-  Standard  deviation  from  three  separate
experiments. Paired t-test statistical analysis of the rolipram data were undertaken
where p<0.05 indicates significant difference in rolipram sensitivity.
IC50:
PDE4D5: 3.8+/-0.2uM
SUMO-PDE4D5: 0.45+/-0.03uM
PDE4D5+SUMO PDE4D5: 1.5 +/-
0.01uM
K323R PDE4D5: 3.9 +/- 0.027uM
     121
          P<0.0001
***Figure 3.9 The effect of SUMOylation and PKA phosphorylation on rolipram
sensitivity of PDE4D5
Dose  response  curves  for    inhibition  of  purified  recombinant  PDE4D5  and
SUMOylated PDE4D5 before  and after  PKA phosphorylation assayed with 1µM
cAMP  for  rolipram.  These  data  are  given  as  IC50  values  in  micro-molar(µM)
concentrations  and  are  mean  values  +/-  Standard  deviation  from  three  separate
experiments. Paired t-test statistical analysis of the rolipram data were undertaken
where p<0.05 indicates significant difference in rolipram sensitivity.
a) IC 50:
Wt: 3.8 +/- 0.2uM
Wt-PKA: 0.5 +/-
0.01uM
P < 0.0001
b) IC 50:
SUMO: 0.47 +/-
0.03uM
SUMO-PKA: 0.15+/-
0.009uM
P < 0.0001
   122
***
***a)
b)
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IC 50:
PDE4D5: 3.8 +/-
0.2uM
IC 50:
SUMO PDE4D5:
0.45 +/- 0.03uM
ERK SUMO PDE4D5:
0.45+/-0.01uM
Figure 3.10 The effect of SUMOylation and  ERK phosphorylation on rolipram
sensitivity of  PDE4D5
Dose response curves for  inhibition of purified recombinant PDE4D5 and SUMOylated
PDE4D5 before  and after  ERK2 phosphorylation assayed with 1µM cAMP for rolipram.
These data are given as IC50 values in micro-molar(µM) concentrations and are mean
values  +/-  Standard  deviation  from  three  separate  experiments.  Paired  t-test  statistical
analysis of the rolipram data were undertaken where p<0.05 indicates significant difference
in rolipram sensitivity.a)
IC50:
PDE4D5  MBP+RACK1 GST: 5.6+/-
0.03uM
PDE4D5 MBP+GST: 3.8 +/- 0.19uM
b)
P<0.0001
P<0.0001
IC50:
SUMO PDE4D5  MBP+RACK1 GST:
1.2 +/- 0.009 uM
SUMO PDE4D5 MBP+GST: 0.45 +/-
0.03 uM
Figure 3.11 The effect of RACK1 binding on rolipram sensitivity of SUMOylated and
unSUMOylated PDE4D5
Dose response curves assayed with 1µM cAMP for rolipram inhibition of purified,
recombinant PDE4D5 MBP and SUMOylated PDE4D5-MBP after RACK1GST binding.
Same dose response curves were carried out on PDE4D5-MBP and SUMO-PDE4D5-
MBP mixed with GST alone as control. These data are given as IC50 values in micro-
molar(µM) concentrations and are mean values +/- Standard deviation from three
separate experiments. Paired t-test statistical analysis of the rolipram data were
undertaken where p<0.05 indicates significant difference in rolipram sensitivity.
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Figure 3.12 Effect of SUMOylation on affinity of PDE4 isoforms for arrestin
A) Purified MBP PDE4A4 and PDE4B1 were incubated with GST βarrestin 1 or GST alone.
Complexes immobilised on amylose resin were washed and analysed by SDS-PAGE.
Detection of bound proteins was carried by immuno blotting using a polyclonal antibody
against beta arrestin 1.
B)    Purified  MBP PDE4A4 and PDE4B1 were SUMOylated in vitro and incubated with GST
βarrestin 1 or GST alone. Complexes immobilised on amylose resin were washed and
analysed  by  SDS-PAGE.  Detection  of  bound  proteins  was  carried  by  immuno  blotting
using a polyclonal antibody against beta arrestin 1. The amount of arrestin bound to each
of the sample was was analysed by densitometry using Quantityone® software. These
results shown were typical of experiments done on three different occasions. Paired t-test
statistical  analysis  of  the  densitometry  data  were  undertaken  where  p<0.05  indicates
significant difference in beta arrestin binding.
   125a)
IP: MBP 4D5
IB: MBP
IP: MBP 4D5
IB: GST arrestin
M
B
P
 
4
D
5
S
U
M
O
 
M
B
P
 
4
D
5
M
B
P
 
K
3
2
3
R
S
U
M
O
 
M
B
P
 
K
3
2
3
R
1) ** 2)
IP: MBP 4D5
IB: GST AKAP 18δ
IP: MBP 4D5
IB: MBP
M
B
P
 
4
D
5
S
U
M
O
 
M
B
P
 
4
D
5
M
B
P
 
K
3
2
3
R
S
U
M
O
 
M
B
P
 
K
3
2
3
R
*
b)
1) 2)
i)
          75 KD
          50 KD
          37 KD
          25 KD
         150 KD
         100KD
          75 KD
          50KD
          25 KD
G
S
T
A
r
r
e
s
t
i
n
 
G
S
T
A
K
A
P
1
8
 
δ
 
G
S
T
E
R
K
2
 
G
S
T
R
A
C
K
1
 
G
S
T
U
B
C
9
 
G
S
T
G
S
T
A
r
r
e
s
t
i
n
 
G
S
T
A
K
A
P
1
8
 
δ
 
G
S
T
E
R
K
2
 
G
S
T
R
A
C
K
1
 
G
S
T
U
B
C
9
 
G
S
T
+4D5 MBP       +MBP
IP: MBP
IB: MBP
IP: MBP
IB: GST
ii)
   1262)
IP: MBP 4D5
IB: GST RACK1
IP: MBP 4D5
IB: MBP
M
B
P
 
4
D
5
S
U
M
O
 
M
B
P
 
4
D
5
M
B
P
 
K
3
2
3
R
S
U
M
O
 
M
B
P
 
K
3
2
3
R
d)
1)
*
IP: MBP 4D5
IB: GST UBC9
IP: MBP 4D5
IB: MBP
M
B
P
 
4
D
5
S
U
M
O
 
M
B
P
 
4
D
5
M
B
P
 
K
3
2
3
R
S
U
M
O
 
M
B
P
 
K
3
2
3
R
e)
1) 2)
**
IP: MBP 4D5
IB: GST ERK2
IP: MBP 4D5
IB: MBP
M
B
P
 
4
D
5
S
U
M
O
 
M
B
P
 
4
D
5
M
B
P
 
K
3
2
3
R
S
U
M
O
 
M
B
P
 
K
3
2
3
R
C)
1) 2)
*
   127Figure 3.13 The effect of SUMOylation on interaction of PDE4D5 with its partners in
vitro
i) Purified MBP and PDE4D5 were incubated with purified GST and GST fusion proteins of
indicated  partner  proteins  respectively.  Complexes  were  immobilised  on  amylose  resin,
washed  and  analysed  by  SDS-PAGE.  Detection  of  bound  proteins  was  carried  out  by
immunoblotting using a monoclonal GST and MBP antibodies.
ii)  Equimolar  amounts  of  MBP  fusion  proteins  of  SUMOylated  and  non-SUMOylated
PDE4D5 and K323R SUMO mutant of PDE4D5 were incubated with purified GST fusion
proteins of indicated proteins. Complexes were immobilised on amylose resin, washed and
analysed by SDS-PAGE. Detection of bound proteins was carried out by immunoblotting
using  a  monoclonal  GST  and  MBP  antibodies.  Quantification  of  bound  proteins  were
carried out by densitometric analysis using Quantityone software ®. The results shown are
examples of experiments done from three separate pull down assays performed by using
purified proteins obtained from a single successful expression experiment undertaken for
all the proteins in E.coli. Paired t-test statistical analysis of the densitometry data were
undertaken where p<0.05 indicates significant difference in interacting partner binding as
indicated.
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Figure 3.14 The effect of SUMOylation on interaction of PDE4D5 with its partners in
HEK293 cells
HEK 293 cells were triple transfected with PDE4D5 VSV or K323R mutant of PDE4D5 VSV
with PDE4D5 interacting partners indicated above and with or without PIASy respectively.
Bound complexes were immunoprecipitated by VSV agarose, washed and analyzed by SDS-
PAGE. Detection of bound complexes was performed by antibody to the respective partner
protein. Non-specific IgG  was used as a control and tubulin was immunoblotted as a loading
control.  Quantification  of  bound  proteins  was  carried  out  by  densitometric  analysis  using
Quantityone  software®. The results shown are examples of experiments done from three
separate transfections and immunoprecipitation assays.   Paired t-test statistical analysis of
the  densitometry  data  were  undertaken  where  p<0.05  indicates  significant  difference  in
interacting partner binding as indicated.
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Chapter 4 Rolipram induced foci formation of PDE4A4 
 
4.1 Introduction 
 
4.1.1 Altered localisation of proteins is regulated by multiple factors  
 
The  localisation  of  a  protein  and  its  function  are  often  inter-dependent. 
Changes in a protein’s sub-cellular localisation are affected by various factors 
including  post-translational  modifications,  alterations  in 
expression/degradation  rates  and  sequestration  into  complex  aggregates. 
Protein  localisation  may  also  alter  between  various  states  of  disease  and 
health  (Chu  et  al,  2007).  For  instance,  Elk-1  transcription  factor  is  a  key 
component of ERK-MAPKinase pathway (Iwata et al; 2001). Elk-1 along with 
alpha-synuclein  is  known  to  form  cytoplasmic  inclusion  bodies  where  it  is 
known to cause MAPKinase attenuation in glial cells in Parkinson’s disease 
and multiple system atrophy (Chu et al, 2007 and Iwata et al; 2001).  Similarly, 
importin α1 is involved in transport of proteins across the nuclear membrane 
into nucleus. In conditions like Alzheimer’s disease, the function of importin α1 
is disrupted and the protein is shown to localise to aggregates called Hirano 
bodies  which  are  also  seen  in  conditions  associated  with  oxidative  stress 
mediated injury (Chu et al; 2007 and Lee et al, 2006).   
 
4.1.2 PDE4A4 redistributes into foci 
 
It has been shown that the PDE4 isoform, PDE4A4 undergoes redistribution 
when  subjected  to  chronic  rolipram  treatment  (Terry  et  al;  2003).  This 
redistribution  is  specific  for  PDE4A4  and  its  rat  ortholog  PDE4A5.  It  was 
demonstrated that the process occurs over 16 hours and is dependent upon 
de novo protein synthesis as inhibition of protein synthesis by cycloheximide 
or puromycin prevents redistribution of the isoform  
 
Rolipram, as well as a few other PDE4-specific inhibitors such as RO20-1724 
and RS25344, induce a profound redistribution of the PDE4A4 isoform. This   134 
occurs in a dose-dependent, reversible manner and leads to the formation of 
accretion foci within the cell (Figure 4.1). Foci formation confers memory in 
that,  cells  having  been  pre-exposed  to  rolipram  form  foci,  which  are  then 
dispersed  upon  the  removal  of  rolipram,  re-form  foci  upon  further  rolipram 
challenge at a faster rate than naïve cells being exposed to rolipram for the 
first time. This is likely due to rolipram-induced initiation of de novo synthesis 
of protein(s) required for foci formation (Terry et al, 2003). 
 
Accretion  foci  formation  is  PDE4  isoform-specific  thus  suggesting  a 
contribution of the N-terminal regions of human PDE4A4 rat PDE4A5 in foci 
formation.  In  support  of  this,  foci  formation  is  not  seen  with  other  long 
isoforms of PDE4A subfamily such as PDE4A10 and PDE4A11 (Wallace et al; 
2005). Foci formation has not been demonstrated by isoforms of the PDE4B, 
PDE4C  and  PDE4D  subfamilies.  However,  it  has  not  been  investigated 
whether  a  chimeric  PDE4B,  4C  or  4D  isoform  expressing  the  unique  N-
terminal region of PDE4A4 would form foci in response to prolonged rolipram 
treatment. Foci formation is known to be blocked by PDE4 inhibitors such as 
Ariflo
® which inhibit the foci formation by displacing rolipram from the catalytic 
site.  
 
4.1.3 Molecular mechanisms of foci formation and inside-out signalling 
 
Since foci formation is only shown by PDE4A4 and PDE4A5, It was proposed 
that the isoform specific N-terminal region along with catalytic region mediates 
conformational changes upon rolipram binding thus leading to foci formation 
(Terry  et  al;  2003).  These  changes  along  with  other  factors  like  protein 
synthesis are collectively called ‘inside-out’ signalling as foci formation is a 
cAMP-independent  action  and  is  thought  to  be  triggered  by  an  altered 
conformation  of  PDE4A4  (Figure  4.1e).  This  model  proposes  that  when 
rolipram binds the catalytic region, conformational changes are induced which 
are exposed to the surface of the PDE4 molecule (Appendix II for image). 
Knowledge  of the  3-D  structure  of  the  catalytic  unit  has  led  to  a model  in 
which a conformational change emanating from the catalytic pocket is relayed 
through the loop connecting helix-7 with helix-8 to the surface of the catalytic   135 
unit via interactions with the N- and C-termini of helix 10 and helix-11. Two 
residues, His
505 and His
506, of loop 7/8 are thought to interact with Val
475 of 
helix-10. These residues play a crucial role in foci formation as mutation at 
any of these sites leads to disruption in foci formation. The 7/8-loop, along 
with helix-10 and helix-11, forms a groove-like structure that could potentially 
serve as a binding pocket for other proteins or PDE4A4’s N-terminal region. 
These rolipram-induced conformational changes, may subsequently allow for 
PDE4A4  partner  protein(s),  or  PDE4A4  itself  to  interact  thus  triggering 
redistribution of the isoform into foci.  
 
4.1.4 Foci formation and signalling pathways 
 
The aim of this investigation was to identify the signalling pathways mediating 
foci formation, maintenance and dispersal. It was also of interest to determine 
if PDE4A4 interacting proteins are components of foci.  
 
4.2 Results  
 
4.2.1 Formation of rolipram-induced foci of PDE4A4 
 
CHO  cells  stably  expressing  a  GFP  fusion  of  PDE4A4  were  analysed  by 
confocal microscopy following incubation with rolipram or DMSO for 10-16hrs. 
Foci could be seen as tiny green aggregates in cells treated with rolipram. 
Cells  treated  with  DMSO  showed  no foci  (Figure  4.1). The  amount of  foci 
formation  was  quantified  by  a  fluorescence  based  plate  reader  assay  as 
described previously (Terry et al; 2003). A similar experiment was carried out 
with CHO cells transiently expressing GFP alone. Rolipram treatment did not 
lead to any aggregation of GFP in CHO cells (Figure 4.1d).  
 
4.2.2 The effect of cAMP signalling on foci formation 
 
Terry  and  co-workers  (Terry  et  al;  2003)  showed  that  foci  formation  was 
independent  of  PKA  action  and  that  cAMP  had  inhibitory  effect  on  foci 
formation by displacing rolipram from the active site. In order to identify the   136 
component(s) of cAMP signalling through which these effects are mediated, 
cells were treated with various cAMP effectors. Elevation of intracellular cAMP 
upon challenge with forskolin alone or forskolin plus the non-selective PDE 
inhibitor, IBMX, in the presence or absence of PKA inhibitor, H89, inhibited 
foci formation. However, augmentation of cAMP levels through activation of 
the  Gs-coupled  β2-AR  with  isoprenaline  treatment  had  no  effect  on  foci 
formation. Similarly, treatment with EPAC agonist (8-CPT-2’-O-Me-cAMP) did 
not alter foci formation (figure 4.2). 
 
4.2.3 The effect of MAP kinase pathway on foci formation 
 
Previous work has shown that ERK MAP kinases are able to regulate PDE4 
activity by phosphorylating isoforms from the PDE4B/C/D sub-families, which 
possess a KIM domain, a proline-directed serine consensus and FQF domain 
in the same order (Mackenzie et al, 2000). Isoforms of the PDE4A subfamily 
have KIM and FQF domains but cannot be phosphorylated and regulated by 
ERK due to the presence of an arginine residue in the proline-directed serine 
consensus making the sequence R-x-Ser-P instead of P-x-Ser-P (Baillie et al; 
2000, Baillie et al; 2001, Hoffmann et al 1999 Mackenzie et al; 2000).  
 
To assess any potential role of ERK and other MAP kinases in regulating the 
foci  formation  of  PDE4A4-GFP,  various  inhibitors  and  activators  of  MAP 
kinases  were  evaluated.  Cells  were  incubated  with MEK  inhibitors (UO126 
and  PD98059),  p38  MAP  kinase  activator,  anisomycin,  p38  MAP  kinase 
inhibitor, SB203580, and a JNK inhibitor (Anthra [1, 9-cd] pyrazol-6(2H)-one 
1, 9-pyrazoloanthrone). The compounds were added to cells individually as 
well  as  in  various  combinations  in  the  presence  or  absence  of  rolipram. 
Inhibition of MEK enhanced foci formation by 50 ± 17 % as determined by the 
fluorescent  plate  reader  assay  whereas  Activation  of  p38  MAP  kinase 
completely  inhibited  foci  formation.  Addition  of  either  the  p38  MAP  kinase 
inhibitor SB203580 (Davies et al; 2000) or the JNK inhibitor did not have any 
effect on foci formation. Cells treated with both anisomycin and SB203580   137 
inhibited  foci  formation.  Similarly,  cells  treated  with  anisomycin  and  JNK 
inhibitor did not form foci (figure 4.3).  
 
4.2.4 The effect of MAP kinase pathway on foci formation 
 
In order to investigate the role of PKC and calcium signalling in foci formation 
of  PDE4A4-GFP,  cells  were  challenged  with  various  PKC  inhibitors  and 
calcium modulators. PMA, a PKC activator, did not affect foci formation nor 
did  EGCG  (Epigallocathecingallate)  Rottlerin,  a  PKCδ  inhibitor,  completely 
inhibited foci formation. PMA treatment reversed the effects of rottlerin on foci 
formation  and  led  to  80%  ±  10.1%  increase  in  foci  formation  compared  to 
incubation  with  rottlerin  alone.  PKC  inhibitors,  RO320432  (PKCα,β1,ε)  and 
GO6983  (PKCα,β,γ,δ)  elicited  a  70-90%  enhancement  in  the  fluorescence 
immobilised  in  PDE4A4-GFP  accretion  foci as  compared  to  treatment  with 
rolipram alone (Figure 4.4a).  
 
To  further  ascertain  the  role  of  PKC-calcium  signalling,  various  calcium 
modulators such as thapsigargin and ionomycin were used. Both compounds 
completely inhibited foci formation as evident by a 98% decrease in immobile 
GFP.  Inhibiting  CaMKII  with  KN62  had  no  effect,  nor  did  inhibition  of 
calcineurin with cyclosporin A (Figure 4.4b), whilst inhibition of calmodulin with 
W-7 and ophiobolin-A treatments led to cell loss/death.  
 
4.2.5 PI3 kinase inhibition enhances foci formation 
 
To assess the possible role of PI3 kinase signalling in foci formation, cells 
were  incubated  with  PI3-K  inhibitor  wortmannin.  This  increased  the 
percentage of immobile GFP in accretion foci to 175% ± 15.5 % (Figure 4.5). 
Furthermore, PI3-K-specific inhibitor LY294002 also increased the percentage 
immobile GFP by a similar extent (196% ± 19.2, 5). However, inhibiting the 
downstream effectors of PI3 kinase, p70S6K and GSK3β, with rapamycin and 
GSK3β Inhibitor respectively, had no effect on rolipram-induced foci formation.  
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4.2.6 The effect of tyrosine kinases on foci formation 
 
Inhibition  of  cellular  tyrosine  kinase  activity  using  Genistein  ablated  foci 
formation (Figure 4.6). To identify the role of individual tyrosine kinase families 
in  foci  formation,  cells  were  challenged  with  Src  tyrosyl  kinase  inhibitors, 
SU66656 and PD163893. Blockade of SRC tyrosyl kinase signalling elicited 
no effect on foci formation. However, inhibition of the PDGF receptor tyrosine 
kinase inhibited rolipram-induced foci formation (figure 4.6). 
 
4.2.7 Role of cdk5 in foci formation  
 
To  evaluate  the  role  of  cdk5  on  foci  formation,  cells  stably  expressing 
PDE4A4-GFP  were  treated  with  Roscovitine.  At  a  concentration  of  10µM, 
Roscovitine  inhibited  foci  formation  but  did  not  have  any  effect  at  1uM 
concentration.  
 
4.2.8 The role of thalidomide in foci formation 
 
PDE4  isoforms,  of  the  PDE4A  and  PDE4B  subfamilies  are  known  to  be 
involved in regulating the functioning of immune cells. PDE4 inhibition blocked 
antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-
stimulated tumour necrosis factor alpha (TNFalpha) release from peripheral 
blood monocytes (Manning et al; 1999). The ability of thalidomide to inhibit 
TNF  production  and  acts  as  an  immunomodulator  in  conditions  including 
Erythema  nudosum  leprosum  is  well  established  (Melchert  and  list;  2007, 
Okafor et al. 2003). Considering the possible link between thalidomide and 
PDE4  signalling,  the  role  of  thalidomide  in  affecting  foci  formation  of 
PDE4A4GFP was examined. It was found that thalidomide was able to inhibit 
foci formation at a concentration of 400µM±3.6uM.  
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4.2.9 PDE4 oligomerisation and foci formation 
 
It has been suggested that PDE4 isoforms may oligomerise by interactions 
involving  their  UCR1 and  UCR2  domains (Richter  et  al;  2002).  In  order  to 
determine  if  PDE4A4  is  able  to  oligomerise,  CHO  cells  stably  expressing 
PDE4A4-GFP were transfected with a V5-tagged PDE4A4. Post-transfection, 
cells were treated with and without rolipram for 16hours to allow foci formation. 
GFP- and V5- immunoprecipitates were blotted for both with both GFP and V5 
antisera  (Figure  4.9).  Similar  experiments  were  carried  out  with  VSV-  and 
Flag-tagged forms of PDE4D3 in transfected CHO cells treated with or without 
rolipram. PDE4A4 oligomerisation was not detected (Figure 4.9b) under these 
conditions  used.  However,  PDE4D3  oligomerisation  was  detected  (Figure 
4.9a).  
 
4.2.10 Role of protein turnover on foci formation 
 
As reported previously, protein synthesis is required for foci formation (Terry 
et  al:  2003).  Assays  were  therefore  carried  out  in  an  effort  to  better 
understand the roles of protein synthesis and degradation on foci formation. 
CHO cells expressing PDE4A4-GFP treated with rolipram were also treated 
with either cycloheximide (CHX) or puromycin to inhibit protein synthesis or 
with MG132 to inhibit proteasomal degradation of proteins. Cells were also 
treated  with  MG132  and  CHX  at  the  same  time  in  order  to  inhibit  protein 
turnover. In all instances, foci formation was blocked (Figure 4.10).  
 
4.2.11 Role of protein turnover on stability of preformed foci 
 
To  evaluate  the  role  of  protein  turnover  on  the  stability  and  dispersal  of 
preformed foci, cells expressing PDE4A4-GFP were pre-treated with rolipram 
for 16hours, followed by treatment with CHX, MG132, or both in the presence 
of  rolipram  over  time.  Cells  treated  with  rolipram  alone  were  used  as  a 
positive control and untreated cells as a negative control. Inhibition of protein 
synthesis by CHX started to disperse rolipram-induced foci within 30 minutes 
of  its  addition  to  the  cells  and  completely  dispersed  foci  after  5  hours.   140 
Inhibition  of  proteasomal  protein  degradation  with  MG132  yielded  similar 
effects on foci dispersal. The rate of foci dispersal did not change when both 
protein synthesis and degradation were inhibited simultaneously (figure 4.11). 
The  half  life  (t1/2)  of  foci  dispersal  after  inhibition  of  protein  turn  over  was 
approximately 75 minutes. 
 
4.2.12 The role of MAP kinases in dispersal of preformed foci of PDE4A4 
 
Having evaluated any potential role of various MAP kinases in formation of 
foci, the effects of MAP kinases on dispersal and stabilisation of foci were 
examined. Cells pre-treated with rolipram were challenged with anisomycin or 
anisomycin/MG132/cyloheximide  in  the  continued  presence  of  rolipram 
(Figure  4.12).  Similar  treatments  were  carried  out  with  UO126,  which  is  a 
MEK  inhibitor.  Cells  treated  with  anisomycin  with  and  without 
cycloheximide+MG132 dispersed foci completely within 30minutes after the 
addition  of  the  drug.  In  a  similar  experiment,  cells  treated  with  UO126, 
incubation with UO126 alone initially led to an increase in foci formation within 
30 minutes of drug exposure by 60% ± 0.06%. After 150 mins, foci levels had 
returned  to  levels  prior  to  UO126  addition  and  within  300  min  foci  were 
completely  dispersed.  In  cells  treated  with UO126  in  the  presence  of both 
cycloheximide and MG132, foci dispersal was observed as early as 30 mins 
after UO126 addition and all foci had dispersed by 300 mins (Figure 4.12). 
The t1/2 of foci dispersal in the presence of UO126 and rolipram was 240 mins 
while in cells pre-treated with CHX and MG132 this was dramatically reduced 
to 90 minutes.  
 
4.2.13 The role of calcium and PKC signalling on stability and dispersal of foci 
 
In order to evaluate the effects of calcium and PKC signalling in stabilising 
pre-formed  foci  and  foci  dispersal,  cells  pre-exposed  to  rolipram  for  16  hr 
were treated with thapsigargin which elevates intracellular calcium levels by 
triggering  Ca
2+ release  from  intracellular  stores  from  endoplasmic  reticulum 
(Won and Orth, 1995). Thapsigargin was added to the cells in the presence or 
absence of MG132 and CHX. Similar treatments were carried out with rottlerin   141 
and RO320432, which is a PKC inhibitor. Thapsigargin initially dispersed the 
foci at a slightly slower rate than rottlerin and RO320432 treatments, both of 
which dispersed all foci within 30 mins. However, all the three compounds 
dispersed foci within 30 mins in cells treated with MG132 and CHX. The t1/2 for 
foci dispersal by thapsigargin in the presence of rolipram was approximately 
45 mins. An accurate measure of the t1/2 of foci dispersal in the presence of 
thapsigargin, rolipram, CHX and MG132 could not be made using the time 
points analysed. A shorter time course with measurements taken at earlier 
time points would be required to evaluate this. 
 
4.2.14 The role of tyrosine kinases in foci dispersal 
 
To evaluate the role of tyrosine kinase action in dispersal of pre-formed foci, 
genistein was added to cells in the presence or absence of MG132 and CHX. 
Genistein treatment alone, as well as in the presence of MG132 and CHX, 
quickly dispersed pre-formed foci within 30 mins (Figure 4.14). The t1/2 of foci 
dispersal  upon  tyrosine  kinase  inhibition  could  not  be  determined  from  the 
existing data and would require measurements over a shorter time course.  
 
4.2.15 The role of PI3 kinases in maintenance of foci 
 
The PI3 kinase inhibitor, LY294002 dispersed pre-formed foci in cells within 
30 mins of inhibitor treatment, both in the presence and absence of MG132 
and CHX (Figure 4.15).  
 
4.2.16 Co-localisation studies 
 
To identify components and localisation of foci, co-localisation studies were 
carried  using  confocal  microscopy  to  examine  the  localisation  of  foci  with 
intracellular  compartments  and  various  known  PDE4  interacting  proteins. 
Table  4.1  lists  some  of  the  proteins  and  treatments  that  were  performed. 
Proteins  that  showed  minimum  interaction  or  co-localisation  with  foci  were 
represented by (+) and those with the strongest interaction/co-localisation with 
foci by (+++). Foci were not found to localise to any of the cellular organelles   142 
examined including mitochondria, Golgi apparatus or lysosomes. CHO cells 
treated with rolipram for 16hrs showed an up regulation of PYK2. Endosomal 
proteins like Rab9 and Rab11, Ubiquitin ligases like mdm2 and cbl, various 
PKCs  and  cytoskeletal  proteins  like  actin,  tubulin  and  vimentin  were  also 
stained  in  CHO  cells  stably  expressing  PDE4A4-GFP  and  treated  with 
rolipram for induction of foci.  (See appendix II for images).  
 
4.3 Discussion 
 
The conformational changes and folding of a protein almost always dictate the 
ability of a protein to function properly. Mis-folding of a protein might lead to 
aggregate  formation  that  may  eventually  lead  to  refolding  to  its  native 
functional  conformation  state  or  to  its  degradation  (Chu  et  al,  2007  and 
Murphy et al, 2007). Proteins aggregates also occur in disease states such as 
Huntington’s  disease,  which  is  characterised  by  poly-glutamine  aggregates 
(Nagaoka et al; 2004). 
 
Previous  work  has  shown  that  wild-type  PDE4A4  as  well  as  PDE4A4 
chimeras  with  various  epitope  tags  undergo  reversible  redistribution  into 
accretion  foci  upon  chronic  rolipram  treatment  (Terry  et  al;  2003).  This 
redistribution  is  isoform-specific  as  only  PDE4A4  and  rat  PDE4A5,  which 
share the same N-terminal sequence, form foci and not any other isoforms 
from other PDE4 sub-family. In order to establish the signalling components in 
promoting and maintaining rolipram-induced foci, CHO cells stably expressing 
a PDE4A4-GFP chimera were subjected to treatments with various inhibitors 
and activators of signalling pathways.  
 
PDE4 isoforms play a pivotal role in controlling cAMP levels within cells. It is 
widely  appreciated  that  PKA  phosphorylation  activates  these  isoforms thus 
making them key regulators of the cAMP signalling cascade. To determine to 
the  role  of  cAMP  in  rolipram-induced foci  formation,  cells  were  challenged 
with  various  effectors  of  this  pathway.  Challenge  with  8-CPT-2’-Me-cAMP 
which activates EPAC, did not affect foci formation or dispersal. To elevate 
cAMP levels, cells were treated with forskolin, to activate adenylate cyclase   143 
independently of Gs-proteins, (Seamon and Daly, 1981) and also in concert 
with  IBMX  to  inhibit  PDE  activity  simultaneously,  thus  maximising  cAMP 
production  (Turner  et  al,  1993  and  Leemhuis  et  al;  2002).  Under  these 
conditions,  foci  formation  was  inhibited.  Inhibition  of  PKA  activity  by  H89 
treatment did not affect foci formation suggesting the effects of cAMP on foci 
formation were not mediated through PKA, or at least through a PKA isoform 
which  was  H89-sensitive.    Increasing  cAMP  levels  via  activation  of  Gs 
signalling of the β2-adrenoceptor with isoproterenol challenge did not affect 
rolipram-induced foci formation thus indicating that foci formation is not driven 
via  a  Gs-adenylyl  cyclase  pathway.  Taken  together,  these  data  show  that 
inhibition  of  foci  formation  occurs  only  with  agents,  which  maximise 
intracellular cAMP levels. It is still unclear which cAMP signalling pathways 
inhibiting foci formation. It is possible that cAMP actions are being mediated 
through  a  PKA  isoform  which  is  H89-insensitive  or  through  other  effectors 
including ion channels. 
 
Isoforms of the PDE4A subfamily are not phosphorylated by ERK due to the 
substitution  of  an  arginine  for  a  proline  in  the  proline  directed  serine 
consensus  (Baillie  et  al;  2000,  Baillie  et  al;  2001,  Hoffmann  et  al  1999 
Mackenzie et al; 2000). However, in order to determine any indirect effects of 
ERK, as well as effects of other members of MAP kinases, on foci formation, 
various inhibitors were tested. Inhibition of MEK using UO126 and PD98059 
did  not  affect  foci  formation.  Activation  of  p38  MAP  kinase  by  anisomycin 
(Hazzalin  et  al;  2002)  ablated  foci  formation.  To  test  the  specificity  of 
anisomycin  treatment  on  foci  formation,  SB203580,  a  p38  MAP  kinase 
inhibitor, (Davies et al; 2000) was used. However, SB203580 did not reverse 
the effects of anisomycin. As anisomycin is also known to activate JNK (c-Jun 
N-terminal kinase) along with p38 MAP kinase (Sampieri et al; 2007), a JNK 
inhibitor (Anthra [1,9-cd] pyrazol-6 (2H)-one1, 9-pyrazoloanthrone) was also 
used to study if the effects of anisomycin were being mediated through a JNK 
pathway. However, JNK inhibition failed to reverse the effects of anisomycin 
treatment  (Figure  4.3).  The  role  of  downstream  targets  of  p38  MAPK  was 
therefore studied to determine their influence on PDE4A4-GFP foci formation.   144 
Rottlerin  was  used  to  inhibit  both  MAPKAPK2  and  PKCδ    (Blanquet  et  al, 
2003). Rottlerin treatment abolished PDE4A4-GFP foci formation. Signalling 
crosstalk  between  the  PKC  and  MAPK  pathways  is  well  documented 
(Blanquet  et  al,  2003).  Considering  the  potential  role  for  MAPK  action  in 
PDE4A4-GFP  foci  formation  and  its  ablation  by  rottlerin,  the  possible 
involvement of PKCδ in this process was investigated using PMA (Powell et al; 
2003). PMA did not trigger PDE4A4-GFP foci formation alone, nor did PMA 
affect rolipram-induction of foci. However, most strikingly, PMA reversed the 
inhibitory  effect  of  rottlerin  on  foci  formation,  restoring  the  percentage 
immobile GFP to ~80% (figure 4.4). This indicated the possible involvement of 
PKC  signalling,  possibly  PKCδ,  in  foci  formation.  PKC  inhibitor  RO320432 
which inhibits isoforms PKCα, β1,ε (Birchall et al; 1994) and GO6983 which 
inhibits  PKCα,β,γ,  δ  isoforms  (Wang  et  al;  2004)  elicited  a  70-90% 
enhancement in the fluorescence immobilised in PDE4A4-GFP accretion foci 
when compared to treatment with rolipram alone (Figure 4.4a). These data 
suggest that signalling of these PKC isoforms has a restraining influence on 
foci formation.  
 
PKC  isoforms  can  be  divided  into  three  classes;  conventional,  novel  and 
atypical.  Conventional  isoforms  includeα,  β1,  β2  andγ;  ε,  η,  θ,  µ  are  novel 
forms and ζ, λ are atypical forms (Mackay and Twelves, 2007). Conventional 
and novel forms are regulated by diacylglycerol and phosphatidylserine while 
atypical  isoforms  are  regulated  by  phosphatidylserine  only.  Activation  of 
conventional  PKC  forms  is  calcium  dependent  whereas  signalling  of  PKC 
isoforms  of  the  other  two  groups  is  calcium  independent  (Mackay  and 
Twelves,  2007).  To  investigate  the  involvement  of  the  calcium-dependent 
PKC  isoforms  in  foci  formation,  intracellular  calcium  modulators  including 
thapsigargin  and  ionomycin  were  used.  Thapsigargin  elevates  intracellular 
calcium levels by inhibiting calcium/ATPase-mediated reuptake of calcium into 
endoplasmic reticulum (Won and Orth, 1995) whereas ionomycin mobilises 
calcium  across  the  cell  membrane  (Aagaard-tillery  and  Jelinek,  1995).  
Raising  intracellular  calcium  with  these  agents  blocked rolipram-induced  of 
PDE4A4-GFP foci formation (Figure 4.4b) suggesting that Ca
2+ ions exert an   145 
inhibitory influence on foci formation. These data are also further suggestive 
of a role of a Ca
2+-dependent PKC isoform in foci formation. To identify the 
downstream targets responsible for the effect of calcium on foci formation, 
various  inhibitors  of  calcium  signalling  were  tested.  Inhibiting  CaMKII  with 
KN62 (Minami et al; 1994) had no effect, nor did inhibition of calcineurin with 
cyclosporin A (Figure 4.4b), while inhibition of Calmodulin with W-7 (Caulfield 
et  al;  1991)  and  ophiobolin-A  led  to  cell  loss/death.    It  is  possible  that 
Ca
2+/PKC  activates  other,  as  yet  unkown,  downstream  targets  or  that 
Ca
2+/PKC inhibits foci formation directly. 
 
Earlier  studies  showed  that  challenging  3T3-F442  fibroblasts  with  growth 
hormone  activates  PDE4A5,  the  mouse  orthologue  of  human  PDE4A4, 
through a PI3 kinase and p70S6 kinase pathway (Mackenzie et al 1998). As 
inositol  phosphates  and  PI3  kinase  signalling  are  critical  in  regulating 
intracellular calcium levels (Balla et al, 2006), various PI3-K inhibitors were 
assessed in their abilities to mediate PDE4A4-GFP foci formation. Blockade 
of  PI3-K  with  wortmannin  increased  the  percentage  immobile  GFP  in 
accretion  foci  to  175%  ±  8.32  %,  indicating  an  inhibitory  input  for  PI3-K 
(Figure  4).  However,  wortmannin  has  also  been  shown  to  function  as  an 
inhibitor of MAPK. To address this, the same experiment was performed with 
the PI3-K-specific inhibitor LY294002 (Baumann and West, 1998), which also 
increased the percentage immobile GFP further to a similar extent. However 
inhibiting PI3-K downstream targets, p70S6K, with rapamycin (Powell et al; 
2003) and GSK3β with GSK3β Inhibitor, (Calbiochem, UK) had no effect on 
rolipram-induced foci formation (Figure 4.5). It is therefore likely the effects of 
PI3-K  signalling  on  foci  formation  are  mediated  through  other  downstream 
effectors. 
 
It is known that PDE4A5/PDE4A4 interact with the SH3 domains of Src, lyn 
and fyn kinases (Beard et al, 1999 and Beard et al, 2002). Hence the role of 
tyrosine  kinases  in  foci  formation  was  determined  using  general  tyrosine 
kinase inhibitor, genistein (Constantinou and Huberman; 1995). Interestingly, 
genistein ablated rolipram-induced foci formation implicating tyrosines kinase 
activity in foci formation. However, the Src family inhibitors PD168393 and   146 
Su6656  (Fry  et  al;  1998,  Bowman  et  al;  2001)  had  no  effect  on  rolipram-
induced foci formation. Inhibitors for JAK2 (AG490) and IR (HNMPA-(AM) 3) 
led  to  cell  loss/death.  Inhibition  of  the  tyrosine  kinase  receptors  VEGF-R 
(oxindole) and EGF-R (PD168393) had no effect on foci formation. However, 
the PDGF-R inhibitor AG17 blocked foci formation (Figure 4.6), indicating that 
this receptor kinase may promote rolipram induction of PDE4A4-GFP foci.  
 
Cyclin-dependent kinase 5 is activated by p35/p39 and is known to regulate 
the  MEK-ERK  pathway  and  calcium  signalling  of  CAMKII  and  the  Ca
2+-
sensitive adenylate cyclase isoform IX (Pareek and Kulkarni, 2006). The role 
of cdk5 signalling in foci formation was examined using its inhibitor roscovitine. 
Cells treated with 1µM roscovitine (Cdk5 IC50 -0.2uM) elicited no effect on foci 
formation. However, at a concentration of 10µM, foci formation was inhibited 
by 40% (Figure 4.7). At this higher concentration, roscovitine can also inhibit 
Cdk1, Cdk2 and ERK1/2 (Dangi and Shapiro, 2005). It is probable, therefore, 
that  the  inhibitory  effect  of  roscovitine  on  foci  formation  is  mediated  via  a 
target other than Cdk5 which can be explained on the basis that cdk5 is a 
brain-specific  kinase  so  it  wouldn’t  be  expressed  in  CHO  cells  (Wei  and 
Tomizawa,  2007);  hence  the  only  effects  of  roscovitine  at  higher 
concentrations  were  seen  when  it  can  inhibit  other  cdks  and  erk.  The 
presence of cdk5 in CHO cells can also be confirmed by immunoblotting the 
CHO cell lysates for the kinase.  
 
PDE4A4  activity  has  been  shown  to  be  of  importance  in  initiation  of  the 
immune response by T-cells (Manning et al; 1999). Thalidomide
® has been 
reported  to  have  immunomodulatory  properties  as  it  is  known  to  have  a 
variety  of  effects  including  decreasing  the  production  of  monocyte  derived 
TNF-alpha,  and  regulates  the  T-helper  cell  response  by  regulating  the 
production of IL-4, 5 and IFN-γ in vitro (Melchert and List, 2007, Okafor, M.C, 
2003).  In  order  to  investigate  a  potential  link  between  foci  formation  and 
PDE4A4’s  immunoregulatory  properties,  cells  were  challenged  with 
thalidomide  to  examine  its  effects  on  foci  formation  (Figure  4.8).  At  a 
concentration  of  400µM,  thalidomide  completely  inhibited  foci  formation  of   147 
PDE4A4-GFP (IC50: 150µM). Thalidomide action is proposed to be mediated 
a  through  Wnt  signalling  pathway.  Gsk3  is  known  to  be  a  component  of 
Bmp/DKK1/Wnt  signalling  and  inhibition  of  any  of  the  three  components 
reverses the effects of Thalidomide treatment (Knobloch et al; 2007). It should 
be noted that although Thalidomide inhibited foci formation, inhibition of GSK3 
had  no  effect.  However,  the  role  of  GSK3  inhibition  in  reversing  the 
Thalidomide-induced effects on foci formation is yet to be determined. It is 
possible that the effect of Thalidomide treatment on PDE4A4 foci formation is 
mediated through other components of the Wnt signalling pathway. 
 
In some instances protein aggregates are due to oligomerisation of misfolded 
proteins. For instance chicken Hsp25 is known to form inclusion bodies when 
over expressed in HeLa cells (Katoh et al; 2004). It has been suggested that 
PDE4 isoforms oligomerise by a process that involves their UCR1 and UCR2 
domains  (Richter  al,  2004,  Richter  and  Conti,  2002).  In  order  to  evaluate 
whether PDE4A can form dimers in these cells, CHO cells stably expressing 
PDE4A4-GFP were transfected with a V5 epitope-tagged form of PDE4A4. In 
parallel,  oligomerisation  experiments  were  carried  out  with  differentially 
epitope-tagged  forms  of  PDE4D3  (FLAG  and  VSV  tags).  PDE4A4  did  not 
show oligomerisation/dimerisation prior to, and after rolipram treatment in co-
immunoprecipitation  experiments.  However,  PDE4D3  oligomerisation  was 
evident in co-immunoprecipitation assays (Figure 4.9). The lack of observed 
oligomerisation  of  PDE4A4  is  curious.    However,  there  are  a  number  of 
possible explanations to support these findings. Although PDE4A4 is able to 
form foci, the isoform may require other extraneous stabilising factors, which 
are lost upon cell disruption, i.e. a dynamic process stabilises foci and upon 
cell  lysis,  foci  disaggregate.  It  is  also  possible  that  the  tagged  PDE4A4  is 
excluded  from  binding  the  GFP-tagged  species.  Immunocytochemical 
analyses  and  FRET/BRET  would  of  interest  to  examine  whether  the 
differentially tagged forms of PDE4A4 co-localise, and potentially dimerise in 
foci in live cells. 
 
Terry and coworkers have shown that protein synthesis is required for foci 
formation  (Terry  et  al;  2003).  To  further  characterise  the  role  of  protein   148 
turnover in PDE4A4 foci formation, cycloheximide (CHX) and MG132 were 
used  to  inhibit  protein  synthesis  and  proteasomal  degradation  of  proteins 
respectively  (Christner  et  al;  1999,  Steinhilb  et  al;  2001).  Both  CHX  and 
MG132 ablated foci formation (Figure 4.10). Furthermore, when both protein 
synthesis and degradation were inhibited simultaneously, foci formation was 
totally blocked suggesting that protein turnover is crucial for foci formation. 
Similar  results  were  obtained  when  puromycin  was  used  to  inhibit  protein 
synthesis (Chow et al; 1995). To further investigate the role of protein turnover 
in continued presence of foci, a time course was carried out of cycloheximide 
and MG132 treatments. Cells pre-treated with rolipram were incubated with 
cycloheximide, MG132 or both over a time course of 5 hours in the continued 
presence of rolipram. In all the cases, foci started to disperse within first 30 
mins of treatment with the t1/2 for dispersal approximately 75 mins. After 5 
hours the total immobile GFP levels was virtually zero (Figure 4.11). This data 
indicated that protein turnover is crucial both for formation and maintenance of 
foci.  
   
As  protein  turnover  had  shown  to  be  of  significance  in  foci  formation  and 
stability,  compounds  activating/inhibiting  various  signalling  pathways  were 
tested in conjunction with CHX and MG132 treatments. The principle behind 
this investigation was to identify and distinguish between signalling pathways 
regulating foci formation from those influencing the stability of the pre-formed 
foci during inhibition of protein turnover. Any compounds that enhance foci 
dispersal presumably do so by a mechanism independent of the effects of 
protein turnover on foci stability.  Activation of p38 MAPK with anisomycin in 
the continued presence of rolipram, after a 16 hr pre-treatment with rolipram, 
dispersed the foci within 30 mins. Addition of CHX and MG132 did not alter 
the effects of anisomycin on foci dispersal. However, inhibition of MEK with 
UO126  delayed the  dispersal  of  pre-formed  foci  for  4  hrs  although  all  foci 
eventually dispersed by the 5 hr timepoint. However, UO126 enhanced the 
dispersal of foci induced by MG132 and CHX. The t1/2 for foci dispersal by 
MEK inhibitor UO126 in the presence of CHX and MG132 was ~120 mins 
while in cells treated with UO126 and rolipram only, the t1/2 was ~240 mins 
suggesting  that  UO126-induced  dispersal  of  foci  occurs  via  a  mechanism   149 
which  is  enhanced  by  protein  turnover  (Figure  4.12).  Similarly,  raising 
intracellular calcium levels using thapsigargin induced foci dispersal with a t1/2 
of ~45 mins, which was shortened to ~ 30 in the presences of MG132 and 
CHX. Rottlerin and RO320432 treatments also dispersed foci within 30 mins 
of  agonist  exposure.  The  presence  of  MG132  and  CHX  enhanced  the 
dispersal in both cases (Figure 4.13). Similar effects were noted with inhibitors 
of  tyrosine  kinases  and  PI3  kinases  using  genistein  and  Ly294002 
respectively where both inhibitors dispersed preformed foci within 30 minutes 
and the presence of CHX and MG132 did not affect the rate of foci dispersal. 
As foci dispersal with these compounds was rapid, a shorter time course of 
treatments  would  be  required  to  accurately  determine  the  rates  of  foci 
dispersal with these agents. However, these data do suggest that the stability 
of foci is dependent upon phosphorylation events mediated by tyrosine kinase 
and/or PI3-K signalling.  
 
A  potential  role  for  PDE4A4  ubiquitination  in  the  turnover  of  PDE4A4  was 
assessed using confocal microscopy and pulse-chase experiments. However, 
in accord to work from our lab (unpublished data) neither ubiquitination nor 
turnover  of  PDE4A4  was  detected  in  pulse  chase  experiments.  This  was 
confirmed by immunocytochemical analysis (Appendix II for images).  
 
In order to identify components of foci, co-localisation studies were carried out 
by confocal microscopy. The proteins studied and the treatments used in the 
process are listed in Table 4.1 (Please refer to Appendix II for images).  
 
Proteins  such  as  ubiquitin  did  not  co-localise  with  foci.  Similarly,  no 
localisation  of  foci  was  observed  with  sub-cellular  organelles  including 
lysosomes and mitochondria. The role of SUMOylation in foci formation was 
also  assessed.  CHO  cells  stably  expressing  PDE4A-GFP  were  immuno-
stained  for  SUMO  modification.  However,  SUMOylation  did  not  affect  foci 
formation and SUMO did not co-localise with foci.  
 
The inhibitor/activator studies implicated multiple signalling pathways in foci 
formation/dispersal  with  the  potential  for  cross-talk  between  pathways,  a   150 
model of which is depicted in the figure 4.16. Foci formation appears to be 
independent of a cAMP/EPAC, and possibly a cAMP/PKA, pathway as shown 
from  figure  4.2.  However,  elevated  cAMP  levels  were  able  it  inhibit  foci 
formation and induce dispersal of pre-formed foci (Figure 4.2 and Terry et al. 
2003).  Inhibition  of  PI3  kinase  signalling  increased  foci  formation  (fig  4.5). 
However, whether the effects of PI3 kinase action are direct or mediated by its 
downstream  targets  or  via  cross  talk  with  other  signalling  pathways  is  yet 
unknown. The PI3 kinase pathway can activate PKC isoforms including PKC 
θ (Theta), ζ (Zeta), δ (Delta) and ε (Epsilon) upon insulin signalling (Sampson 
and cooper, 2006, Campbell et al; 2004, Hirai and Chida; 2003). Inhibition of 
PKC-ε (Epsilon) by RO320432 enhanced foci formation. RO320432, however, 
is not a PKC-ε specific inhibitor and can inhibit other PKC isoforms such as β1 
and α. Hence the effects of other PKC isoforms cannot be ruled out. Similarly, 
PKC θ is also activated by PI3 kinases and its effects on foci are still unknown 
as there are no specific inhibitor compounds available to assess its effects. 
Inhibition  of  PKC-δ  by  rottlerin  ablated  foci  formation  suggesting  a  role  of 
PKC-δ in foci formation. However, the pathway through which PKC-δ inhibitor 
rottlerin inhibits foci, as well as the mechanisms of PKC-δ regulation, has yet 
to  be  determined.  PKCs  might  act  directly  or  influence  other  pathways  to 
regulate foci formation. It is possible that PKC signalling cross-talks with the 
MAP kinase pathway. MAP kinase pathway is a canonical pathway that is 
activated  by  various  growth  factors  and  controls  cell  growth  and  division 
(Pimienta and Pascual; 2006). Cross-talk between MAP kinase signalling and 
pathways including PKC signalling (Rozengurt; 2007, Baillie et al 2001), PI3 
kinase signalling (Kim et al; 2007, Xu and Yu, 2007) and cAMP signalling is 
well documented (Baillie et al; 2001, Pyne et al; 1997, Pyne et al; 1994). It 
would be of interest to assess the MAP kinase activity in response to inhibition 
or activation of PI3 kinase signalling in the PDE4A4-GFP cell line to determine 
if  there  is  cross-talk  between  these  pathways.  Unpublished  work  from  our 
group  indicates  PDE4A4  can  be  phosphorylated  within  its  N-terminus  by 
MAKAP kinase-2 after stimulation of the PDE4A4-GFP cells with anysomycin, 
a  p38  MAP  kinase  activator.  It  was  therefore  of  relevance  to examine the 
effects  of  anisomycin  on  foci  formation.  Inhibition  and  activation  of  MAP 
kinase signalling had conflicting effects on foci formation. Activation of p38   151 
MAPK  led  to  scattering  of  foci  whereas  MEK  inhibition  enhanced  foci 
formation (Figure 4.3). It has yet to be assessed whether these differential 
effects of MAP-K signalling are directly influencing foci formation or if their 
actions are being mediated through other downstream signalling complexes. It 
would  be  of  interest  to  establish  whether  mutation  of  PDE4A4’s  MAPKAP 
kinase-2 phosphorylation site altered the effects of anisomycin/MEK inhibition 
on foci formation.  
           PI3 kinase has also been reported to influence cAMP levels in the cells 
through its downstream effector Akt (Hans et al; 2006). Hans and co-workers 
(Hans et al; 2006) have shown that Akt phosphorylates PDE3A which leads to 
activation  of  the  isoform.  PDE3A  is  a  cAMP-specific  PDE  (Beavo;  1995). 
Since cAMP has an inhibitory effect on foci, it could be suggested that PI3 
kinase-Akt-PDE3A pathway might affect foci formation by modulating cAMP 
levels.   
Thalidomide
® is an anti-inflammatory agent and is known to have teratogenic 
properties (Okafor; 2003) Thalidomide inhibited foci formation. However, the 
mechanism  for  this  action  is  unknown  and  requires  further  investigation. 
Thalidomide
®  is  known  to  affect  various  pathways  including  Wnt  signalling 
(Knobloch, 2007), PI3 kinase/Akt pathway (Gockel et al; 2004) and signalling 
of some PKC isoforms including PKC-θ (Payvandi et al; 2005). It is probable 
that the effects of thalidomide on foci formation are transduced via one or 
more of these pathways.  
The involvement of multitude of signalling pathways renders understanding 
foci formation rather complex as it hinders identifying the signalling pathway 
involved  in  the  process.  Furthermore,  the  lability  of  foci  in  cell  lysates 
complicates the identification of components by proteomic analyses, where 
preliminary studies were not of sufficient quality to be useful. In conclusion, 
foci formation of PDE4A4 is a very unique phenomenon not noticed with any 
other PDE4 isoforms. The ability of PDE4A4 to form foci reversibly only in the 
presence of rolipram and its analogues is a very novel finding. Also, the ability 
of only those PDE4 inhibitors that cause emesis to form foci and not the non-
emetic  ones  suggest  that  PDE4A4  foci  formation  might  be  a  key  to 
understanding the mechanism of the side-effects caused by PDE4 inhibitor 
usage as therapeutics. Although Terry and coworkers (Terry et al 2003) have   152 
identified  PDE4  domains  that  could  potentially  lead  to  foci  formation, 
extensive truncation mutational analyses is needed to identify the signalling 
complexes and components involved in the process.  
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CHO cells stably expressing PDE4A4-GFP were plated 1×10
5 per well in a cell culture 
treated 96-well plate for a quantitative plate reader assay. The following day, cells were 
then treated with inhibitors as indicated above for 16hrs. Post-treatment, total GFP was 
measured from live cells in Packard Bell Fusion
® plate reader. Cells were then subjcted to 
extraction of mobile GFP using an extraction buffer for 10 minutes at room temperature. 
Cells were then fixed in 4% formaldehyde buffer and Hoescht33258 for further 10 minutes 
followed by three washes in PBS. Once the extraction, fixation and Hoescht staining were 
finished, immobile GFP was measured in the plate reader and corrected for cell number 
using Hoescht signal. All the data was background corrected. Untreated cells were used 
as negative control and rolipram alone treated cells as positive control. All the results are 
represented  as  a  percentage  of  rolipram  induced  foci.  All  the  data  shown  are 
representative of results obtained from three separate experiments. Paired t-test statistical 
analysis of the quantified immobile GFP data were undertaken, where p<0.05 indicates a 
statistically significant difference level of inhibition.    157 
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Antibody/probe/Treatment                                            Target                 Interaction with foci 
MG132      proteasome inhibitor  Inhibits foci formation 
Brefeldin A      protein transport inhibitor    No effect 
Leptomycin B     nuclear export inhibitor  No effect 
Ubiquitin  ubiquitinated proteins  + 
P27kip1  ubiquitinated Cdk inhibitor  + 
TGM-76  golgi    + 
GM130  golgi    + 
Rab9  endosome  + 
Rab11  endosome  + 
Lysotracker  lysosomes  + 
 -adaptin  Golgi protein targeting  + 
Actin        actin filaments  + 
Tubulin    microtubules  + 
Vimentin      intermediate filaments  + 
MitoTracker    mitochondria  + 
PKC      PKC    + 
PKC         PKC     + 
PKC         PKC     + 
PKC         PKC     + 
PKC         PKC     + 
PIP3        PIP3  + 
Phospho-tyrosine  tyrosine phosphorylated proteins    + 
Pyk2  Pyk2    none detected 
Phospho-Pyk2  phosphorylated Pyk2        upregulated in rolipram treated cells 
Cdk5        Cdk5  None detected 
DISC1       DISC1  None detected 
Mdm2  E3 ubiquitin ligase  + 
cbl  E3 ubiquitin ligase  + 
Calpastatin   Endogenous Protease inhibitor  + 
+      Represents minimum or no interaction. 
++    Represents moderate interaction 
+++ Represents high strong interaction 
Figure 4.16 A schematic model of depict the effects of various s ignalling pathways on 
PDE4A4GFP - Foci formation. 
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Chapter 5   RhoGAPs, Arrestins and PDE4 isoforms 
 
5.1 Introduction 
 
5.1.1 Rho Signalling  
 
Guanine  nucleotide-binding  proteins  (GNBP)  regulate  a  plethora  of  vital 
cellular processes including cytoskeletal reorganisation, cell adhesion and cell 
cycle progression (Lundquist; 2006, Bishop and Hall; 2000, Jaffe and Hall, 
2005,  Luo,  2000).  Small  GTPases  of  the  Ras  superfamily  are  the  most 
studied GNBPs with the monomeric 20-30 KDa Rho GTPases being the best 
characterised among the GTPases of the Ras super family (Bishop and Hall; 
2000).  
 
It is now well appreciated that Rho GTPases are involved in actin-dynamics 
(Aspenstrom, 2004 and Luo, 2000). However, Rho-GTPases have also been 
shown  to  interact  with  a  wide  range  of  effector  proteins,  modulating  their 
activity and thus participating in various signalling pathways (Jaffe and Hall; 
2005).  Rho GTPases interact with their effectors through a so-called “switch 
region” that is also necessary for their GTPase activity. Point mutations within 
this region have been shown to ablate the interaction of Rho GTPases, such 
as cdc42, Rho and Rac, with most of their effectors (Joneson et al; 1996 and 
Lamarche et al; 1996).  
 
The  functioning  of  GNBPs  is  activated  by  the  binding  of  GTP  and  is 
terminated by the hydrolysis of GTP to GDP by its intrinsic GTPase activity. 
The  GTP-GDP  cycle  is  regulated  by  three  different  classes  of  proteins.  In 
resting cellular conditions GNBPs exist in a complex with guanine dissociation 
inhibitors (GDIs), which stabilise GDP-bound Rho proteins. GEFs are guanine 
exchange factors that facilitate the exchange of GDP to GTP in the catalytic 
region  of  Rho  proteins.  The  third  class  of  proteins,  GAPs,  are  GTPase 
activating  proteins,  which  interact  with  and  enhance  the  otherwise  slow   175 
intrinsic  GTPase  activity  of  species  such  as  Rho  proteins  (Scheffzek  and 
Ahmadian; 2005).  
 
5.1.2 RhoGAPs  
 
RhoGAPs act as negative regulators of GNBPs by enhancing the GTPase 
activity of Rho, consequently shifting Rho into an inactive state (Willars; 2006). 
Almost all members of Rho family have been shown to have specific GAPs. 
Rho-GAPs  of  different  subfamilies  possess  subfamily-specific  structural 
domains  that  play  an  important  role  in  regulation  and  targeting  of  GAPs 
(Bernards and Settleman; 2005).  
 
GAPs play an important role in brain development. The NR2B subunit of the 
NMDA  (N-methyl-D-aspartate)  receptor  has  been  shown  to  interact  with 
p250GAP,  a  GAP  for  Rho-cdc42.  This  promotes  the  dephosphorylation  of 
NR2B  as  well  as  altering  its  sub-cellular  localisation  thereby  regulating 
synaptic plasticity by reorganising actin in dendritic spines from hippocampal 
slices stimulated with NMDA (Nakazawa et al; 2003). Similarly, p250GAP is 
phosphorylated  by  src  kinase,  Fyn,  and  leads  to  differentiation  of 
oligodendrocytes (Taniguchi et al; 2003). A detailed description of RhoGAPs 
is discussed in section 1.11.1.3.  
 
5.1.3 Role of cAMP signalling components in Rho transduction pathways 
 
A role for cAMP and its signalling components in Rho signalling pathways has 
been suggested by various studies (Appert-collin et al; 2007, Flemming et al; 
2004, Diviani et al; 2004, Diviani et al; 2006, Howe et al; 2004). In particular, 
elevation  of  PKA  has  been  shown  to  both  activate  and  inactivate  Rho 
signalling pathways (Howe A, 2004). 
 
In  REF52  cells,  elevation  of  cAMP  levels  by  rolipram  inhibition  of  PDE4 
activity  was  found  to  downregulate  integrin-dependent  actin  adhesion 
microspikes.  It  was  shown  that  these  effects  were  mediated  by  PKA 
regulation of the Rho A-ROCK-Myosin pathway (Fleming et al; 2004).    176 
α1  adrenergic  receptors  have  been  shown  to  be  involved  in  cardiac 
hypertrophy (O’Connell et al; 2003) which was showed by double knockout of 
α1A/C and α1B adrenoceptors in male mice where the heart size was smaller 
than wild type and the heart function was affected by the knock out of the 
receptors (O’Connell et al; 2003). In further support to this, AKAP-Lbc has 
been shown to possess GEF activity aside from its PKA anchoring function. In 
cardiomyocytes, activation of its GEF activity has been reported to mediate 
through its interaction with heterotrimeric G protein 12 (G12) downstream to α1 
adrenergic  receptors,  which  subsequently  promote  Rho-A  activation,  by 
AKAP-LBc. PKA-mediated phosphorylation and recruitment of 14-3-3 protein 
leads to inactivation of the AKAP-GEF.  The GEF activity of AKAP-Lbc has 
been  shown  to  play  a  significant  role  in  cardiac  hypertrophy,  which  was 
evident  by  hypertrophic  responses  of  heart  cells  subjected  to  lentiviral 
suppression of AKAP-Lbc (Appert-collin et al; 2007, Diviani et al; 2006, Diviani 
et al; 2004). Furthermore, anchored PKA has been shown to have a key role 
in the formation of pseudopodia and chemotactic cell migration by activating 
Rac  GTPase  through  phosphorylation  of  vasodilator  stimulated 
phosphoprotein  (VASP)  and  protein  tyrosine  phosphatase  localised  to 
pseudopodia (Howe et al; 2005).  
 
The studies mentioned above indicate the potential of cAMP signalling, PKA 
action and PDE activity in cytoskeletal rearrangement and cell migration. The 
aim of this study is to try and elucidate the role of the cAMP signalling in Rho 
transduction pathways through PDE4 interactions with ARHGAP21/10.  
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Figure 5.1 Schematic representation of Rho signalling cascade. 
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 5.2 Results  
 
5.2.1 Expression and purification of ARHGAP21/10 
 
ARHGAP21,  also  known  as  ARHGAP  10  is  a  novel  Rho/Rac/cdc42-like 
GTPase  activating  protein  expressed  in  chondrosarcoma,  breast  cancer, 
kidney and brain tumours (Katoh and Katoh; 2004).  
 
A yeast two hybrid analysis by our group, in collaboration with Hybrigenics, 
France, to look for novel binding partners for βarrestin identified ARHGAP21 
as a potential interactor (Please refer to appendix II for list of constructs used 
in  yeast  two  hybrid  analyses).  Assays  were  performed  to  validate  these 
findings. However, ARHGAP 21 is a huge 1957 amino acid protein and no as 
yet, a cDNA construct encoding the full-length protein is still to be generated. 
However, specific ARHGAP21 antisera, allowed for pull-down studies of the 
endogenous protein to be performed. Furthermore seven truncates covering 
amino acids 885-1346 (Figure 5.2), which were gifted from Philippe Chavrier’s 
group at the Curie institute, Paris as previously (Dubois et al, 2005) were used 
to assess ARHGAP21: PDE4 interactions. 
 
In order to examine the potential interaction of ARHGAP21 with β-arrestin, 
various GST truncates of ARHGAP21 were expressed as soluble proteins in 
E. coli and purified on glutathione sepharose beads. These purified proteins 
were analysed by SDS-PAGE and expression was visualised by coommassie 
staining. Truncate-1 corresponds to ARHGAP21 residues 885-1096 (75 KD) 
which includes the ARF binding domain of ARHGAP21 (Dubois et al; 2005). 
Truncate  2  comprises  amino  acids  929-1052  (37KD);  truncate  3  includes 
residues 885-1052 (45 KD); truncate 4 is of amino acid region 929-1096 (45 
KD);  truncate  5  incorporates  amino  acids  929-1346  (160  KD);  truncate  6, 
which comprises residues 1064-1346, contains both the ARF binding domain 
and RhoGAP domain, and truncate 7, which is 150 KD, includes amino acids 
1042-1346.  A schematic of full-length ARHGAP21 and truncates described 
here are depicted in figure 5.2 along with a coomassie stained gel analysis of 
the same purified GST fusion proteins.   179 
5.2.2 Mapping the binding sites of β-arrestin-1 on ARHGAP21 using peptide 
array analysis 
 
A peptide array analysis was used to identify the potential binding sites of β-
arrestins  on  ARHGAP21.  For  this  analysis  a  full-length  peptide  array  of 
ARHGAP21 was incubated with a purified recombinant GST fusion protein of 
β-arrestin1  and  probed  with  a  GST  antibody.  GST  alone  was  used  as  a 
control  to  determine  non-specific  interactions  (Figure  5.3).  This  process 
identified a binding site mapped to amino acids 1321-1360 within the RhoGAP 
region  of  ARHGAP  21.  This  potential  binding  site  is  consistent  with  the 
residues of the ARHGAP21 fragment identified in yeast-two hybrid analysis 
carried out by Hyrbigenics, France as well as with previously published data 
by (Xiao et al; 2007), where both RhoGAP10 and RanGAP1 were identified as 
potential β-arrestin interaction proteins in a proteomics analysis study of β-
arrestin immunoprecipitates.  
 
5.2.3  β-arrestin  1-GST  binding  to  an  ARHGAP21  alanine-scanning 
substitution array 
   
To determine key amino acid residues within the identified β-arrestin 1 binding 
domain  of  ARHGAP21,  an  alanine  scanning  substitution  array  of  the 
ARHGAP21  parent  peptides  was  used.  Each  amino  acid  from  the  parent 
peptide identified within the binding site (figure 5.3) was sequentially mutated 
to alanine while alanine residues in the parent peptide were substituted with 
aspartic acid (Figure 5.4).  
In  this  study  it  was  found  that  substitution  of  Thr1329Ala  reduced  the 
interaction  severely.  Similar  substitution  of  Thr1348Ala  and  Thr1349Ala 
reduced  the  interaction  to  a  lesser  extent.  Substitution  of  Glu1344Ala  and 
Glu1345Ala  also  ablated  the  interaction.  However,  a  double  mutation  of 
Glu1344Ala  and  Glu1345Ala  actually  served  to  increase  the  binding  of  β-
arrestin  to  ARHGAP21  compared  to  individual  substitutions  of  Glu1344Ala 
and  Glu1345Ala.  Furthermore,  substitution  of  Glu1340Ala,  Glu341Ala, 
Glu1344Ala  and  Glu1345Ala  drastically  reduced  the  interaction.  Double 
substitutions  of  Phe1337Ala  and  Phe1338Ala  decreased  the  binding.   180 
Individual  single  substitutions  of  Leu1330Ala,  Leu1347Ala  and  Pro1346Ala 
decreased  the  binding.  No  effect  was  seen  upon  substituting  Histidine 
residues at 1334 and 1334 with alanine (Figure 5.4).  
 
5.2.4 A RhoGAP fragment of ARHGAP21 binds to the N-domain of β-arrestin1 
 
To identify the sites of interaction of ARHGAP21 on βarrestin1, a β-arrestin 1 
peptide array was incubated with a purified GST-RhoGAP fragment (amino 
acids 1064-1346) of ARHGAP21 and probed with a GST antibody. GST alone 
was  used  as  control  to  identify  any  non-specific  interactions  (Figure  5.5). 
Probing with the RhoGAP fragment yielded only three positive spots. These 
peptide spots correspond to β-arrestin 1 residues 96-130 which are located 
within the protein’s N-domain (Figure 5.5). Peptide spots of residues 96-125 
showed a stronger interaction than the spot of amino acids 106-130. Probing 
the peptide array with purified ARHGAP21 fragments, which did not include 
the RhoGAP domain did not yield any positive spots.  
 
5.2.5  Binding  of  ARHGAP21  RhoGAP  domain  to  β-arrestin1  alanine 
substitution scans 
 
To  gain  further  insight  into  ARHGAP21  binding  regions  of  βarrestin1,  an 
alanine  substitution-scanning  array  was  generated.  The  purified  RhoGAP 
domain of ARHGAP21 (amino acids 1064-1346) was overlaid on an alanine 
substitution scan of parent peptides (amino acids 96-130) from the previously 
identified binding region (figure 5.6). Substitution of any of the amino acids 
within  the  stretch  from  Lys102  to  His106  (sequence  KLGEH)  to  alanine 
ablated the binding of ARHGAP21’s RhoGAP domain. Similarly, substitutions 
within the stretch Pro109 to Glu133 (sequence PFTFE) partially reduced the 
binding of the RhoGAP domain of ARHGAP21 (figure 5.6).  
 
 
 
5.2.6 The interaction of β-arrestin1 with ARHGAP21 in pull-down assays 
   181 
Equimolar amounts of various purified GST fusions of ARHGAP21 truncates 
were  used  in  pull-down  assays  to  determine  their  ability  to  interact  with  a 
purified  recombinant  MBP  fusion  of  β-arrestin  1.  As  shown  in  Figure  5.7, 
MBP-β-arrestin1  was  able  to  interact  directly  with  the  RhoGAP  domain-
containing fragments 5, 6 and 7 (lanes 6-8; bottom panel, figure 5.7) but with 
fragments 1-4 of ARHGAP21 (lanes 2-5, fig 5.7). MBP-β-arrestin1 did not bind 
to GST alone (lane 1, figure 5.7).  
 
5.2.7 Activation of Rho in HEK 293-AT1aR cells.  
 
Rho GTPases are involved in regulation of F-actin dynamics in cells (Jaffe 
and  Hall;  2005,  Aspenstrom  et  al;  2004).  HEK293  cells  expressing  the 
angiotensin AT1a receptor have been shown exhibit stress fibre formation in 
response to angiotensin II challenge through a Gαq/11/Rho-mediated pathway 
(Barnes et al; 2005). In order to evaluate the Rho activation profiles in these 
cells, a Rho activity assay was performed. Figure 5.8(a) shows that in resting 
conditions (0 minutes) there is minimal Rho activity. However, in response to 
angiotensin  II  challenge  this  activity  is  increased  transiently  for  up  to  10 
minutes after which activity returns to basal levels within 20 minutes of agonist 
exposure.  Confocal  analysis  (Figure  5.8(b)  of  the  HEK293  cell  line  stably 
expressing  the  AT1a  receptor  demonstrates  the  formation  of  stress  fibres 
upon stimulation with Angiotensin II.  
 
5.2.8 Interaction of β-arrestin 1 with ARHGAP21 in HEK293-At1aR cells 
 
In order to determine whether full length ARHGAP21 interacts with β-arrestin1, 
a co-immunoprecipitation assay was performed. HEK293-AT1aR cells were 
transfected with β-arrestin 1-GFP and then treated with angiotensin II for 10 
minutes in order to activate the Rho signalling. Panel 1 of Figure 5.9 showed 
that  β-arrestin  1  interacted  with  full-length  ARHGAP21  in  both  resting  and 
stimulated cells. However, agonist stimulation did not appear to have an effect 
on the interaction. Panel 2 of figure 5.9 shows the expression of ARHAGP21, 
immuno-detected as a ~250 KD species.  
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5.2.9 PDE4D5 interacts with ARHAGP21 in HEK293-AT1aR cells  
 
Βoth β-arrestin 1 and β-arrestin 2 have been shown to interact with PDE4 
isoforms  and  recruit  them  to  G-protein  coupled  receptors  at  the  plasma 
membrane in response to agonist challenge (Perry et al; 2002 and Baillie et al; 
2003). β-arrestins can interact with all PDE4 isoforms through a common β-
arrestin binding site located within the catalytic subunit. However, β-arrestin 
shows preference for interaction with the PDE4D5 isoform due the presence 
of an additional binding site within PDE4D5’s unique N-terminal region (Baillie 
et al; 2003).  
 
In  order  to  assess  whether  PDE4D5  can  also  be  sequestered  to  the 
ARHGAP21-β-arrestin  1  complex,  immunoprecipitation  experiments  were 
carried  out.  Endogenous  ARHGAP21  was  immunoprecipitated  from  the 
HEK293-AT1aR  cells  using  an  ARHGAP21  antibody  and  precipitates  were 
then  probed  for  endogenous  PDE4D5  using  a  PDE4D5  N-terminal-specific 
antibody.  Panel  1)  of  figure  5.10  shows  the  endogenous  PDE4D5  from 
HEK293-AT1aR  cells  and  its  pull-down  in  ARHGAP21  precipitates  as 
detected  by  immunoblotting  with  the  PDE4D5  N-terminal-specific  antibody. 
Panel 2) of figure 5.10 shows the immuno-detected ARHGAP21 from the cell 
lysate as well as IP using ARHGAP21 antisera.  
 
5.2.10 PDE4D5 interacts with ARHAGP21 in vitro 
 
Full-length purified PDE4D5-MBP and GST fragments 1 (residues 885-1096) 
and 6 (residues 1064-1346) of ARHGAP21 were used in pull-down assays to 
determine whether PDE4D5 interaction with ARHGAP21 is direct. Panel 2) of 
figure 5.11 shows that purified recombinant PDE4D5-MBP interacted directly 
with the fragments containing ARF binding domain of ARHGAP21 as well as 
the Rho binding domain of ARHGAP21 (figure 5.11). However there are some 
overlapping  regions  in  both  fragments.  As  a  control,  purified  fragments  of 
ARHGAP21-GST were also incubated with MBP alone (lanes 4 and 5, figure   183 
5.11). A similar control was set up with PDE4D5 MBP and GST alone (lane 3, 
figure 5.11). No interaction was seen in the control lanes.  
 
5.2.11 Effect of PDE4 activity on interaction of ARHGAP21 with PDE4D5 and 
β -arrestin1 
 
For scaffolding proteins such as DISC1, its interaction with PDE4 isoforms 
can be altered by elevating intracellular cAMP levels (Murdoch et al; 2007). It 
was therefore of interest to determine whether the interaction of PDE4D5 with 
the  ARHGAP21/β-arrestin1  complex  is  dynamically  regulated  by  increasing 
cAMP  levels,  PDE4  activity  or  Rho  activation  in  cells.  ARHGAP21  was 
immunoprecipitated  from  HEK293-AT1aR  cells  under  basal  conditions  and 
from  cells,  which  had  been  treated  with  cAMP  activators  Forskolin/IBMX, 
PDE4  inhibitors  like  Rolipram  and  Gq/11/Rho  activator,  Angiotensin  II  either 
alone or in combination. The lysates and IPs were then immunoblotted for 
PDE4D5 and Arrestin.  Panel 1 of figure 5.12 confirmed that neither elevated 
Rho activity nor cAMP levels had an impact on Arrestin-ARHGAP21-PDE4D5 
complex.  Panel  2  of  figure  5.12  shows  that  increased  intracellular  cAMP 
levels and PDE4 activity do not alter PDE4-ARHGAP21-arrestin interaction. 
Similarly, Rho activation did not alter the dynamics of ARHGAP21-Arrestin-
PDE4D5 complex. Both the blots were stripped with stripping buffer and were 
reblotted for a PKA phosphorylation using PKA phospho substrate antibody 
as an indicator of PKA activation upon elevation of cAMP levels. 
 
 
 
 
 
 
 
 
 
5.3 Discussion  
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RhoGTPases along with their regulators are involved in important cytological 
functions including cytoskeletal rearrangement, cell migration, cytokinesis and 
cell  cycle  regulation  (Jaffe  and  Hall  2005).  The  ability  to  participate  and 
regulate  in  multiple  signalling  pathways  requires  co-ordination,  with  the 
recruitment signalling scaffolds through protein-protein interactions playing an 
important role (Pawson; 2007, Pawson and Warner, 2007).   
 
RhoGTPases  have  been  shown  to  interact with  a  wide  variety  of  proteins, 
which  they  use  as  their  effectors  (Bishop  and  Hall;  2000,  Boguski  and 
McCormick; 1993). The dynamics of these interactions can be modified by 
conformational changes of the RhoGTPase induced by GDP/GTP binding and 
its intrinsic GTPase activity the activity of which can be regulated by GAFs 
and GAPs (Bishop and Hall 2000).   
 
ARHGAP21 is a novel GTPase activating protein (GAP) for cdc42 (Khato et al; 
2004, Basseres et al; 2002). Using a novel peptide array analysis technique, 
along  with  co-immunoprecipitation  studies,  it  was  shown  that  interaction  of 
ARHGAP21 with β-arrestin1 and PDE4D5 occurs both in vitro and in vivo. 
ARHGAP21 contains a PDZ domain, a pleckstrin homology (PH) domain and 
a RhoGAP domain (Basseres et al; 2002). Recently it has been reported that 
ARHGAP21  region  corresponding  to  amino  acids  885-1096  interacts  with 
ARF1  (Figure  5.2  for  schematic)  implicating  it  in  the  regulation  of  F-actin 
dynamics  through  the  Arp2/3  complex  (Dubois  et  al  2005).    All  identified 
domains  of  ARHGAP21  have  individual  functions. The pleckstrin  homology 
domain  is  known  to  be  involved  in  translocation  of  proteins  to  plasma 
membrane in response to PI3 kinase activity (Bernards and Settleman 2004, 
Bos et al; 2007). The Rho GAP domain is involved in regulating the activity of 
GTPases.  
 
Yeast  two-hybrid  analysis  of  β-arrestin  1  performed  commercially  for  our 
group by Hybrigenics, France, as well as a large-scale proteomic study (Xiao 
et al; 2007) have revealed ARHGAP21 as a potential binding partner for β-
arrestin1 and β-arrestin2.  
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Here, a peptide array of full-length ARHGAP21/10 was overlaid with purified 
β-arrestin1-GST (Figure 5.3). β-arrestin 1 strongly interacted with residues of 
the  RhoGAP  domain  (amino  acids  1321-1360),  supporting  the  yeast–two-
hybrid  analyses,    and  further  indicating  that  the  RhoGAP  domain  acts  a 
interaction site for β-arrestin 1 (Figure 5.3).   
 
In  order  to  identify  the  key  residues  involved  in  β-arrestin/ARHGAP21 
interaction, an alanine substitution peptide array scan was performed (Figure 
5.4). The alanine substitution scan of the RhoGAP domain (amino acids 1321-
1360)  of  ARHGAP21  demonstrated  a  strip  of  acidic  and  basic  residues 
interspersed  with  aromatic  and  hydrophobic  residues  to  be  crucial  for  β-
arrestin  interaction.  The  Glu1328Ala  substitution  led  to  a  decrease  in  β-
arrestin  binding  by  around  30%  compared  to  control,  whereas  individual 
alanine substitutions of T1329 and L1330 reduced the interaction by 80 and 
20%  respectively  (Figure  5.4  top  panel).  Individual  alanine  substitutions  of 
Glu1344  and  Glu1345  led  to  an  80%  decrease  in  binding  of  β-arrestin. 
Combined alanine substitutions at Glu1340, Glu1341, Glu1344 and Glu1345 
decreased the binding of β-arrestin by 60%. Double alanine substitutions at 
Glu1340 and Glu1341 elicited a 50% decrease in binding whereas the double 
alanine substitution at Glu1344 and Glu1345 produced only a 20% decrease 
in binding. A combined alanine substitution at His1333 and His1334 did alter 
binding  (Figure  5.4  top  panel).  Single  alanine  substitutions  at  Pro1346, 
Leu1347, Thr1348  and  Thr1349  reduced  the  binding  of  arrestin  by  ~  30% 
respectively (Figure 5.4 bottom panel). Similarly, double alanine substitutions 
at  Phe1337  and  Phe1338,  Thr1348  and  Thr1349,  Glu1352  and  Glu1353 
reduced  the  binding  by  ~20%.  Multiple  alanine  substitution  of  glutamate 
residues  at  positions  1340,  1341,  1344,  1345,  1352  and  1353  together 
reduced  the  peptide’s  interaction  with  by  β-arrestin  only  ~20%  (Figure  5.4 
bottom  panel).  Taken  together,  these  data  suggest  that  residues  Thr1329, 
Glu1341,  Gly1342,  Glu1344,  and  Glu1345  are  critical  in  determining  the 
interaction of β-arrestin 1 with RhoGAP domain of ARHGAP21.   
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To  further  characterise  the  interaction,  in  vitro  pull-down  assays  were 
performed  using  purified  GST  truncates  of  ARHGAP10/21  (Figure  5.7).  A 
purified  MBP  fusion  of  β-arrestin  1  MBP  exhibited  an  interaction  with  only 
truncates  containing  the  RhoGAP  domain  (truncates  5,  6  and  7)  of 
ARHGAP10/21  in  pull-down  assays  but  not  with  fragments  containing 
comprising the ARF binding domain or the PH domain. These data suggested 
that the interaction of β−arrestin with ARHGAP21 is mediated by the RhoGAP 
domain of ARHGAP21/10 and that the interaction is direct (Figure 5.7). 
 
In reciprocal binding studies, in which a full-length peptide array of β−arrestin 
1  was  overlaid  with  purified  GST-RhoGAP  domain  (1064-1346)  of 
ARHGAP21,  an  interaction  site  within  the  N-domain  of  β−arrestin  1  was 
identified  (Figure  5.5  top  panel).  No  interaction  was  observed  with  GST-
ARHGAP21 fragments 1-4.  
 
To  further  define  the  residues  of  β−arrestin  involved  in  its  interaction  with 
ARHGAP21,  an  alanine  substitution-scanning  array  was  used.  Individual 
mutations of any of residues within the region 102-106 (sequence KLGEH) 
abolished the interaction of β−arrestin with ARHGAP21 (Figure 5.6). Alanine 
substitution  of  residues  Pro109  and  Phe110  attenuated  the  interaction 
severely.  A  similar  effect  was  observed  with  substitutions  at  Phe112  and 
Glu113 (Figure 5.6).  
 
From  the  peptide  array  analyses,  it  could  be  suggested  that  there  is  a 
consensus site for ARHGAP21 binding to β-arrestin of E- (X) 4-KLGEH- (X) 5-E 
(Figure  5.6).  However,  analyses  also  showed  that  βarrestin-ARHGAP21 
interaction appears to involve a strip of acidic amino acids on each protein. 
These  observations  are  somewhat  curious  as  it  would  be  expected  that  if 
electrostatic interactions were involved in binding then the  key acidic amino 
acids of β-arrestin would be complemented by a strip of basic residues on 
ARHGAP21 and vice versa. Mutagenesis of these identified residues in the 
full-length proteins would be required to define the sites of interaction more 
clearly.  It  is  possible  these  stretches  of  acidic  amino  acids  are  involved  in   187 
presenting correctly other key amino acids on each peptide that are important 
for binding but are not affected upon alanine substitution. This needs further 
investigation.  
 
A GAP domain is present in all GAPs of Ras GTPase family including Ras, 
Rho,  Rac,  Rap,  Rab,  Arf,  Ran  and  RGS  proteins  which  are  GαGAPs 
(Scheffzek  and  Ahmadian,  2005).  Since  the  GAP  domains  of  most  GAPs 
share  a  high  degree  of  homology,  it  would  be  of  interest  to  study  the 
interaction of β−arrestin with GAP domains of other Ras proteins. All GAP 
domains  are  involved  in  regulating  the  GTPase  activity  of  GNBPs.  GAPs 
enhance the intrinsic GTPase activity of GTPases and, consequently, inhibit 
the  GTPase  as  described  in  section  1.11.1.3.  In  one  model  they  either 
stabilise the catalytic domain of GTPases or provide a key arginine residue 
into  the  catalytic  domain  of  the  GTPase  (Scheffzek  and  Ahmadian  1997, 
Moore and Eccleston, 1991). The significance of the second model is better 
explained  in  that  the  long  side  chain  of  the  arginine  residue  can  act  as a 
bridge to bring intra-protein distances closer and its guanidium group can act 
like a stabiliser of the transition states involved in GTP hydrolysis by GNBPs. 
However,  recent  work  by  Fidyk  and  Cerione,  2002  has  shown  that  GAPs 
enhance the GTPase activity by both stabilising the catalytic domain as well 
as providing the arginine residue. Given the initial role of GAPs in enhancing 
the GTPase activity of GNBPs and from the data presented on β−arrestin-
ARHGAP21 interaction, it could be argued that binding of β−arrestins to the 
RhoGAP  domain  might  influence  GAP  activity  either  by  interrupting  the 
inherent  ability  of  GAP  to  enhance  the  catalytic  activity  of  GTPases  or  by 
acting  as  a  physical  barrier  by  preventing  the  ability  of  GAP  to  bind  its 
respective GTPase altogether, leaving the GTPase in a constitutively active 
state.  
 
To understand the functional outcome of ARHGAP21-β−arrestin interaction, 
functional  assays  were  carried  out  using  a HEK293-AT1ar  stable  cell  line. 
This cell line was chosen to study functional nature of these interactions as 
activation  of  Rho  signalling  is  shown  to  be  triggered  by  Angiotensin  II   188 
treatment  of  these  cells  (Barnes  et  al,  2005).  Rho  activation  assays  were 
carried out using these cells as described in section 2.11.3.  A peak transient 
activation of Rho was seen after stimulation with Angiotensin II for 10 min with 
Rho activity returning to basal levels after 20 min (Figure 5.8 a). Confocal 
analyses  revealed  that  the  activation  of  Rho  upon  incubation  of  cells  with 
Angiotnesin II, induced stress fibre formation (Figure 5.8 b). Rho activation by 
GαQ/11  is  mediated  either  in  a  phoshpolipase  C/PKC  dependent  manner  or 
through  activation  of  tyrosine  kinases  (Kuwahara  and  Kuwahara;  2002, 
Hirshman and Emala, 1999). It has been reported that β−arrestin–1-mediated 
activation  of  Rho,  and  subsequent  actin  reorganisation  and  stress  fibre 
formation in angiotensin II-stimulated HEK293-AT1aR cells requires GαQ/G11 
signalling (Barnes et al; 2005). Recruitment of β-arrestin 1 to agonist-activated 
AT1a receptors not only activates Rho, but also regulates β-arrestin-mediated 
activation of the ERK MAP kinase pathway. This regulation is hypothesised to 
be due to competition between the βarrestin1 and 2 for binding sites on At1a 
receptor (Barnes et al; 2005). It has also been proposed that upon receptor 
stimulation, β-arrestin 1 and GαQ/11 co-ordinate to potentiate the activation of 
Rho,  which,  in  turn,  activates  Rho  kinase,  ROCK,  and  thus  leads  to  actin 
rearrangement for the formation of stress fibres (Barnes et al; 2005). Here, 
HEK293-AT1ar cells were transfected with a β-arrestin-1-GFP fusion protein 
and cells were stimulated to attain maximum Rho activation in the cells. Co-
immunoprecipitation  studies  of  cell  lysates  revealed  that  interactions  were 
unaltered  in  response  to  Angiotensin  II  exposure  as  compared  to  non-
stimulated cells (figure 5.9 top panels). Since β−arrestins activate Rho, and if 
they also bind to RhoGAPs, which have an inhibitory affect on Rho, it would 
be logical to assume binding of βarrestin to ARHGAP21 would be augmented 
under  conditions  of  maximum  Rho  activation.  The  data  suggests  that  Rho 
activation by β−arrestin is independent of its interaction with the RhoGAP and 
binding of β−arrestin to ARHGAP21 is not affected by Rho activity (Figure 5.9). 
The stable association of β−arrestin 1 with ARHGAP21 in both resting and 
agonist-stimulated  cells  is  perhaps  mediated  by  the  RhoGAP  domain, 
functioning  independently  of  ARHGAP21.  Studies  of  other  ARHGAP21 
interacting proteins has shown that ARHGAP10/21 is able to bind ARF1 (ADP   189 
ribosylation factor 1), which allows for the regulation of cdc42 activity at Golgi 
membranes (Dubois et al; 2005). ARHGAP21 interacts with ARF1 through its 
PH  domain  plus a  α-helix  motif  located towards  its  C-terminus  with  switch 
regions of ARF1. Eventhough the PH domain is necessary for this interaction, 
it  cannot  on  its  own  bind  to  ARF1  independent  of  the  C-terminal  α-helix 
(Menetrey et al; 2007). ARHGAP21/10 acts as GAP for CDC42 recruited to 
Golgi  in  ARF1-dependent  manner  and  regulates  the  function  of  its 
downstream effectors, Arp2/3, which are involved in F-actin dynamics in the 
proximity of the Golgi membranes. Arp2/3 is also implicated in the transport of 
clathrin-coated vesicles via the trans-Golgi network (Dubois et al; 2005).  
 
It is known that β-arrestins play an important role in GPCR desensitisation, 
internalisation and resensitisation (Oakley et al, 1999, Laporte et al; 1999). 
When receptor is internalised in a complex with β-arrestin, dephosphorylation 
of the receptor by phosphatase PP2A, followed by dissociation of β-arrestin 
from the receptor promotes the recycling of receptor from endosomal vesicles 
back  to  the  plasma  membrane.  If  β−arrestin  fails  to  dissociate  from  the 
receptor,  then  receptor  is  targeted  to  proteasomal  degradation  thus 
preventing receptor resensitisation (Simaan et al; 2004, Zhang et al; 1999, 
Zhang  et  al;  1997).  β-arrestin  dissociation  from  the  lutenising 
hormone/Chorionic gonadotrophin receptor (LH/CGR) has been shown to be 
ARF6-dependent (Mukherjee et al; 2000). Although the role of β−arrestin in 
directly regulating the vesicle transport is poorly understood, given their role in 
receptor  desensitisation/resensitisation,  and  their  interaction  with  ARFs,  it 
could be suggested that the β−arrestin-ARHGAP10 complex might function in 
regulating F-actin dynamics at the Golgi thereby regulating the transport of 
clathrin-coated  vesicles to  plasma  membrane  surface.  β−arrestin  has  been 
shown to mediate PI3 kinase activation in MEF cells in a manner independent 
of ERK and Gi signalling (DeWire et al; 2007 and Povsic et al; 2003). Most 
RhoGAPs,  including  ARHGAP21,  possess  a  PH  domain,  which  binds 
phosphotidylinositides, thus altering substrate specificity of the RhoGAP and 
its translocation to plasma membrane (Ligeti and Settleman; 2006, Bernards 
and  Settleman;  2004).  Given  these  findings  it  could  be  argued  that   190 
ARHGAP21 might act as a chaperone in response to phosphatidylinositide 
signalling,  recruiting  β-arrestins  to  plasma  membrane  to  mediate  GPCR 
receptor desensitisation and internalisation.  
 
Considering  β−arrestins  also  function  as  scaffolds,  anchoring  proteins 
involved in many signalling pathways, the interaction with ARHGAP10/21 may 
be  important  for  regulating  Rho  activity  associated  with  these  β-arrestin 
complexes  in  different  subcellular  locations.  β-arrestin  complexes  have 
previously been shown to mediate β2-AR desensitisation by recruiting PDE4 
isoforms to the plasma membrane. PDE4 binding to β-arrestin regulates PKA 
phosphorylation and consequent the Gs-Gi switching of the receptor (Baillie et 
al; 2003 and Perry et al; 2002). βarrestin recruitment of PDE4 has also been 
shown  to  occur  within  lipid  rafts  of  T-cell  membranes,  regulates  T-cell 
activation and cytokine production (Abrahamsen et al, 2004).  
 
Of  all  PDE4  isoforms,  PDE4D5  shows  preference  for  binding  to  β−arrestin 
due to the presence of an extra site for βarrestin interaction located within its 
isoform-specific N-terminal region (Baillie et al, 2007, Bolger et al; 2003). The 
potential  interaction  of  PDE4D5,  with  an  ARHGAP21/β−arrestin  1  complex 
and its possible role in actin dynamics was therefore investigated. PDE4 has 
previously been shown to be involved in Rho-mediated cell migration (Fleming 
et  al;  2004).  In  REF52  cells,  rolipram  inhibition  of  PDE4  resulted  in 
suppression of the RhoA-ROCK-Myosin signalling pathway which is required 
for  integrin-mediated  actin-adhesion  spike  formation.  Furthermore,  PDE4 
inhibition led to impaired cell migration (Fleming et al; 2004).  
In  this  study  the  HEK293-AT1aR  cell  line  was  used  to  study  PDE4D5 
interaction with this complex. Immunoprecipitated ARHGAP21 was shown to 
interact  with  PDE4D5  both  in  resting  and  Angiotensin  II  stimulated  cells 
(Figure  5.10  top  panel).  As  noted  previously  in  β-arrestin/ARHGAP21  co-
immunoprecipitation  experiments,  interaction  of  PDE4D5  with  ARHGAP21 
was unaltered by activation of Rho. In vitro pull-down assays were performed 
to  determine  if  PDE4D5  is  able  to  bind  directly  to  ARHGAP21  or  is  the 
interaction observed in vivo mediated by β-arrestin recruitment of the enzyme.   191 
Purified recombinant PDE4D5 was found to interact directly with fragments 
RhoGAP  domain  and  ARF  binding  domains  of  purified  ARHGAP21-GST 
(Figure  5.11  bottom  panel).  However  both  the  fragments  have  some 
overlapping regions. Interestingly, PDE4D5, but not β-arrestin, was shown to 
interact with the ARF binding domain of ARHGAP21 (Figure 5.7 top panel and 
Figure 5.11 bottom panel). It could be inferred that PDE4D5 and β-arrestin 
might  interact  with  ARHGAP21  independent  of  each  other.  However,  both 
proteins are able to interact with the RhoGAP domain of ARHGAP21. It is 
possible  that  β−arrestin  and  PDE4D5  compete  for  binding  to  the  RhoGAP 
domain.  
 
Interaction of PDE4s with some partner proteins can, in certain instances, be 
regulated by cAMP. Elevation of cAMP levels and subsequent activation of 
PKA has been shown to mediate the dissociation of PDE4D3 and PDE4C2 
isoforms from DISC1, a scaffold protein implicated in schizophrenia (Murdoch 
et  al;  2007). Furthermore,  in neuronal  SHSY5Y  cells,  the  interaction  of  an 
endogenous 71KD DISC1 species with the PDE4B1 isoform is attenuated by 
increased cAMP levels (Millar et al; 2005). 
 
Conversely,  the  interaction  of  PDE4D3  with  mAKAP  has  been  shown  to 
increase in response to elevated cAMP levels, whereby cAMP-mediated PKA 
phosphorylation of PDE4D3 on the Ser13 within its unique N-terminal region, 
increases PDE4D3 affinity for mAKAP (Carlisle et al; 2004).  
It was therefore of interest to assess the functional consequences of elevated 
cAMP  levels  in  the  protein-protein  interactions  of  a  β−arrestin-ARHGAP21-
PDE4D5 complex. In HEK293-AT1aR cells treated with or without Angiotensin 
II, forskolin/IBMX-induced elevation of cAMP had no impact on the affinities of 
PDE4D5-ARHGAP21 and β−arrestin-ARHGAP21 interactions as revealed in 
co-immunprecipitation  experiments  (Figure  5.12).  Similarly,  inhibiting  PDE4 
activity with rolipram, in the presence or absence of elevated Rho activity, did 
not  alter  the  interactions  of  the  protein  complexes  (Figure  5.12).  Small 
interfering (si) RNA to knock down ARHGAP21 expression in HEK293-AT1aR 
cells  was  used  to  further  characterise  the  interactions  of  the  β-  192 
arrestin/ARHGAP21/PDE4D5 complex and its role in stress fibre formation. 
However treatment with ARHGAP21 siRNA resulted only in a 15% reduction 
in ARHGAP21 expression in cells, which was insufficient to exploit functionally. 
Further  work  is  therefore  required  to  optimise  the  transfection  efficiency  of 
ARHGAP21 siRNA with these cells.  
 
ARHGAP21 is a poorly characterised RhoGAP. Its functional role in signalling 
complexes has yet to be elucidated. Although the cAMP-PKA pathway has 
been shown to be involved in regulation of cell migration and motility (Howe et 
al; 2005, Howe, 2004 and Fleming et al; 2004), the role of PDE4 isoforms in 
these  processes  is  still  unclear.  As  cAMP  signalling  in  cells  is 
compartmentalised (Lynch et al; 2006, Houslay and Adams, 2003, Zaccolo 
and Pozzan, 2002), it could be postulated that PDE4D and β−arrestin might 
co-ordinate  Rho  signalling  pathways  by  interacting  with  and  regulating  the 
activity of ARHGAP21. The functional significance of ARHGAP21/β-arrestin, 
ARHGAP21/PDE4D5  and,  potentially,  ARHGAP21/β-arrestin/PDE4D5 
interactions in these cells needs further investigation.  
 
As  it  has  been  shown  that  both  β−arrestin  and  PDE4D5  bind  ARHGAP21 
within its RhoGAP domain, it is possible the two proteins compete for binding 
to  ARHGAP21.  The  amounts  of  ARHGAP21  complexing  with  β-arrestin, 
PDE4D5 or both may vary with cell type with the possibility that interactions 
are also altered in response to extracellular stimuli. Considering PDE4D5 also 
binds  ARHGAP21  within  its  ARF  binding  region,  a  PDE4D5-ARHGAP21 
complex may be sequestered to different sub-cellular compartments than β-
arrestin-ARHGAP21  and  β−arrestin-PDE4D5-ARHGAP21  complexes.  Since 
the pull-down assays were not performed with full-length ARHGAP21 protein, 
it  is  possible  that  β−arrestin,  as  well  as  PDE4D5,  might  have  additional 
binding sites on ARHGAP21 aside from those identified and discussed here.  
Sequence  analysis  of  ARHGAP21/10  using  scansite 
(http://scansite.mit.edu/motifscanseq.phtml)  identified  a  potential  PKA 
consensus motif within the protein. However, as shown in Figure 5.12, when 
ARHGAP21 was immunoblotted with a PKA substrate-specific antiserum, no   193 
phospho-band  of  the  molecular  weight  of  ARHGAP21  was  observed  in 
precipitates as well as in lysates. However, a 100kD phosphorylated species 
was detected (Fig 5.12) One possible PKA substrate, which migrates at this 
size  is  PDE4D5.  Selective  immunoprecipitation  of  PDE4D5  with  PDE4D5-
specific  antisera  followed  by  probing  with  a  PKA  substrate  antibody  would 
indicate  whether  or  not  the  unknown  phospho-protein  is  PDE4D5. 
Notwithstanding this, PDE4D5 is known to be phosphorylated and activated 
by PKA (Baillie et al, 2001).  
In conclusion, these studies suggest ARHGAP21 is a binding partner for both 
β−arrestins  and  PDE4  isoforms.  Investigating  these  interactions  and  their 
functional  roles  may  be  of  importance  in  the  development  of  therapeutic 
targets in disease states linked to changes in cell migration and cytoskeletal 
rearrangement including tumour metastasis, asthma and COPD.  
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Figure 5.2 Expression and purification of GST-truncates of ARHAGP21 in E coli. 
 
ARHGAP21 and different truncates used in this are schematically represented. ARHGAP21 
contains an N-terminal PDZ domain, a PH domain and a conserved RhoGAP domain. GST 
and different ARHGAP constructs were expressed and purified from E.coli as described in 
chapter 2.4.2.  Purified proteins were analysed by SDS-PAGE and Coommassie staining as 
described in section 2.10.  The gels represent the single successful expression experiment 
undertaken for all the proteins in E.coli 
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Figure 5.4 Alanine-scanning substitution analyses to probe the binding sites for β-
arrestin1-GST in the RhoGAP domain of ARHGAP10/21 
 
ARHGAP21/10 peptide arrays were probed for β-arrestin1–GST binding based upon the 
indicated 25-mer ‘parent’ ARHGAP21/10 peptide, where the indicated amino acids were 
sequentially and individually replaced by alanine. Ct refers to the native peptide and all 
other spots reflect alanine substitutions of individual amino acids in the native spot. The 
peptide array interaction data are from experiments done once. 
N-Domain      C-Domain
ß-arrestin1
peptide array
N-Domain      C-Domain
ß-arrestin1
peptide array
N-Domain      C-Domain N-Domain      C-Domain
ß-arrestin1
peptide array
B10 ARB1 (96-120) P-L-T-R-L-Q-E-R-L-I-K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P
C1 ARB1 (101-125) Q-E-R-L-I-K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P-P-N-L-P-C
C2 ARB1 (106-130) K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P-P-N-L-P-C-S-V-T-L-Q
B10
C1     C2
Probed with 1064-
1346 a.acids of
ARHGAP21-GST
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C1 ARB1 (101-125) Q-E-R-L-I-K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P-P-N-L-P-C
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Figure 5.5 Probing a β-arrestin1 array with ARHGAP10/21 (1064-1346) –GST 
 
Beta  arrestin-1  is  shown  schematically  with  its  N  and  C-domains.  Results  show 
immobilized peptide ‘spots’ of overlapping 25-mer peptides each shifted along by five 
amino  acids  in  the  entire  Beta-arrestin-1  sequence  probed  for  interaction  with 
ARHGAP21 fragment with 1064-1346 amino acids and detection by immunoblotting. 
Positively  interacting  peptides  generate  dark  spots,  while  those  that  do  not  interact 
leave white (blank) spots. In all other sections of the array, spots were blank with either 
probe. Spot numbers relate to peptides in the scanned array and whose sequence is 
given as indicated. Arrays probed with a. acids 885-1096 of purified ARHGAP21 GST 
did not yield any spots. Arrays probed with purified GST did not yield any positively 
interacting spots. The peptide array interaction data are from experiments done once. 
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Figure  5.6  Alanine  scanning  substitution  analyses  to  probe  binding  sites 
ARHGAP21-GST in the N-domain of β-arrestin 1 
 
β-arrestin1peptide arrays were probed for ARHGAP21/10 binding based upon the 
indicated 25-mer ‘parent’ β-arrestin1 peptide, where the indicated amino acids were 
sequentially and individually replaced by alanine. Ct refers to the native peptide and 
all  other  spots  reflect  alanine  substitutions of  individual  amino  acids  in  the native 
spot. The peptide array interaction data are from experiments done once. 
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Chapter 6 Final discussion 
 
PDE4 enzymes play a crucial role in regulating cAMP levels within various 
sub-cellular compartments (Houslay et al; 2007, Zaccolo 2006, Zaccolo et al; 
2006, Lissandron et al; 2006, Terrin et al; 2006, Houslay and Adams, 2003). 
Compartmentalization of cAMP signalling is now well documented due to the 
advent  of  genetically  encoded  sensors  of  cAMP  that  have  allowed  for  the 
detection of cAMP gradients within live cells (Willoughby and Cooper, 2008, 
Tasken and Aandahl 2004, Zaccolo et al, 2002, Dunn et al; 2006, Dal molin et 
al;  2006,  Willoughby  and  Cooper,  2007).  Components  of  cAMP  signalling 
including AKAPs (Dodge-Kafka et al; 2006), adenylate cyclases (Cooper and 
Crossthwaite, 2006) and PDEs (Houslay et al; 2007) are specifically recruited 
to  intracellular  micro-domains  where  they  respond  to  and  modulate  cAMP 
pools.  Proper targeting of these proteins is of critical importance for functional 
cAMP signalling within cells.  
 
To date 21 PDE4 isoforms have been identified, each of which has an isoform 
specific N-terminal region that confers capability to interact with a variety of 
proteins  that  regulate  various  signalling  molecules  and  their  transduction 
pathways (Houslay et al; 2007, Houslay and Adams, 2003, Lynch et al; 2006). 
Many of these PDE4-signalling scaffold protein complexes are discussed in 
detail in section 1.8.   
 
6.1 SUMOylation of PDE4 isoforms in HEK293 cells 
 
Post-translational modifications of a protein play a major role in regulation of 
its structure, function and subcellular localisation. The most well established 
post-translational  modification  of  PDE4s  is  phosphorylation,  which  is 
catalysed  by  kinases  including  PKA,  ERK,  and  an  as  yet  unknown  kinase 
downstream of PI3 kinase, (Mackenzie et al, 2002, Mackenzie et al, 2000, 
Mackenzie  et  al;  1998  and  Ekholm  et  al,  1997,  Hill  et  al;  2006).  Sections 
1.7.4.2, 4.3 and 4.4 discuss the regulation of PDE4 isoforms by PKA and ERK 
in detail.    208 
 
SUMOylation is relatively a newly identified post-translational modification and 
is known to affect the localisation of proteins, and their functioning (Kerscher, 
O; 2007 and Johnson, E; 2004). SUMO plot (www.abgent.com/doc/sumoplot) 
analysis  of  PDE4s  identified  two  of  the  subfamilies  as  potential  SUMO 
substrates. Accordingly, in chapter 3, analysis was performed to characterise 
the SUMO modification of PDE4 isoforms particularly, PDE4D5. Although the 
conditions  in  which  PDE4D5  is  SUMOylated  were  initially  unknown.  Co-
transfection with PIASy E3 ligase led to conjugation of PDE4D5 with SUMO-1 
whilst co-transfections with other E3 ligases such as PIAS1 and PIAS2 did not 
induce PDE4D5 SUMOylation (Figure 3.2). The SUMO conjugation motif is 
ΨKXE, where Ψ is an aliphatic residue and X is any amino acid (Hay 2005). 
This SUMO conjugation consensus motif is located within the catalytic region 
of  PDE4D5.  In  confirmation  of  this  being  the  site  of  SUMOylation  within 
PDE4D5,  mutation  of  the  lysine  residue  within  this  sequence  to  arginine, 
abrogated SUMOylation of PDE4D5 (Figure 3.2a). Sequence alignment of the 
long isoforms from the four sub-families revealed that only the 4A and 4D sub-
families possess a potential SUMOylation site within their primary structures. 
This  was  verified  in  SUMOylation  assays  whereby  HEK293  cells  were 
transfected with PDE4A4, 4B1, 4C2 and 4D5 isoforms plus PIASy E3 ligase. 
Only in cells expressing the PDE4D and PDE4A isoforms was SUMOylation 
detected (Figure 3.2 c). It would be of interest to determine whether PDE4 
isoforms  are  differently  conjugated  to  other  SUMO  molecules,  such  as 
SUMO2-4  and  if  this  process  is  altered  under  different  physiological 
conditions.  Identification  of  the  mechanisms  regulating  SUMOylation  would 
offer means to modulate of functioning of the PDE4A and PDE4D subfamilies.  
 
UBC9 is a SUMO E2 ligase (Johnson and Blobel 1997, Johnson et al, 1997). 
Figure 3.3 shows that UBC9 interacts at the FQF ‘multi-functional’ docking 
domain  of  PDE4D5.  The  FQF  docking  domain  is  conserved  in  all  PDE4 
isoforms.  However,  only  4A  and  4D  subfamilies  were  shown  to  be 
SUMOylation substrates thus demonstrating that UBC9 binding alone is not 
sufficient  for  SUMOylation  to  occur  in  vivo.  The  FQF  multi-protein  docking 
domain of PDE4 isoforms serves as a site for interaction for proteins including   209 
￿ arrestin (Bolger et al, 2006), ERK2 (Mackenzie et al, 2000) and AKAP18δ 
(McSorley  et  al,  2006).  Further  analysis  is  required  to  characterise  the 
interactions  of  these  various  partners  at  the  FQF  and  whether  their 
interactions  are  competitive.  If  the  interactions  are  dynamic,  then,  for 
example, would ERK binding to the FQF domain block interaction of UBC9 
with  the  PDE4  isoform  and  subsequently  preventing  it  from  being 
SUMOylated. Changes in the level of expression of the scaffolds competing 
for  binding  to  this  site  is  likely  to  have  functional  consequences  for  PDE4 
regulation and its subcellular localisation.  
PIAS proteins are Protein inhibitors of activated STAT and possess SUMO E3 
ligase activity (Takahashi et al, 2003). PIAS proteins interact with a variety of 
proteins  and  act  as  transcriptional  repressors.  This  repressor  activity  can 
either  be  dependent  or  independent  of  their  SUMO  E3  ligase  activity 
(Palmivo; 2007). There are four different PIAS proteins PIAS1, PIAS3, PIASx 
and  PIASy  (Jackson;  2001  and  Gross  et  al;  2001).  As  co-transfection  of 
PIASy and PDE4D5 was shown to induce SUMOylation of the isoform, the 
interaction of PIASy with PDE4D5 was examined in further detail (Figure 3.4). 
Wild  type  PDE4D5  interacted  with  PIASy  and  was  SUMOylated.  The 
F670A/Q671/F672A  mutant  of  PDE4D5  which  was  unable  to  interact  with 
UBC9, plus the K323R mutant of PDE4D5 (both of which were still able to 
bind E3 ligase) were not conjugated with SUMO suggesting that a functional 
FQF  region  as  well  as  a  conserved  motif  for  SUMO  are  necessary  for 
SUMOylation  (Figure  3.4  a2  and  a3).  Truncation  analyses  to  identify  the 
PIASy  binding  site(s)  on  PDE4  revealed  that  PIASy  bound  only  full-length 
PDE4D5 protein but not to any of the individual PDE4 domains (Figure 3.4 b) 
suggesting that interaction of PIASy with PDE4 is complex and requires more 
than  one  binding  site  on  the  molecule.  In  support  of  this,  further 
characterisation  of  the  interaction  using  scanning  peptide  array  analysis 
identified  (figure  3.4c)  two  potential  PIASy  interaction  sites  on  a  PDE4D5 
peptide array (figure 3.4c); one site in close proximity to PKA phosphorylation 
site within the UCR1 region (amino acids 111-145) of PDE4D5 and another 
site within the PDE4D catalytic region (amino acids 486-530).  Confirmation of 
these PDE4D5 regions as binding domains of PIASy, plus the identification of   210 
the  residues  of  PIASy  required  for  this  interaction,  would  require  further 
mutagenesis studies.   
Other  members  of  the  E3  ligase  family  include  the  RNBP2/NUP358  and 
polycomb group protein PC2 proteins (Johnson, 2006). The potential role of 
these E3 ligases in SUMOylation of PDE4D5 is still to be determined.  
 
Treatments  with  various  signalling  activators  and  inhibitors  were  used  to 
assess  the  influence  of  cell  signal  transduction  on  PDE4D5  SUMOylation. 
None  of  the  treatments  and  associated  pathways  studied  altered  the 
SUMOylation status of PDE4D5 under experimental conditions. It therefore 
still  remains  to  be  determined  which  factors  drive  SUMOylation  of  PDE4 
enzymes in vivo. SUMOylation patterns of proteins have been shown to be 
variable  during  different  phases  of  cell  cycle  (Bischof  and  Dejean,  2007, 
Bischof  et  al,  2006).  It  would  therefore  be  of  interest  to  examine  whether 
PDE4 SUMOylation varies during different phases of cell cycle. 
 
SUMOylation of proteins is known to affect their localisation within cells. For 
PDGF-C,  conjugation  with  SUMO-1  targets  the  protein  to  the  nucleus 
(Reigstad  et  al;  2006).  Nuclear  localisation  and  subcellular  fractionation 
studies of SUMOylated and non-SUMOylated PDE4D5 (Figure 3.6a) revealed 
that  PDE4D5  remained  in  soluble  fraction  of  the  cells  before  and  after 
SUMOylation.  However,  a  small  amount  of  SUMOylated  and  non-
SUMOylated PDE4D5 species were present in the P1 cellular fraction, which 
includes  both  nuclear  membranes  and  unbroken  cells.  As  PDE4D5 
expression  appears  to  be  cytosolic  within  HEK293  cells,  the  detection  of 
PDE4D5 within the P1 fraction is likely due to the presence of unbroken cells 
within  this  fraction.  Although  SUMOylation  did  not  effect  localisation  of 
PDE4D5 in HEK293 cells, it would be of importance to investigate whether the 
localisation PDE4 isoforms is altered upon SUMOylation in other cells types 
and if the localisation is affected by cellular stimuli.  
PDE4 enzyme action is an integral part of cAMP signalling as it is the sole 
means  of  decreasing  cAMP  levels  within  cells.  Hence  any  cellular  effects, 
which  mediate  changes  in  PDE4  activity,  would  directly  influence  cAMP 
signalling.  A  potential  role  for  SUMOylation  in  regulating  the  PDE4  activity   211 
was therefore examined. SUMOylation did not affect the activation of PDE4D5 
both in in vitro and in vivo assays. However, it was found that SUMOylation 
potentiated  the  effect  of  PKA  phosphorylation  in  activating  PDE4D5. 
Furthermore, and somewhat surprisingly, SUMOylation of PDE4D5 appeared 
to negate the inhibitory effect of ERK phosphorylation on PDE4D5 activity in 
vitro (Figure 3.7). A possible explanation for the loss of ERK effect is that 
conjugation  of  SUMO  to  the  catalytic  unit  of  PDE4D5  induces  a 
conformational  change  affecting  its  interaction  with  the  UCR1/UCR2 
regulatory module. This is consistent with previous studies showing that PKA 
phosphorylation  of  UCR1  is  able  to  override  the  inhibitory  effect  of  ERK 
phosphorylation  on  PDE4  activity  by  attenuating  the  interactions  of  the 
UCR1/UCR2  module (Beard et  al; 1999).  Furthermore,  the  PDE  activity  of 
short  PDE4  isoforms,  which  lack  a  UCR1  domain,  is  not affected by  ERK 
phosphorylation.  Further studies are required to assess the ERK response on 
SUMOylated  PDE4  in  vivo.  Based  on  this  novel  finding  from  the  in  vitro 
studies, it could be suggested that in cells PDE4 SUMOylation functions to 
further compartmentalise cAMP signalling whereby subpopulations of PDE4s 
are able to remain active in the presence of an ERK stimulus.  
 
Although SUMOylation did not affect the overall enzyme activity of PDE4D5, it 
was  shown  to  increase  its  rolipram  sensitivity.  SUMOylated  PDE4D5  was 
found to be 10 times more sensitive to inhibition by rolipram than its non-
SUMOylated  form.  PDE4  isoforms  exist  in  two  different  states  of  rolipram 
sensitivity, namely HARBS and LARBS (Souness and Rao, 1997). Binding of 
proteins such Src tyrosyl kinases and XAP2, as well as PKA phosphorylation, 
have  been  reported  to  induce  switching  between  the  LARBS  and  HARBS 
states  (Bolger  et  al;  2003,  McPhee  et  al,  1996).  It  is  possible  that  the 
increased sensitivity of rolipram elicited by SUMOylated PDE4D5 is due to 
switching  to  the  HARBS  conformational  state.  Since  SUMO  is  a  ~11KD 
molecule,  it  is  possible  its  conjugation  to  the  PDE4  at  the  catalytic  region 
stabilises the isoform in the HARBS configuration.  
 
PKA  phosphorylation  of  PDE4D5,  which  evokes  a  shift  from  LARBS  to 
HARBS,  was  shown  to  increase  the  rolipram  sensitivity  of  both  non-  212 
SUMOylated and SUMOylated PDE4D5 to a similar extent. SUMOylation did 
not  appear  to  enhance  the  PKA-mediated  increase  in  PDE4D5’s  rolipram 
sensitivity as it is likely the SUMOylated form already exists predominantly in 
a HARBS state.  
 
SUMOylated  PDE4D5  was  completely  unaffected  by  ERK  action  and  its 
rolipram  sensitivity  was  same  as  that  of  the  non-phosphorylated  species 
(Figures 3.8, 3.9 and 3.10). Similar experiments with PDE4D5 binding partner 
RACK1, following earlier findings of Yarwood and co workers (Yarwood et al 
1999) who showed that binding of RACK1 to PDE4D5 N-terminus decreased 
the  rolipram  sensitivity  of  the  isoform,  revealed  that  both  wild  type  and 
SUMOylated  PDE4D5  exhibited  a  decreased  sensitivity  to  rolipram  in  the 
presence of purified recombinant RACK1 (figure 3.11). As RACK 1 binds to 
the N-terminal region as well as to the catalytic region (Bolger et al; 2006) and 
SUMO  conjugation  occurs  in  the  catalytic  region,  it  is  possible  that  the 
HARBS  induced  by  linkage  of  SUMO  is  reversed  to  a  certain  extent  by 
RACK1 binding to the N-terminus and catalytic region of PDE4D5. 
 
The effects of SUMOylation on the binding of PDE4D5 to known interactors 
including RACK1, ￿ arrestins, ERK, AKAP18δ and UBC9 was evaluated both 
in vivo and in vitro. All partners studied exhibited an increased binding to the 
SUMOylated  species  of  PDE4D5  compared  to  its  non-SUMOylated  form 
(Figure  3.13  and  3.14).  However,  the  extent  by  which  binding  affinities 
increased differed between in vitro and in vivo studies.  In in vivo assays, it is 
likely many other proteins in addition to PDE4D5 are being SUMOylated and 
this  may  subsequently  affect  the  affinity  of  PDE4D5  interactions  with  its 
binding partners.  
 
As only the PDE4A and PDE4D sub-families are SUMOylated, it is possible 
that SUMOylation provides a means for subfamily-specific regulation of PDE4 
signalling  within  cells.  Since  cAMP  signalling  is  compartmentalised, 
SUMOylation might offer a way of modulating PDE4 activity within specific 
sub-cellular  compartments  without  altering  the  PDE4  activity  globally. 
Furthermore,  the  increased  affinity  of  PDE4  interactors  for  the  PDE4   213 
SUMOylated  species  would  offer  a  way  of redistributing  the  cellular  PDE4 
population.  Future  work  would  entail  identifying  the  processes  which  drive 
SUMOylation  of  PDE4  enzymes  in  an  effort  to  further  characterise  its 
functional roles. 
For the in vivo experiments performed in this study, both PDE4 isoforms and 
SUMO ligases were overexpressed in the cells. However, given the lability of 
SUMOylated  proteins  and  the  ability  of  SUMO  isopeptidases  to  quickly 
deSUMOylate conjugated proteins, it would be necessary to repeat this study 
focussing  on  endogenous  proteins  so  as  to  get  a  better  understanding  of 
SUMOylation of PDE4s under normal physiological conditions. It would also 
be  of  interest  to  carry  out  structural analysis  to  resolve  the  conformational 
state of SUMOylated PDE4 in an effort to further understand the effects of 
SUMOylation on rolipram sensitivity. As SUMOylation is likely to trigger the 
HARBS conformation of PDE4, PDE4 SUMOylation may eliminate the emetic 
effects  caused  by  PDE4  inhibitors.  Compounds  or  small  molecules,  which 
trigger PDE4 SUMOylation may therefore be of therapeutic use.  
 
6.2 Rolipram induced foci formation of PDE4A4 
 
PDE4  isoforms  in  a  basal  state  are  known  to  exist  in  the  LARBS 
conformation. The formation of complexes with proteins such as SRC tyrosyl 
kinases  is  known  to  confer  switching  of  PDE4A4  to  the  HARBS  state  as 
described in section 1.7.2 (McPhee et al; 1996). PDE4A4 is known to form 
accretion  foci  in  cells  subjected  to  chronic  rolipram  treatment  (Terry  et  al; 
2003). Chapter 4 describes the process in detail and the experiments carried 
out  in  an effort  to  identify  the  signalling  pathways  and  associated  proteins 
involved in the process of PDE4A4 foci formation.  These accretion foci are 
independent of cytoskeletal proteins and sub-cellular organelles such as Golgi 
(Figure 4.1 and table 4.1). cAMP has an inhibitory effect on foci formation and 
quickly  disperses  any  pre-formed  foci  by  competing  with  rolipram  for  the 
binding  site  on  PDE4.  Similarly,  non-foci  forming  PDE4  selective  inhibitors 
similarly antagonise the action of rolipram by displacing it from the active site 
of  PDE4A4.  Activation/inhibition  of  the  components  of  cAMP  signalling   214 
including  PKA  and  EPAC  did  not  have  any  clear  effects  on  foci  formation 
(Figure 4.2). It is therefore likely that the cAMP molecule binding directly to 
the  active  site  of  PDE4A4  mediates  the  effects  of  cAMP  signalling  on  foci 
formation.  
 
Earlier studies (Terry et al; 2003) proposed a model for foci formation known 
as  “inside-out  signalling”  whereby  binding  of  rolipram  to  PDE4A4  induces 
conformational changes within the catalytic site that are transferred through 
helix 10/11 and loops 7/8 to the surface of the catalytic unit. This, presumably 
together  with  the  unique  N-terminal  region  of  PDE4A4,  forms  a  new 
conformation  that  interacts  with  yet  unidentified  proteins  to  couple  to  the 
formation  of  foci  in  a  process  that  depends  upon  active  protein  synthesis 
(Figure 4.1).  
 
It is widely known that ERK phosphorylation inhibits activity of all long PDE4 
isoforms except those of the PDE4A sub-family, which lack a proline in the 
consensus site for ERK phosphorylation within their catalytic unit (Mackenzie 
et  al.  2000).  In  order  to  investigate  the  role  of  other  MAP  kinases  in  foci 
formation and maintenance, various MAP kinase inhibitors were used to treat 
cells stably expressing a GFP fusion protein of PDE4A4B. Inhibition of MEK 
did not affect rolipram-induced foci formation nor did the inhibition of MAPKAP 
kinase2. Inhibition of either kinase did not induce foci formation either. 
 
Activation of MAPKAP kinase-2, via activation of p38 MAPK with anisomycin, 
abrogated rolipram-induced foci formation. However, strangely, the effects of 
anisomycin were not reversed by SB203580, a p38 inhibitor. Anisomycin is 
known  to  stimulate  other  effectors,  such  as  JNK  (Sampieri  et  al;  2007). 
However  concomitant  treatment  with  the  JNK  inhibitor  did  not  reverse  the 
effects  of  anisomycin  on  foci  formation  (Figure  4.3).  Anisomycin  can  also 
inhibit  protein  synthesis  at  concentrations  above  10ug/ml  (Sampieri  et  al; 
2007)  and  it  is  possible  that  this  might  be  the  process  through  which  it 
attenuates foci formation. However in these studies anisomycin was used at a 
lower concentration concentration. It would be of interest to assess the action 
of anisomycin on protein synthesis in these cells at the concentrations used.    215 
 
The cdk5 inhibitor roscovitine, when used at higher concentrations where it is 
known to affect both cdks and MAP kinases resulted in inhibition of foci thus 
reiterating a potential role of MAP kinases in foci formation (Figure 4.7). 
 
 MAPKAP kinase 2 can also be inhibited by rottlerin, which is also an inhibitor 
of PKC (Blanquet et al, 2003). Rottlerin was found to inhibit foci formation. In 
order to rule out PKC action in this process, treatments were performed with 
PMA and EGCG. Although PMA did not affect foci formation on its own, it 
reversed  the  effects  of  rottlerin  by  increasing  the  immobile  fraction  of 
PDE4A4-GFP foci. Inhibition of PKC isoforms PKCα, β1,ε  with RO320432 
(Birchall et al; 1994) and GO6983 to inhibit PKCα, β, γ, δ (Wang et al; 2004) 
increased the levels of foci in cells suggesting the signalling of PKC isoforms 
α, β, γ, δ, or ε  is involved in foci formation. To confirm PKC involvement in foci 
formation future work would entail the selective siRNA-mediated knockdown 
of specific PKC isoforms.  
 
Calcium  is  an  important  intracellular  messenger  regulating  many  signalling 
pathways.  In  order  to  evaluate  its  effects  on  foci  formation/dispersal, 
treatments  were  performed  with  calcium  modulators  thapsigargin  and 
ionomycin  (Won  and  Orth,  1995,  Aagaard-tillery  and  Jelinek,  1995).  Both 
ionomycin and thapsigargin inhibited foci formation, indicating an involvement 
of calcium, derived either from intracellular stores or externally, in regulating 
this process.  
 
One effector of calcium signalling is PKC. Only conventional but not novel and 
atypical isoforms of PKC is known to be activated by calcium (Mackay and 
Twelves, 2007). It is possible that such species are indeed involved in foci 
regulation,  as  PKC  inhibition  appears to  facilitate  foci formation.  To  further 
investigate possible downstream effectors of calcium signalling, inhibitors or 
calmodulin  Kinase  II  (KN62)  and  calcineurin  (Cyclosporin)  were  used. 
However, both of these had no effect on foci formation (Figure 4.4).  
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PDE4A4B can be activated upon stimulation of p70S6 kinase and PI3 Kinase 
in  response  to  growth hormone  stimulation in  fibroblasts  (Mackenzie et  al, 
1998).  Hence  to  ascertain  the  potential  role  of  PI3  kinase  pathway  in  foci 
formation, CHO cells stably expressing PDE4A4GFP were treated with the 
PI3 kinase inhibitors, wortmanin and Ly294002, both of which enhanced the 
foci formation. However, inhibition of p70S6 kinase by rapamycin and GSK3 
by the GSK3β inhibitor had no effect on foci formation thus ruling out the role 
of both of these kinases. PI3 kinase, however, triggers a complex pathway of 
events  in  cells  whereupon  it  activates  a  myriad  of  kinases,  including  PKC 
(Hirai and Chida; 2003) and ERK (Kim et al; 2007, Xu and Yu, 2007), leaving 
a number of possible actions and thereby routes to pursue in further research, 
thus the downstream targets for PI3 kinase effects have still to be determined 
(Figure 4.5).  
 
PDE4A4 is known to associate with Src tyrosyl kinases (Beard et al, 2002 and 
McPhee et al, 1999). In order to determine the possible involvement of tyrosyl 
kinases  in  foci  formation  the  general  tyrosyl  kinase  inhibitor  genistein  was 
used. Genistein treatment was found to abolish foci formation. In order to get 
further insight into a possible role of specific tyrosyl kinases in foci formation 
more  inhibitors  were  assayed.  These  included  inhibitors  for  Src  tryosyl 
kinases  (Su6656);  EGFR  tyrosyl  kinases  (PD168393)  and  PDGFR  tyrosyl 
kinase  (AG17).  However,  of  these  only  the  PDGF  receptor  Tyrosyl  kinase 
inhibitor AG17 inhibited foci formation (Figure 4.6).  This suggests that the 
PDGF receptor may be important in foci formation. In order to address this 
future studies should be done to see if the PDGR receptor accumulates in foci 
or if siRNA-mediated knockdown of the PDGFR inhibits foci formation. The 
PDGF  receptor  is  well  known  to  dimerise  upon  ligand  binding.  The bound 
ligand is known to induce transphosphorylation of the intracellular domains of 
the receptors. These phosphorylated intracellular regions are known to initiate 
various signalling responses. Downregulation of PDGF receptor is achieved 
by its internalisation upon ligand binding to the receptor. The receptor is either 
then subjected to proteasomal degradation or recycled back to the surface of 
the receptor (Chiarugi et al; 2002).  
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Researchers  have  showed  that  inhibition  of  PDE4  activity  regulates 
immunomodulatory functions (Jin et al, 2005, Jin and Conti 2002). Similarly, 
immunomodulatory functions of thalidomide have been recently established 
(OKafor, 2003, Powell 1999); a potential role of thalidomide in regulating foci 
formation  was  therefore  studied.  Thalidomide  treatment  inhibited  foci 
formation.  Thalidomide  is  known  to  act  as  an  anti-inflammatory  agent  by 
decreasing the levels of TNFα yet at the same time it is shown to increase the 
production of IFNγ and IL-5 in mononuclear cells (Direskeneli et al; 2007). 
Conversely, PDE4 isoforms have been shown to decrease the production of 
IFNγ and IL-5 in T-cells (Peter et al, 2007). Hence it could be hypothesised 
that foci formation might be a net result of the balance of these two affects, 
the confirmation of which requires further investigation.  
 
It has been suggested that PDE4 isoforms may form oligomers by a process 
involving their regulatory domains UCR1 and UCR2 (Richter and Conti, 2002).  
However,  work  form  our  laboratory  suggests  that  whilst  this  may  occur  in 
transfected cells overexpressing PDE4 isoforms it is less likely to occur in vivo 
due to the interaction of PDE4 isoforms with partner proteins, which would 
prevent dimerisation occurring. Furthermore, UCR1/2 is conserved amongst 
sub-families implying that heterodimers may occur between different isoforms. 
This  very  clearly  does  not  occur  in  vivo  as  isoforms  can  be  selectively 
immunoprecipitated.  Thus  dimerisation  may  only  be  a  feature  of 
overexpression systems or exist only under certain cellular conditions. 
 
When it occurs, dimerization has been suggested to regulate the sensitivity of 
PDE4 isoforms to rolipram inhibition (Richter et al 2004). In order to evaluate 
any potential role of oligomerization in foci formation, co-immunoprecipitation 
studies  were  carried  out  using  differently  tagged  PDE4A4  species  and,  in 
separate experiments with differently tagged PDE4D3 species (Figure 4.9). 
Doing  this,  it  was  found  that  overexpressed  PDE4D3  oligomerized  in  cells 
whilst overexpressed PDE4A4 did not appear to show any dimerisation in the 
presence or absence of rolipram. It might be that the residues required for 
oligomerisation  are  not  well  conserved  in  PDE4A4  thus  preventing  the 
oligomerisation. Another explanation is that PDE4A4 foci formation perhaps   218 
requires  stabilising  factors  that  are  lost upon  cell  lysis  thus  disrupting foci. 
However,  the  role  of  experimental  conditions  cannot  be  ruled  out.  Further 
investigations  are  required  to  identify  the  key  residues  as  well  as  their 
conservation  in  various  PDE4  sub-families  to  understand  the  role  of 
oligomerisation  in  foci  formation.    Although  it  is  clear  that  foci  PDE4A4 
species  must  co-exist  the  interaction  may  not  be  direct  but  mediated  by a 
linker  protein.  Perhaps  this  is  the  induced  species  that  requires  protein 
synthesis  and  this  may  be  released  upon  cell  disruption.    It  may  then  be 
useful  to  treat  cells  with  a  membrane permeable  cross-linker  to  see  if  this 
causes the rolipram-induced association of species with PDE4A4. Indeed, this 
may be the route in future to analyse immunoprecipitates by proteomics. 
 
Previous  reports  (Terry  et  al;  2003)  established  that  protein  synthesis  is 
required for foci formation as well as maintenance. To further investigate the 
role of protein turnover in foci formation cells were treated with the protein 
synthesis inhibitor, cycloheximide as well as the protein degradation inhibitor 
MG132 respectively. Both cycloheximide and MG132 strongly inhibited foci 
formation.  Also  they  started  dispersing  rolipram-preformed  foci  within  30 
minutes and completely dispersed them by the end of 5 hours. Inhibition of 
total cell protein turnover yielded similar results (Figure 4.10 and 4.11).  
 
PDE4A4  did  not  show  any  ubiquitination  in  the  presence  or  absence  of 
rolipram  as  determined  by  immunoblotting  nor  did  it  co-localise  with 
ubiqutinylated  proteins  in  confocal  studies.  Further  studies  are  required  to 
unravel the role of protein turnover in foci stability as well as in formation.  
 
To further ascertain the role of protein turnover in conjunction with signalling 
pathways on foci stability, various inhibitors that were used in foci formation 
assays as described above were assayed. This was based upon the idea of 
trying  to  discriminate  compounds  that  regulated  foci  formation  from  foci 
stabilisation. By blocking protein synthesis and degradation we can observe a 
rate of decay of foci. However, any compounds that accelerated the decay, 
presumably  could  exert  an  effect  on  the  machinery  that  held  foci  together 
independent of any action of protein synthesis and turnover.    219 
 
Thapsigargin  caused  complete  dispersal  of  foci  within  30  minutes  in  the 
absence  of  active  protein  turnover  and  started  dispersing  foci  within  30 
minutes in the presence of active protein turnover. However by the end of 5 
hours all the foci were dispersed as measured by plate reader assay, whereas  
PKC  inhibition  with  Rottlerin  and  RO320432  dispersed  all  foci  within  30 
minutes both in the presence and absence of active protein turnover. 
 
Similarly,  activation  of p38 MAPK  by  anisomycin  dispersed  foci  completely 
within  30  minutes  in  the  presence  or  absence  of  active  protein  turnover. 
However,  inhibition  of  MEK  using  UO126  although  initially  enhanced  the 
immobile  fraction of  GFP  eventually  stimulated  the dispersal  of  foci  (figure 
4.12).  It  should  be  noted  that  anisomycin  and  UO126  have  inhibitory  and 
promoting affects on foci formation respectively which reflects their effects on 
foci stability.  
 
The  general  tyrosine  kinase  inhibitor,  genistein  and  PI3  kinase  inhibitor, 
Ly294002 yielded similar results as anisomycin suggesting an inhibitory effect 
on foci formation (figure 4.13 and 4.14). 
 
In  general  it  could  be  proposed  that  these  signalling  inhibitors  and  their 
respective signalling complexes could act in three different ways. Firstly, they 
might affect foci formation and stability directly. Secondly, they might alter the 
signals for protein turnover thereby influencing foci indirectly and finally they 
might act to affect foci formation as well as protein turnover thus enhancing or 
slowing foci formation as well as dispersal. Unravelling the components of foci 
formation  and  the  signalling  complexes  will  require  further  rigorous 
investigations  using  techniques  such  as  truncation  studies  and  proteomics 
analysis,  plus  electron  microscopy  to  identify  whether  foci  are  confined  to 
vesicles or other sub-cellular organelles etc.  
6.3 RhoGAPs, Arrestins and PDE4 isoforms 
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Rho  family  of  GTPases  regulate  F-actin  and  microtubule  dynamics.  These 
GTPases are activated by guanine exchange factors (GEFs) and are inhibited 
by  GTPase  activating  proteins  (GAP)  and  guanine  dissociation  inhibitors 
(GDI) (Buchsbaum et al; 2007). ￿ arrestins have been shown to be an integral 
part of wide variety of processes like chemotaxis, endocytosis and stress fibre 
formation  by  interacting  or  regulating  Rho  GTPases  (Kim  and  Han,  2007, 
Barnes  et  al,  2005,  Goodman  et  al,  1996).  Similarly,  PDE4  isoforms  are 
known to regulate cell migration by regulating the activity of Rho GTPases 
(Fleming  et  al;  2004).  Chapter  5  describes these  interactions  in  detail  and 
attempts to characterise their functional outcome.  
 
ARHGAP21 is ~1957 amino acid protein and is a novel GTPase activating 
protein (GAP) for Cdc42 comprising PDZ, ARF binding, PH and Rho binding 
domains along with a GAP domain (Menetrey et al; 2007, Dubois et al, 2005, 
Basseres et al, 2002). ARHGAP21 was shown to interact with ￿ arrestins in a 
yeast  two-hybrid  screen  (DeWire  et  al  2007).  In  order  to  characterise  the 
interaction  of  arrestin-ARHGAP21,  various  truncates  of  ARHGAP21  were 
used (Figure 5.2). To identify the binding site of ￿ arrestin on ARHGAP21, a 
full  length  ARHGAP21  peptide  array  was  probed  with  purified  β-arrestin-1 
GST. ￿ arrestin showed strong interaction with the RhoGAP domain (1321-
1360)  of  the  ARHGAP21  peptide  array  (Figure  5.2).  Alanine  substitution 
analysis  of  selected  residues  within  the  region  revealed  key  residues 
important for the interaction. In particular, alanine substitution of a series of 
glutamic  acid  residues,  namely  E1341,  E1342,  E1344,  and  E1345,  either 
collectively or individually severely affected β-arrestin interaction (Figure 5.3). 
In reciprocal studies to further characterise the interaction sites of ARHGAP21 
on  ￿ arrestins,  a  peptide  array  of  β-arrestin  1  was  probed  with  truncates 
containing  the  purified  RhoGAP  domain  of  ARHGAP21  (Figure  5.4).  The 
RhoGAP domain of ARHGAP21 showed interaction with peptides containing 
residues 96-130, mapping to N-domain of β-arrestin 1. Chapter 5 attempted to 
characterise the interaction with ￿ arrestin1. Understanding the interaction of 
ARHGAP21  with  ￿ arrestin  2  comprises  a  part  of  future  work.  Alanine 
substitution scan of binding regions revealed key residues on ￿ arrestin that   221 
interact with ARHGAP21. From peptide array analysis, it could be proposed 
that ARHGAP21 interacts with an E-(X) 4-KLGEH-(X) 5-E site on ￿ arrestin 1 
(Figure 5.5 and Figure 5.6).  
 
Pull down assays with purified fragments of ARHGAP21 and ￿ arrestin 1 were 
carried  out  to  ascertain  the  nature  of  the  interaction.  Purified  ￿ arrestin  1 
interacted  with  fragments  of  ARHGAP21  containing  the  RhoGAP  domain 
(figure  5.7).  To  further  elucidate  the  interaction,  HEK293  cells  stably 
expressing  the  angiotensin  AT1A  receptor  were  used.  The  AT1A  receptor 
activates Rho through the Gq/G11 pathway with β-arrestin (Figure 5.8, Barnes 
et al 2005). Hence these cells would prove valuable for understanding the 
interaction of ￿ arrestin with ARHGAP21, a Rho GTPase activating protein. 
￿ arrestin interacted with ARHGAP21 in basal conditions and the interaction 
did not change even after Gq/G11 activation, suggesting that the interaction is 
governed by factors independent of Gq/G11 pathway (Figure 5.9).  
 
All  PDE4  isoforms  are  known  to  interact  with  ￿ arrestins  through  their 
conserved  catalytic  unit.  In  the  case  of  PDE4D5,  this  interaction  leads  to 
translocation of ￿ arrestin/PDE4D5 complex to the β2-adrenoceptor and leads 
to consequent desensitisation of the receptor (Perry et al, 2002). Of all the 
PDE4  isoforms  studied  so  far,  ￿ arrestins  show  preferential  binding  to 
PDE4D5 due an extra binding site present in its isoform specific N-terminal 
region  (Bolger  et  al,  2003).  Thus  to  determine  the  involvement  of  PDE4 
isoforms,  particularly  PDE4D5,  in  ￿ arrestin/ARHGAP21  interaction,  lysates 
the  AT1A  receptor  stable  cell  line  were  used  for  co-immunoprecipitation 
studies. Endogenous ARHGAP21 was found to interact with PDE4D5 (Figure 
5.10). PDE4D5 directly interacted with both the ARF binding domain as well 
as the RhoGAP domain of ARHGAP21 (Figure 5.11). Since only truncates 
were used in this study, it is still not clear if PDE4D5 has other binding sites 
on  ARHGAP21.  Further  investigations  are  required  to  identify  any  extra 
binding sites if any and also the residues involved in the interaction by peptide 
array analysis and through further mutation and truncation analyses. Also, it 
would  be  of  interest  to  establish  whether  isoforms  from  other  PDE4  sub-
families  are  able  to  interact  with  ARHGAP21.  It  should  be  noted  that   222 
￿ arrestins only bind to RhoGAP domain whereas PDE4D5 binds to both ARF 
and  RhoGAP  domains  of  ARHGAP21.  Whether  ￿ arrestin  and  PDE4D5 
compete with each other for binding to the RhoGAP domain of ARHGAP21 is 
yet to be determined.  
 
PDE4 activation is sometimes known to alter the affinity of these enzymes to 
certain interacting partners. For instance, PKA phosphorylation and activation 
is shown to release PDE4D3 and PDE4C2, but not PDE4B1, from the full-
length DISC1 isoform (Murdoch et al; 2007). Henceforth, the role of PDE4 
activity and PKA phosphorylation in regulating the interaction of ARHGAP21 
with  PDE4D5  was  determined  in  the  presence  or  absence  of  Gq/G11 
activation.  Neither  PDE4  inhibition  in  cells  nor  PKA  phosphorylation  (with 
subsequent activation of PDE4 activity) affected the interaction of PDE4D5 
with ARHGAP21 (Figure 5.12). It could be inferred from the above results that 
ARHGAP21/PDE4D5/β-arrestin interaction is independent of Gq/G11 activity or 
PKA activity or PDE4 activity. 
 
Future work would involve delineation of binding sites of PDE4s on ARHGAP 
and  vice  versa  along  with  understanding  the  dynamics  of  the  interaction 
including the role of signalling pathways, but most importantly, the functional 
outcome  of  the  interaction.  Since  ARHGAP21  is  a  novel  GAP  it  is  poorly 
characterised  and  its  functions  are  not  fully  understood.  Dubois  and 
coworkers have shown that ARHGAP21/10 acts as a GAP for cdc42 in Golgi 
and regulates the F-actin dynamics (Dubois et al; 2005). Given that ￿ arrestin 
and  PDE4D5  bind  to  the  RhoGAP  domain  of  ARHGAP21,  it  could  be 
speculated  that  either  of  these  proteins,  or both,  would  have  an  affect  the 
GAP activity of ARHGAP21. PDE4 activity is required for cell migration as 
reported  previously  (Fleming  et  al.  2004).  One  possibility  is  that 
ARHGAP21/PDE4D5 along with ￿ arrestin might play a role in cell migration. 
Also, the PH domains of ARHGAP21 might play a crucial role in membrane 
translocation  of  this  GAP,  which  might  help  recruit  the  ￿ arrestin/PDE4D5 
complex to membrane receptors under the influence of appropriate stimulus 
such as PI3 kinase activity. Since the ￿ arrestin-PDE4D5 complex is involved   223 
in receptor desensitisation, ARGAP21 might play a role in endocytosis and 
recycling of the complex to and from Golgi to the plasma membrane.  
 
In conclusion, the ￿ arrestin/PDE4D5/ARHGAP21 interaction is a novel finding 
and needs extensive characterisation to understand the functional outcome. It 
still needs to be determined whether all the three proteins function together or 
in individual complexes.  
 
6.4 Final Conclusion 
 
These  studies  have  given  further  insight  into  the  complexity  of  PDE4 
regulation.  The  identification  of  effects  of  SUMOylation  on  PDE4  function 
paves  a  way  to  understand  the  complex  compartmentalisation  of  cAMP 
signalling. Foci studies attempted to shed light on the role of PDE4 inhibitors 
in  regulating  the  localisation  of  the  PDE4A4  isoform.  Identification  of  β-
arrestin/ARHGAP21/PDE4D5 interaction complex gives further insight into the 
role  of  cAMP  signalling  in  regulating  cell  migration  which  is  the  basis  for 
conditions such as tumour metastasis and wound repair.  
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Appendix I 
 
List of constructs used for Yeast two hybrid screening by Hybrigenics 
for mapping arrestin-Arhagp21 interaction 
 
 
 
 
 
 
  Clone name  Type Seq 
 
Start  Stop 
1  hgx1193v1_pB27C-48 
 
5p 3p  4743 
 
5274 
 
2  hgx1193v1_pB27C-2 
 
5p 3p  4737 
 
5274 
 
3  hgx1193v1_pB27C-37 
 
5p 3p  4557 
 
5274 
 
4  hgx1193v1_pB27C-8 
 
5p 3p  4557 
 
5274 
 
5  hgx1193v1_pB27C-63 
 
5p 3p  4557 
 
5274 
 
6  hgx1193v1_pB27C-36 
 
5p 3p  4557 
 
5274 
 
7  hgx1193v1_pB27C-27 
 
5p 3p  4557 
 
5274 
 
8  hgx1193v1_pB27C-5 
 
5p 3p  4530 
 
5032 
9  hgx1193v1_pB27C-68 
 
5p 3p  4746 
 
5627 
10  hgx1193v1_pB27C-55 
 
5p 3p  4746 
 
5627 
11  hgx1193v1_pB27C-19 
 
5p 3p  4746 
 
5627 
12  hgx1193v1_pB27C-46 
 
5p 3p  4626 
 
5659 
13  hgx1193v1_pB27C-56 
 
5p 3p  4683 
 
5668 
14  hgx1193v1_pB27C-15 
 
5p 3p  4749 
 
5277 
15  hgx1193v1_pB27C-9 
 
5p 3p  4521 
 
5312 
16  hgx1193v1_pB27C-25 
 
5p 3p  4521 
 
5312 
17  hgx1193v1_pB27C-69 
 
5p 3p  4749 
 
5277 
18  hgx1193v1_pB27C-26 
 
5p 3p  4626 
 
5393 
19  hgx1193v1_pB27C-65 
 
5p 3p  4749 
 
5277 
20  hgx1193v1_pB27C-47 
 
5p 3p  4749 
 
5277   226 
Clone 1- hgx1193v1_pB27C-48 
 
5'CATCACCTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGC
CTGGACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGC
AAGGGGGACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGG
CGGCCTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACA
GCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTA
AGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGG
AAGTTTAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATA
AACTCATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAG
TCAGATAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTT
CGTTAACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGAGT
TTACTGACACCCACCAGAGGCGAATCCGAAAAACAGGAACCC-3' 
 
Clone 2- hgx1193v1_pB27C-2 
 
5'CAGCACCATCACCTCAGATTATTCCACCACATCGTCTGCTACATACTTG
ACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCA
GAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCGAACTCATCAGT
GAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTC
CCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAG
TGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCAC
CGAGGGAAGTTTAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTT
CCCATAAACTCATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGA
TTCAAGTCAGATAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAG
CACCTTCGTTAACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACT
GGGAGTTTACTGACACCCACCAGAGGCGAATCCGAAAAACAGGAACCC-
3' 
 
Clone 3-hgx1193v1_pB27C-37 
 
5'CTTTGCCATCCTGAAAGAGAGCCCCAGGTCACTTCTGGCACAGAAGTC
CTCCCACCTTGAAGAGACAGGCTCTGACTCTGGCACTTTGCTCAGCACG
TCTTCCCAGGCCTCCCTGGCAAGGTTTTCCATGAAGAAATCAACCAGTC
CAGAAACGAAACATAGCGAGTTTTTGGCCAACGTCAGCACCATCACCTC
AGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGGACTCCA
GTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGGGGGACG
AGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGCCTGTGG
AAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTTGACTTC
AGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGCAGCCGG
AGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTTTAACATC
AAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTCATCGAAT
GTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGATAGTGGA
AGTCTAGGAGATGCCAAGAATGAGAAAGAGCACCTTCGTTAACTAAAGT
GTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGGAGTTTACTGACACCC
ACCAGAGCGAATCCGAAAAACAGGACCCCTTCGTGG-3' 
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Clone 8-hgx1193v1_pB27C-5 
 
CAACAAGTCACCAACTCTCAGCTGTCGCTTTGCCATCCTGAAAGAGAGC
CCCAGGTCACTTCTGGCACAGAAGTCCTCCCACCTTGAAGAGACAGGCT
CTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCCCTGGCAAG
GTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTTTT
TGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTGCT
ACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCAAT
CCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCGAA
CTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGTTT
CCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAAC
TGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATT
AAGTTGCACCGAGG 
 
Clone 9- hgx1193v1_pB27C-68 
 
CACCTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGG
ACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGG
GGGACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGC
CTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTT
GACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGC
AGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTT
TAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTC
ATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGA
TAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTTCGTTA
ACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGAGTTTACT
GACACCCACCAGAGGCGAATCCGAAAAACAGGAACCCACATGGAAAAC
GAAAATAGCAGATCGGTTAAAACTGAGACCCAGAGCCCCTGCGGATGAC
ATGTTTGGAGTAGGGAATCACAAAGTGAATGCCGAGACTGCTAAAAGGA
AAAGCATCCCGGCGCAGACATACACTAGGAGGGCACAGAGATGCTACC
GAAATCAGCGTTTTGAATTTTTGGGAAAGTGCATGAGCA 
 
Clone 12- hgx1193v1_pB27C-46 
 
CTCTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCCCTGGCA
AGGTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTT
TTTGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTG
CTACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCA
ATCCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCG
AACTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGT
TTCCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAA
ACTGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAA
TTAAGTTGCACCGAGGGAAGTTTAACATCAGTTTTACAATGCTTGGAGAC
GGCGGGAAAGTTCTTTTATTCCCCTAAAACCTGGAAGGGGATACCCTTTC
CGGGCAAAATAGCTCAGTTCAATTCAGAGAAGGCATGCAGGAGCAGCCC
ACGATGAAAAAGAACCCCCTCGTTAACTAACTGTTTATATTTTTTGGTAAG
AAAAGAAAACAGAGAGTGTGTTGTGT 
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Clone 13-hgx1193v1_pB27C-56 
 
CATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTTTTTGGCCA
ACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTGCTACATAC
TTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGG
CAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCGAACTCATCA
GTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGT
TCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGA
AGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGC
ACCGAGGGAAGTTTAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCA
GTTCCCATAAACTCATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCT
AGATTCAAGTCAGATAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAG
AAGCACCTTCGTTAACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCA
ACTGGGAGTTTACTGACACCCACCAGAGGCGAATCCGAAAAACAGGAAC
CCACATGGAAAACGAAAATAGCAGATCGGTTAAAACTGAGACCCAGAGC
CCCTGCGGATGACATGTTTGGAGTAGGGAATCACAAAGTGAATGCCGAG
ACTGCTAAAAGGAAAAGCATCCCGCG  
 
Clone 14-hgx1193v1_pB27C-15 
 
CTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGGACT
CCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGGGGG
ACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGCCTG
TGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTTGAC
TTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGCAGC
CGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTTTAA
CATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTCATC
GAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGATAG
TGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTTCGTTAACT
AAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGAGTTTTACTGA
CACCCACCAGAGGCGAATCCGAAAAACAGGAACCCACGT 
 
Clone 15- hgx1193v1_pB27C-9 
 
CTCAAAACACAACAAGTCACCAACTCTCAGCTGTCGCTTTGCCATCCTGA
AAGAGAGCCCCAGGTCACTTCTGGCACAGAAGTCCTCCCACCTTGAAGA
GACAGGCTCTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCC
CTGGCAAGGTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAG
CGAGTTTTTGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACAT
CGTCTGCTACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGA
GGTGCAATCCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGA
GAAGCGAACTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGA
GCGAGTTTCCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCG
AGGAAAACTGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGA
AGTGAATTAAGTTGCACCGAGGGAAGTTTAACATCAAGTTTAGATAGCCG
GAGACAGCTCTTCAGTTCCCATAAACTCATCGAATGTGATACTCTTTCCA
GAAAAAAATCAGCTAGATTCAAGTCAGATAGTGAAGTCTAGGAGATGCCA
AGAATGAGAAAGAGCACCTTCGTTAACTAAAGTGTTTGATGTTATGAAAA
AAGGAAAGTCAACTGGGGAGTTTACTGACCCCCCACCAG 
Clone 17-hgx1193v1_pB27C-69   229 
 
CTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGGACT
CCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGGGGG
ACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGCCTG
TGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTTGAC
TTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGCAGC
CGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTTTAA
CATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTCATC
GAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGATAG
TGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTTCGTTAACT
AAAGTGTTTGATGTTATGAAAAAGGAAAGTCAACTGGGAGTTTACTGACA
CCCACCAGAGGCGAATCCCGAAAAACAGGAACCCACCGTTTCGGGGGC
CCCTGGGGCCCCTCGAGTAGCCTAGTGTCTAGAGGCCCGGGTCCCCAT
TTGGCCCTAATGTGAGGTCGGAATAACAATTCATTGGGCGTGCCTTTTTG
CAA 
 
Clone 18-hgx1193v1_pB27C-26 
 
CTCTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCCCTGGCA
AGGTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTT
TTTGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTG
CTACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCA
ATCCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCG
AACTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGT
TTCCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAA
ACTGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAA
TTAAGTTGCACCGAGGGAAGTTTAACATCAAGTTTAGATAGCCGGAGACA
GCTCTTCAGTTCCCATAAACTCATCGAATGTGATACTCTTTCCAGGAAAA
AATCAGCTAGATTCAAGTCAGATAGTGGAAGTCTAGGAGATGCCAAGAAT
GAGAAAGAAGCACCTTCGTTAACTAAAGTGTTTTGATGTTATGAAAAAAG
GAAAGTCAACTGGGGAGTTTACTGACACCCACCAGAGGCGAATCCGAAA
AACAGGAACCCACATGGGAAAACGAAAATAGCAGATCGGTTAAAACTGA
GACCCAGAGCCCCTGCGGATGACATGTTTGGGAGTAGGGATCACA   230 
Appendix II 
 
Section II.I  
 
Structure-activity relationship of PDE4 inhibitors- A preliminary study 
 
Rolipram is an active site directed inhibitor and is classified as first generation 
PDE4 selective inhibitor along with Ro 20-1724. Second generation of PDE4 
inhibitors include Ariflo
® and Roflumilast
®.  Third generation PDE4 inhibitors 
include  Xanthine  derivatives.  Rolipram  inhibits  isoforms  of  all  PDE4 
subfamilies  and  is  not  subfamily  specific  (Houslay  and  Adams,  2003, 
Lugnier,et al 1986, Lugnier, 2006). It is widely known that the side effects like 
nausea and emesis caused by rolipram have limited the use of rolipram as a 
therapeutic agent (Houslay et al; 2005).  
 
It  has  been  shown  (Terry  et  al,  2003)  that  PDE4A4  and  its  orthologue 
PDE4A5  when  subjected  to  chronic  rolipram  treatment  (10-18hrs)  can 
undergo  redistribution  in  cells and  form accretion  foci.  In  that  study  it  was 
proposed that various of the side-effects caused by rolipram may be mediated 
through cAMP-independent foci formation due to the redistribution of PDE4A4 
and associated proteins within the cell (Terry et al; 2003). 
 
This  concept  was  formulated  from  observing  that  various  of  the  PDE4 
inhibitors  that  are  known  to  have  pronounced  side  effects  induce  foci 
formation (example; Rolipram, RO 20-17240), whereas, other PDE4 inhibitors 
like Ariflo
® do not induce foci formation of PDE4A4 and have lesser effects 
(Terry et al; 2003).  
 
I set out to gain further insight into this by screening a large panel of PDE4 
inhibitors  using  a  plate  reader  assay  to  identify  inhibitors  that  allowed  foci 
formation and to quantify their action, as described in section 2.15.  
   231 
All  PDE4  inhibitors  that  induce  foci  were  then  to  be  analysed  by  our 
collaborator,  Dr  David  Adams  (Herriot-Watt  University,  Dept  Chemistry)  so 
that their structures can be compared in order to try and identify features that 
might potentially contribute to foci formation. In so doing we hoped to gain 
novel insight into an approach that would allow us to design a novel PDE4 
inhibitor  that  is  devoid  of  side  effects.  This  section  of  appendix  presents 
various  compounds  that  have  been  studied  as  a  part  of  structure-activity 
relationship.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rolipram 
Ro 20-1724 
Ariflo (Cilomilast)  Roflumilast 
Denbufylline 
Figure II.I: Chemical structures of various PDE4 inhibitors. Chemical structures 
taken from Houslay et al; 2005   232 
Compound                   IC50                      Induces foci                       Inhibits foci  
RS-33793 (10mg/ml)         ---                                Yes                                        No   
 
YM-907 (10mg/ml)             ---                                No                                        Yes 
 
YM-976 (20mM)               2.2nM                           No                                         Yes 
  
Roflumilast (50mM)          1nM                              No                                         Yes  
 
CDP-40 (50mM)                4nM                             No                                         Yes    
 
ICI-63,197 (1mM)              4.6uM                          No                                         Yes 
 
Denbufylline (50mM)         1uM                             No                                         Yes 
 
Zardaverine (5mM)            2.5uM                         No                                         Yes 
 
Trequensin (1mM)             500nM                        No                                         Yes 
 
Milrinone (50mM)               1uM                           No                                          No  
 
CC-1069 (50mM)               10uM                         No                                         Yes 
 
CC-1003 (50mM)               10uM                         No                                          No 
 
CC-1104 (2.5mM)              2.5uM                        No                                          Yes 
 
CC-1018 (1mM)                  5uM                          No                                         Yes   233 
CC-1115 (50mM)                1uM                          No                                   No 
 
CC-9088 (50mM)               10uM                         No                                   Yes 
 
CC-7034 (50mM)               50nM                         No                                   Yes 
 
Enoximone (10mM)            0.25uM                      No                                   Yes 
 
Amrinone (10mM)             5uM                      No                                          Yes 
 
Papverine (10mM)            10uM                    No                                          Yes 
 
CP-80633 (20mg/ml)         1.5uM                  No                                           Yes 
 
AH-8883 (200mM)             8uM                    Yes                                           No 
 
Z-15370A (20mg/ml)          ----                      No                                            Yes   
 
CH-4259 (50mm)               1uM                     No                                            Yes 
 
CT-2396 (20mM)               2uM                     Yes                                           No 
 
NCS-613 (100mM)             1uM                     No                                            Yes 
 
ICI-118,233 (20mg/ml)        ----                       No                                            No 
 
PMNPQ (100mM)                1uM                    Yes                                           No 
Cinpanfylline (100mM)         1uM                    Yes                                           No   234 
 
APF-1 (50mM)                      5uM                   Yes                                           No 
 
APF-2 (20mM)                      2uM                    No                                          Yes 
 
RO-1067146 (4mM)              0.5uM                 Yes                                          No 
 
Pyradizanone  I (250mM)      2.0uM                  No                                          Yes 
 
Pyradizanone II  (250mM)      2.0uM                 No                                          Yes          
 
RWJ-22867 (50mM)              1uM                     No                                          No 
 
RO-458, 2640 (10mM)           1uM                     Yes                                        No 
 
Table  II.I:  A  table  showing  various  PDE4  inhibitors,  stock  concentrations  and 
their IC/EC50 values for foci induction and inhibition as determined in a foci plate 
reader assay described in section 2.15 APF-1 induction of foci
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Figure II.II The effect of various PDE4 inhibitors on Rolipram induced foci of PDE4A4
Various PDE4 inhibitors were tested for their affects on rolipram (3uM) induced foci formation of GFP fusion protein of PDE4A4
in CHO cells using a florescent plate reader assay as described in section 2.15Figure II.III Sequence alignment of human PDE4A4 and PDE4B2.
Sequence alignment was performed using ClustalW (Larkin et al; 2007).
240Figure II.IV: Crystal structure of catalytic domain of PDE4B2B
Image showing chain A of the dimeric PDE4B2B with rolipram bound. (1R06.pdb). Xu,
R.X., et al. (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B
complexed with rolipram and AMP and the corresponding amino acids of PDE4A4 are
shown  in  the  parentheses.  JMB.  337.  355-365.  Images  were  made  using  Chimera
(Petterson et al; 2004).
241Leptomycin
 No Rolipram                                Rolipram
Phospho tyrosine
No Rolipram                              Rolipram
Ubiquitin
 No Rolipram                                 Rolipram
DISC1
 No Rolipram                                     Rolipram
PYK2
 No Rolipram                                 Rolipram
Actin
No Rolipram                                Rolipram
Tubulin
 No Rolipram                              Rolipram
Rab 11
 No Rolipram                                  Rolipram
Rab 9
 No Rolipram                                Rolipram
mdm2
 No Rolipram                                 Rolipram
242Mitochondria
 No Rolipram                               Rolipram
UBC9
 No Rolipram                                 Rolipram
Calpastatin
 No Rolipram                            Rolipram
 No Rolipram                                 Rolipram
Lysosomes
Figure II.V: Immunocytochemical studies of foci interacting proteins
Immunocytochemical analysis of CHO cells stably expressing PDE4A4-GFP treated
with and without rolipram (10uM-16hrs) and stained for various proteins and various
sub-cellular  organelles.  All  data  shown  are  representatives  of  the  results  obtained
from three separate experiments.
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